id	sid	tid	token	lemma	pos
ajlm-2375	1	1	abstract	abstract	ADJ
ajlm-2375	1	2	introduction	introduction	NOUN
ajlm-2375	1	3	methods	method	NOUN
ajlm-2375	1	4	results	result	VERB
ajlm-2375	1	5	discussion	discussion	NOUN
ajlm-2375	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2375	1	7	references	reference	NOUN
ajlm-2375	1	8	about	about	ADP
ajlm-2375	1	9	the	the	DET
ajlm-2375	1	10	author(s	author(s	PROPN
ajlm-2375	1	11	)	)	PUNCT
ajlm-2375	1	12	walaa	walaa	PROPN
ajlm-2375	1	13	samy	samy	PROPN
ajlm-2375	1	14	department	department	PROPN
ajlm-2375	1	15	of	of	ADP
ajlm-2375	1	16	medical	medical	ADJ
ajlm-2375	1	17	biochemistry	biochemistry	NOUN
ajlm-2375	1	18	,	,	PUNCT
ajlm-2375	1	19	faculty	faculty	NOUN
ajlm-2375	1	20	of	of	ADP
ajlm-2375	1	21	medicine	medicine	NOUN
ajlm-2375	1	22	,	,	PUNCT
ajlm-2375	1	23	zagazig	zagazig	PROPN
ajlm-2375	1	24	university	university	PROPN
ajlm-2375	1	25	,	,	PUNCT
ajlm-2375	1	26	zagazig	zagazig	PROPN
ajlm-2375	1	27	,	,	PUNCT
ajlm-2375	1	28	egypt	egypt	PROPN
ajlm-2375	1	29	osama	osama	PROPN
ajlm-2375	1	30	a.	a.	PROPN
ajlm-2375	1	31	gaber	gaber	PROPN
ajlm-2375	1	32	department	department	PROPN
ajlm-2375	1	33	of	of	ADP
ajlm-2375	1	34	medical	medical	ADJ
ajlm-2375	1	35	microbiology	microbiology	NOUN
ajlm-2375	1	36	and	and	CCONJ
ajlm-2375	1	37	immunology	immunology	NOUN
ajlm-2375	1	38	,	,	PUNCT
ajlm-2375	1	39	faculty	faculty	NOUN
ajlm-2375	1	40	of	of	ADP
ajlm-2375	1	41	medicine	medicine	NOUN
ajlm-2375	1	42	,	,	PUNCT
ajlm-2375	1	43	zagazig	zagazig	PROPN
ajlm-2375	1	44	university	university	PROPN
ajlm-2375	1	45	,	,	PUNCT
ajlm-2375	1	46	zagazig	zagazig	PROPN
ajlm-2375	1	47	,	,	PUNCT
ajlm-2375	1	48	egypt	egypt	PROPN
ajlm-2375	1	49	rania	rania	PROPN
ajlm-2375	1	50	m.	m.	PROPN
ajlm-2375	1	51	amer	amer	PROPN
ajlm-2375	1	52	department	department	PROPN
ajlm-2375	1	53	of	of	ADP
ajlm-2375	1	54	medical	medical	ADJ
ajlm-2375	1	55	microbiology	microbiology	NOUN
ajlm-2375	1	56	and	and	CCONJ
ajlm-2375	1	57	immunology	immunology	NOUN
ajlm-2375	1	58	,	,	PUNCT
ajlm-2375	1	59	faculty	faculty	NOUN
ajlm-2375	1	60	of	of	ADP
ajlm-2375	1	61	medicine	medicine	NOUN
ajlm-2375	1	62	,	,	PUNCT
ajlm-2375	1	63	zagazig	zagazig	PROPN
ajlm-2375	1	64	university	university	PROPN
ajlm-2375	1	65	,	,	PUNCT
ajlm-2375	1	66	zagazig	zagazig	PROPN
ajlm-2375	1	67	,	,	PUNCT
ajlm-2375	1	68	egypt	egypt	PROPN
ajlm-2375	1	69	nahawand	nahawand	PROPN
ajlm-2375	1	70	a.	a.	PROPN
ajlm-2375	1	71	el	el	PROPN
ajlm-2375	1	72	-	-	PUNCT
ajlm-2375	1	73	deeb	deeb	PROPN
ajlm-2375	1	74	department	department	PROPN
ajlm-2375	1	75	of	of	ADP
ajlm-2375	1	76	internal	internal	ADJ
ajlm-2375	1	77	medicine	medicine	NOUN
ajlm-2375	1	78	,	,	PUNCT
ajlm-2375	1	79	faculty	faculty	NOUN
ajlm-2375	1	80	of	of	ADP
ajlm-2375	1	81	medicine	medicine	NOUN
ajlm-2375	1	82	,	,	PUNCT
ajlm-2375	1	83	zagazig	zagazig	PROPN
ajlm-2375	1	84	university	university	PROPN
ajlm-2375	1	85	,	,	PUNCT
ajlm-2375	1	86	zagazig	zagazig	PROPN
ajlm-2375	1	87	,	,	PUNCT
ajlm-2375	1	88	egypt	egypt	PROPN
ajlm-2375	1	89	ahmed	ahmed	PROPN
ajlm-2375	1	90	a.	a.	PROPN
ajlm-2375	1	91	abdelmoaty	abdelmoaty	PROPN
ajlm-2375	1	92	department	department	PROPN
ajlm-2375	1	93	of	of	ADP
ajlm-2375	1	94	tropical	tropical	ADJ
ajlm-2375	1	95	medicine	medicine	NOUN
ajlm-2375	1	96	,	,	PUNCT
ajlm-2375	1	97	faculty	faculty	NOUN
ajlm-2375	1	98	of	of	ADP
ajlm-2375	1	99	medicine	medicine	NOUN
ajlm-2375	1	100	,	,	PUNCT
ajlm-2375	1	101	zagazig	zagazig	PROPN
ajlm-2375	1	102	university	university	PROPN
ajlm-2375	1	103	,	,	PUNCT
ajlm-2375	1	104	zagazig	zagazig	PROPN
ajlm-2375	1	105	,	,	PUNCT
ajlm-2375	1	106	egypt	egypt	PROPN
ajlm-2375	1	107	ahmed	ahmed	PROPN
ajlm-2375	1	108	l.	l.	PROPN
ajlm-2375	1	109	sharaf	sharaf	PROPN
ajlm-2375	1	110	department	department	PROPN
ajlm-2375	1	111	of	of	ADP
ajlm-2375	1	112	tropical	tropical	ADJ
ajlm-2375	1	113	medicine	medicine	NOUN
ajlm-2375	1	114	,	,	PUNCT
ajlm-2375	1	115	faculty	faculty	NOUN
ajlm-2375	1	116	of	of	ADP
ajlm-2375	1	117	medicine	medicine	NOUN
ajlm-2375	1	118	,	,	PUNCT
ajlm-2375	1	119	zagazig	zagazig	PROPN
ajlm-2375	1	120	university	university	PROPN
ajlm-2375	1	121	,	,	PUNCT
ajlm-2375	1	122	zagazig	zagazig	PROPN
ajlm-2375	1	123	,	,	PUNCT
ajlm-2375	1	124	egypt	egypt	PROPN
ajlm-2375	1	125	ahmed	ahmed	PROPN
ajlm-2375	1	126	m.	m.	PROPN
ajlm-2375	2	1	el	el	PROPN
ajlm-2375	2	2	-	-	PROPN
ajlm-2375	2	3	gebaly	gebaly	PROPN
ajlm-2375	2	4	department	department	PROPN
ajlm-2375	2	5	of	of	ADP
ajlm-2375	2	6	tropical	tropical	ADJ
ajlm-2375	2	7	medicine	medicine	NOUN
ajlm-2375	2	8	,	,	PUNCT
ajlm-2375	2	9	faculty	faculty	NOUN
ajlm-2375	2	10	of	of	ADP
ajlm-2375	2	11	medicine	medicine	NOUN
ajlm-2375	2	12	,	,	PUNCT
ajlm-2375	2	13	zagazig	zagazig	PROPN
ajlm-2375	2	14	university	university	PROPN
ajlm-2375	2	15	,	,	PUNCT
ajlm-2375	2	16	zagazig	zagazig	PROPN
ajlm-2375	2	17	,	,	PUNCT
ajlm-2375	2	18	egypt	egypt	PROPN
ajlm-2375	2	19	rasha	rasha	PROPN
ajlm-2375	2	20	mosbah	mosbah	PROPN
ajlm-2375	2	21	department	department	PROPN
ajlm-2375	2	22	of	of	ADP
ajlm-2375	2	23	infection	infection	NOUN
ajlm-2375	2	24	prevention	prevention	NOUN
ajlm-2375	2	25	and	and	CCONJ
ajlm-2375	2	26	control	control	NOUN
ajlm-2375	2	27	,	,	PUNCT
ajlm-2375	2	28	zagazig	zagazig	PROPN
ajlm-2375	2	29	university	university	NOUN
ajlm-2375	2	30	hospitals	hospital	NOUN
ajlm-2375	2	31	,	,	PUNCT
ajlm-2375	2	32	zagazig	zagazig	PROPN
ajlm-2375	2	33	university	university	PROPN
ajlm-2375	2	34	,	,	PUNCT
ajlm-2375	2	35	zagazig	zagazig	PROPN
ajlm-2375	2	36	,	,	PUNCT
ajlm-2375	2	37	egypt	egypt	PROPN
ajlm-2375	2	38	maha	maha	PROPN
ajlm-2375	2	39	e.	e.	PROPN
ajlm-2375	2	40	alsadik	alsadik	PROPN
ajlm-2375	2	41	chest	chest	PROPN
ajlm-2375	2	42	department	department	PROPN
ajlm-2375	2	43	,	,	PUNCT
ajlm-2375	2	44	faculty	faculty	NOUN
ajlm-2375	2	45	of	of	ADP
ajlm-2375	2	46	medicine	medicine	NOUN
ajlm-2375	2	47	,	,	PUNCT
ajlm-2375	2	48	zagazig	zagazig	PROPN
ajlm-2375	2	49	university	university	PROPN
ajlm-2375	2	50	,	,	PUNCT
ajlm-2375	2	51	zagazig	zagazig	PROPN
ajlm-2375	2	52	,	,	PUNCT
ajlm-2375	2	53	egypt	egypt	PROPN
ajlm-2375	2	54	amal	amal	PROPN
ajlm-2375	2	55	fawzy	fawzy	PROPN
ajlm-2375	2	56	department	department	PROPN
ajlm-2375	2	57	of	of	ADP
ajlm-2375	2	58	medical	medical	ADJ
ajlm-2375	2	59	biochemistry	biochemistry	NOUN
ajlm-2375	2	60	,	,	PUNCT
ajlm-2375	2	61	faculty	faculty	NOUN
ajlm-2375	2	62	of	of	ADP
ajlm-2375	2	63	medicine	medicine	NOUN
ajlm-2375	2	64	,	,	PUNCT
ajlm-2375	2	65	zagazig	zagazig	PROPN
ajlm-2375	2	66	university	university	PROPN
ajlm-2375	2	67	,	,	PUNCT
ajlm-2375	2	68	zagazig	zagazig	PROPN
ajlm-2375	2	69	,	,	PUNCT
ajlm-2375	2	70	egypt	egypt	PROPN
ajlm-2375	2	71	alshymaa	alshymaa	PROPN
ajlm-2375	2	72	a.	a.	PROPN
ajlm-2375	2	73	ahmed	ahmed	PROPN
ajlm-2375	2	74	department	department	PROPN
ajlm-2375	2	75	of	of	ADP
ajlm-2375	2	76	clinical	clinical	ADJ
ajlm-2375	2	77	pathology	pathology	NOUN
ajlm-2375	2	78	,	,	PUNCT
ajlm-2375	2	79	faculty	faculty	NOUN
ajlm-2375	2	80	of	of	ADP
ajlm-2375	2	81	medicine	medicine	NOUN
ajlm-2375	2	82	,	,	PUNCT
ajlm-2375	2	83	zagazig	zagazig	PROPN
ajlm-2375	2	84	university	university	PROPN
ajlm-2375	2	85	,	,	PUNCT
ajlm-2375	2	86	zagazig	zagazig	PROPN
ajlm-2375	2	87	,	,	PUNCT
ajlm-2375	2	88	egypt	egypt	PROPN
ajlm-2375	2	89	citation	citation	PROPN
ajlm-2375	2	90	samy	samy	PROPN
ajlm-2375	2	91	w	w	PROPN
ajlm-2375	2	92	,	,	PUNCT
ajlm-2375	2	93	gaber	gaber	PROPN
ajlm-2375	2	94	oa	oa	PROPN
ajlm-2375	2	95	,	,	PUNCT
ajlm-2375	2	96	amer	amer	PROPN
ajlm-2375	2	97	rm	rm	PROPN
ajlm-2375	2	98	,	,	PUNCT
ajlm-2375	2	99	et	et	PROPN
ajlm-2375	2	100	al	al	PROPN
ajlm-2375	2	101	.	.	PUNCT
ajlm-2375	2	102	role	role	NOUN
ajlm-2375	2	103	of	of	ADP
ajlm-2375	2	104	ace2	ace2	PROPN
ajlm-2375	2	105	and	and	CCONJ
ajlm-2375	2	106	tmprss2	tmprss2	ADP
ajlm-2375	2	107	polymorphisms	polymorphism	NOUN
ajlm-2375	2	108	in	in	ADP
ajlm-2375	2	109	clinical	clinical	ADJ
ajlm-2375	2	110	severity	severity	NOUN
ajlm-2375	2	111	and	and	CCONJ
ajlm-2375	2	112	outcomes	outcome	NOUN
ajlm-2375	2	113	of	of	ADP
ajlm-2375	2	114	covid-19	covid-19	PROPN
ajlm-2375	2	115	in	in	ADP
ajlm-2375	2	116	egypt	egypt	PROPN
ajlm-2375	2	117	.	.	PUNCT
ajlm-2375	3	1	afr	afr	PROPN
ajlm-2375	3	2	j	j	PROPN
ajlm-2375	3	3	lab	lab	PROPN
ajlm-2375	3	4	med	me	VERB
ajlm-2375	3	5	.	.	PUNCT
ajlm-2375	4	1	2024;13(1	2024;13(1	NUM
ajlm-2375	4	2	)	)	PUNCT
ajlm-2375	4	3	,	,	PUNCT
ajlm-2375	4	4	a2375	a2375	PROPN
ajlm-2375	4	5	.	.	PUNCT
ajlm-2375	4	6	https://doi.org/10.4102/ajlm.v13i1.2375	https://doi.org/10.4102/ajlm.v13i1.2375	PROPN
ajlm-2375	4	7	note	note	VERB
ajlm-2375	4	8	:	:	PUNCT
ajlm-2375	4	9	additional	additional	ADJ
ajlm-2375	4	10	supporting	support	VERB
ajlm-2375	4	11	information	information	NOUN
ajlm-2375	4	12	may	may	AUX
ajlm-2375	4	13	be	be	AUX
ajlm-2375	4	14	found	find	VERB
ajlm-2375	4	15	in	in	ADP
ajlm-2375	4	16	the	the	DET
ajlm-2375	4	17	online	online	ADJ
ajlm-2375	4	18	version	version	NOUN
ajlm-2375	4	19	of	of	ADP
ajlm-2375	4	20	this	this	DET
ajlm-2375	4	21	article	article	NOUN
ajlm-2375	4	22	as	as	ADP
ajlm-2375	4	23	online	online	ADJ
ajlm-2375	4	24	supplementary	supplementary	ADJ
ajlm-2375	4	25	document	document	NOUN
ajlm-2375	4	26	1	1	NUM
ajlm-2375	4	27	.	.	PUNCT
ajlm-2375	4	28	original	original	ADJ
ajlm-2375	4	29	research	research	NOUN
ajlm-2375	4	30	role	role	NOUN
ajlm-2375	4	31	of	of	ADP
ajlm-2375	4	32	ace2	ace2	PROPN
ajlm-2375	4	33	and	and	CCONJ
ajlm-2375	4	34	tmprss2	tmprss2	ADP
ajlm-2375	4	35	polymorphisms	polymorphism	NOUN
ajlm-2375	4	36	in	in	ADP
ajlm-2375	4	37	clinical	clinical	ADJ
ajlm-2375	4	38	severity	severity	NOUN
ajlm-2375	4	39	and	and	CCONJ
ajlm-2375	4	40	outcomes	outcome	NOUN
ajlm-2375	4	41	of	of	ADP
ajlm-2375	4	42	covid-19	covid-19	PROPN
ajlm-2375	4	43	in	in	ADP
ajlm-2375	4	44	egypt	egypt	PROPN
ajlm-2375	4	45	walaa	walaa	PROPN
ajlm-2375	4	46	samy	samy	PROPN
ajlm-2375	4	47	,	,	PUNCT
ajlm-2375	4	48	osama	osama	PROPN
ajlm-2375	4	49	a.	a.	NOUN
ajlm-2375	4	50	gaber	gaber	PROPN
ajlm-2375	4	51	,	,	PUNCT
ajlm-2375	4	52	rania	rania	PROPN
ajlm-2375	4	53	m.	m.	PROPN
ajlm-2375	4	54	amer	amer	PROPN
ajlm-2375	4	55	,	,	PUNCT
ajlm-2375	4	56	nahawand	nahawand	PROPN
ajlm-2375	4	57	a.	a.	PROPN
ajlm-2375	4	58	el	el	PROPN
ajlm-2375	4	59	-	-	PUNCT
ajlm-2375	4	60	deeb	deeb	PROPN
ajlm-2375	4	61	,	,	PUNCT
ajlm-2375	4	62	ahmed	ahmed	PROPN
ajlm-2375	4	63	a.	a.	PROPN
ajlm-2375	4	64	abdelmoaty	abdelmoaty	PROPN
ajlm-2375	4	65	,	,	PUNCT
ajlm-2375	4	66	ahmed	ahmed	PROPN
ajlm-2375	4	67	l.	l.	PROPN
ajlm-2375	4	68	sharaf	sharaf	PROPN
ajlm-2375	4	69	,	,	PUNCT
ajlm-2375	5	1	ahmed	ahmed	PROPN
ajlm-2375	5	2	m.	m.	PROPN
ajlm-2375	5	3	el	el	PROPN
ajlm-2375	5	4	-	-	PROPN
ajlm-2375	5	5	gebaly	gebaly	PROPN
ajlm-2375	5	6	,	,	PUNCT
ajlm-2375	5	7	rasha	rasha	PROPN
ajlm-2375	5	8	mosbah	mosbah	PROPN
ajlm-2375	5	9	,	,	PUNCT
ajlm-2375	5	10	maha	maha	PROPN
ajlm-2375	5	11	e.	e.	PROPN
ajlm-2375	5	12	alsadik	alsadik	PROPN
ajlm-2375	5	13	,	,	PUNCT
ajlm-2375	5	14	amal	amal	PROPN
ajlm-2375	5	15	fawzy	fawzy	PROPN
ajlm-2375	5	16	,	,	PUNCT
ajlm-2375	5	17	alshymaa	alshymaa	PROPN
ajlm-2375	5	18	a.	a.	PROPN
ajlm-2375	5	19	ahmed	ahmed	PROPN
ajlm-2375	5	20	received	receive	VERB
ajlm-2375	5	21	:	:	PUNCT
ajlm-2375	5	22	21	21	NUM
ajlm-2375	5	23	nov	nov	PROPN
ajlm-2375	5	24	.	.	PROPN
ajlm-2375	5	25	2023	2023	NUM
ajlm-2375	5	26	;	;	PUNCT
ajlm-2375	5	27	accepted	accept	VERB
ajlm-2375	5	28	:	:	PUNCT
ajlm-2375	5	29	23	23	NUM
ajlm-2375	5	30	may	may	PROPN
ajlm-2375	5	31	2024	2024	NUM
ajlm-2375	5	32	;	;	PUNCT
ajlm-2375	5	33	published	publish	VERB
ajlm-2375	5	34	:	:	PUNCT
ajlm-2375	5	35	27	27	NUM
ajlm-2375	5	36	aug	aug	PROPN
ajlm-2375	5	37	.	.	PROPN
ajlm-2375	5	38	2024	2024	NUM
ajlm-2375	5	39	copyright	copyright	NOUN
ajlm-2375	5	40	:	:	PUNCT
ajlm-2375	5	41	©	©	PROPN
ajlm-2375	5	42	2024	2024	NUM
ajlm-2375	5	43	.	.	PUNCT
ajlm-2375	6	1	the	the	DET
ajlm-2375	6	2	author(s	author(s	PROPN
ajlm-2375	6	3	)	)	PUNCT
ajlm-2375	6	4	.	.	PUNCT
ajlm-2375	7	1	licensee	licensee	NOUN
ajlm-2375	7	2	:	:	PUNCT
ajlm-2375	7	3	aosis	aosis	NOUN
ajlm-2375	7	4	.	.	PUNCT
ajlm-2375	8	1	this	this	PRON
ajlm-2375	8	2	is	be	AUX
ajlm-2375	8	3	an	an	DET
ajlm-2375	8	4	open	open	ADJ
ajlm-2375	8	5	access	access	NOUN
ajlm-2375	8	6	article	article	NOUN
ajlm-2375	8	7	distributed	distribute	VERB
ajlm-2375	8	8	under	under	ADP
ajlm-2375	8	9	the	the	DET
ajlm-2375	8	10	terms	term	NOUN
ajlm-2375	8	11	of	of	ADP
ajlm-2375	8	12	the	the	DET
ajlm-2375	8	13	creative	creative	ADJ
ajlm-2375	8	14	commons	common	NOUN
ajlm-2375	8	15	attribution	attribution	NOUN
ajlm-2375	8	16	license	license	NOUN
ajlm-2375	8	17	,	,	PUNCT
ajlm-2375	8	18	which	which	PRON
ajlm-2375	8	19	permits	permit	VERB
ajlm-2375	8	20	unrestricted	unrestricted	ADJ
ajlm-2375	8	21	use	use	NOUN
ajlm-2375	8	22	,	,	PUNCT
ajlm-2375	8	23	distribution	distribution	NOUN
ajlm-2375	8	24	,	,	PUNCT
ajlm-2375	8	25	and	and	CCONJ
ajlm-2375	8	26	reproduction	reproduction	NOUN
ajlm-2375	8	27	in	in	ADP
ajlm-2375	8	28	any	any	DET
ajlm-2375	8	29	medium	medium	NOUN
ajlm-2375	8	30	,	,	PUNCT
ajlm-2375	8	31	provided	provide	VERB
ajlm-2375	8	32	the	the	DET
ajlm-2375	8	33	original	original	ADJ
ajlm-2375	8	34	work	work	NOUN
ajlm-2375	8	35	is	be	AUX
ajlm-2375	8	36	properly	properly	ADV
ajlm-2375	8	37	cited	cite	VERB
ajlm-2375	8	38	.	.	PUNCT
ajlm-2375	9	1	abstract	abstract	ADJ
ajlm-2375	9	2	background	background	NOUN
ajlm-2375	9	3	:	:	PUNCT
ajlm-2375	9	4	the	the	DET
ajlm-2375	9	5	clinical	clinical	ADJ
ajlm-2375	9	6	presentations	presentation	NOUN
ajlm-2375	9	7	of	of	ADP
ajlm-2375	9	8	coronavirus	coronavirus	NOUN
ajlm-2375	9	9	disease	disease	NOUN
ajlm-2375	9	10	2019	2019	NUM
ajlm-2375	9	11	(	(	PUNCT
ajlm-2375	9	12	covid-19	covid-19	PROPN
ajlm-2375	9	13	)	)	PUNCT
ajlm-2375	9	14	exhibit	exhibit	VERB
ajlm-2375	9	15	significant	significant	ADJ
ajlm-2375	9	16	variation	variation	NOUN
ajlm-2375	9	17	,	,	PUNCT
ajlm-2375	9	18	ranging	range	VERB
ajlm-2375	9	19	from	from	ADP
ajlm-2375	9	20	asymptomatic	asymptomatic	ADJ
ajlm-2375	9	21	cases	case	NOUN
ajlm-2375	9	22	to	to	ADP
ajlm-2375	9	23	mortality	mortality	NOUN
ajlm-2375	9	24	resulting	result	VERB
ajlm-2375	9	25	from	from	ADP
ajlm-2375	9	26	severe	severe	ADJ
ajlm-2375	9	27	pneumonia	pneumonia	NOUN
ajlm-2375	9	28	.	.	PUNCT
ajlm-2375	10	1	host	host	NOUN
ajlm-2375	10	2	genetics	genetic	NOUN
ajlm-2375	10	3	can	can	AUX
ajlm-2375	10	4	partially	partially	ADV
ajlm-2375	10	5	explain	explain	VERB
ajlm-2375	10	6	this	this	DET
ajlm-2375	10	7	variation	variation	NOUN
ajlm-2375	10	8	.	.	PUNCT
ajlm-2375	11	1	objective	objective	NOUN
ajlm-2375	11	2	:	:	PUNCT
ajlm-2375	11	3	this	this	DET
ajlm-2375	11	4	study	study	NOUN
ajlm-2375	11	5	evaluated	evaluate	VERB
ajlm-2375	11	6	possible	possible	ADJ
ajlm-2375	11	7	associations	association	NOUN
ajlm-2375	11	8	between	between	ADP
ajlm-2375	11	9	severity	severity	NOUN
ajlm-2375	11	10	and	and	CCONJ
ajlm-2375	11	11	outcome	outcome	NOUN
ajlm-2375	11	12	of	of	ADP
ajlm-2375	11	13	covid-19	covid-19	PROPN
ajlm-2375	11	14	and	and	CCONJ
ajlm-2375	11	15	single	single	ADJ
ajlm-2375	11	16	nucleotide	nucleotide	ADJ
ajlm-2375	11	17	polymorphism	polymorphism	NOUN
ajlm-2375	11	18	(	(	PUNCT
ajlm-2375	11	19	snp	snp	ADJ
ajlm-2375	11	20	)	)	PUNCT
ajlm-2375	11	21	rs2285666	rs2285666	NOUN
ajlm-2375	11	22	in	in	ADP
ajlm-2375	11	23	the	the	DET
ajlm-2375	11	24	ace2	ace2	PROPN
ajlm-2375	11	25	gene	gene	NOUN
ajlm-2375	11	26	and	and	CCONJ
ajlm-2375	11	27	snp	snp	ADJ
ajlm-2375	11	28	rs2070788	rs2070788	NOUN
ajlm-2375	11	29	in	in	ADP
ajlm-2375	11	30	the	the	DET
ajlm-2375	11	31	tmprss2	tmprss2	ADJ
ajlm-2375	11	32	gene	gene	NOUN
ajlm-2375	11	33	.	.	PUNCT
ajlm-2375	12	1	methods	method	NOUN
ajlm-2375	12	2	:	:	PUNCT
ajlm-2375	12	3	the	the	DET
ajlm-2375	12	4	study	study	NOUN
ajlm-2375	12	5	included	include	VERB
ajlm-2375	12	6	a	a	DET
ajlm-2375	12	7	sample	sample	NOUN
ajlm-2375	12	8	of	of	ADP
ajlm-2375	12	9	100	100	NUM
ajlm-2375	12	10	consecutive	consecutive	ADJ
ajlm-2375	12	11	adult	adult	NOUN
ajlm-2375	12	12	patients	patient	NOUN
ajlm-2375	12	13	admitted	admit	VERB
ajlm-2375	12	14	to	to	ADP
ajlm-2375	12	15	the	the	DET
ajlm-2375	12	16	covid-19	covid-19	PROPN
ajlm-2375	12	17	isolation	isolation	NOUN
ajlm-2375	12	18	and	and	CCONJ
ajlm-2375	12	19	intensive	intensive	ADJ
ajlm-2375	12	20	care	care	NOUN
ajlm-2375	12	21	units	unit	NOUN
ajlm-2375	12	22	of	of	ADP
ajlm-2375	12	23	the	the	DET
ajlm-2375	12	24	zagazig	zagazig	PROPN
ajlm-2375	12	25	university	university	PROPN
ajlm-2375	12	26	hospitals	hospital	NOUN
ajlm-2375	12	27	,	,	PUNCT
ajlm-2375	12	28	zagazig	zagazig	PROPN
ajlm-2375	12	29	,	,	PUNCT
ajlm-2375	12	30	egypt	egypt	PROPN
ajlm-2375	12	31	from	from	ADP
ajlm-2375	12	32	july	july	PROPN
ajlm-2375	12	33	2021	2021	NUM
ajlm-2375	12	34	to	to	ADP
ajlm-2375	12	35	november	november	PROPN
ajlm-2375	12	36	2021	2021	NUM
ajlm-2375	12	37	.	.	PUNCT
ajlm-2375	13	1	for	for	ADP
ajlm-2375	13	2	rs2285666	rs2285666	NOUN
ajlm-2375	13	3	,	,	PUNCT
ajlm-2375	13	4	polymerase	polymerase	NOUN
ajlm-2375	13	5	chain	chain	NOUN
ajlm-2375	13	6	reaction	reaction	NOUN
ajlm-2375	13	7	-	-	PUNCT
ajlm-2375	13	8	restriction	restriction	NOUN
ajlm-2375	13	9	fragment	fragment	NOUN
ajlm-2375	13	10	length	length	NOUN
ajlm-2375	13	11	polymorphism	polymorphism	NOUN
ajlm-2375	13	12	was	be	AUX
ajlm-2375	13	13	carried	carry	VERB
ajlm-2375	13	14	out	out	ADP
ajlm-2375	13	15	.	.	PUNCT
ajlm-2375	14	1	for	for	ADP
ajlm-2375	14	2	rs2070788	rs2070788	NOUN
ajlm-2375	14	3	,	,	PUNCT
ajlm-2375	14	4	real	real	ADJ
ajlm-2375	14	5	-	-	PUNCT
ajlm-2375	14	6	time	time	NOUN
ajlm-2375	14	7	polymerase	polymerase	NOUN
ajlm-2375	14	8	chain	chain	NOUN
ajlm-2375	14	9	reaction	reaction	NOUN
ajlm-2375	14	10	was	be	AUX
ajlm-2375	14	11	performed	perform	VERB
ajlm-2375	14	12	.	.	PUNCT
ajlm-2375	15	1	results	result	NOUN
ajlm-2375	15	2	:	:	PUNCT
ajlm-2375	15	3	for	for	ADP
ajlm-2375	15	4	rs2285666	rs2285666	NOUN
ajlm-2375	15	5	,	,	PUNCT
ajlm-2375	15	6	the	the	DET
ajlm-2375	15	7	ga	ga	PROPN
ajlm-2375	15	8	genotype	genotype	NOUN
ajlm-2375	15	9	was	be	AUX
ajlm-2375	15	10	the	the	DET
ajlm-2375	15	11	most	most	ADV
ajlm-2375	15	12	frequent	frequent	ADJ
ajlm-2375	15	13	among	among	ADP
ajlm-2375	15	14	female	female	ADJ
ajlm-2375	15	15	patients	patient	NOUN
ajlm-2375	15	16	(	(	PUNCT
ajlm-2375	15	17	39	39	NUM
ajlm-2375	15	18	%	%	NOUN
ajlm-2375	16	1	[	[	X
ajlm-2375	16	2	16/41	16/41	NUM
ajlm-2375	16	3	]	]	PUNCT
ajlm-2375	16	4	)	)	PUNCT
ajlm-2375	16	5	and	and	CCONJ
ajlm-2375	16	6	the	the	DET
ajlm-2375	16	7	a	a	DET
ajlm-2375	16	8	genotype	genotype	NOUN
ajlm-2375	16	9	was	be	AUX
ajlm-2375	16	10	more	more	ADV
ajlm-2375	16	11	prevalent	prevalent	ADJ
ajlm-2375	16	12	among	among	ADP
ajlm-2375	16	13	male	male	ADJ
ajlm-2375	16	14	patients	patient	NOUN
ajlm-2375	16	15	(	(	PUNCT
ajlm-2375	16	16	54.2	54.2	NUM
ajlm-2375	16	17	%	%	NOUN
ajlm-2375	16	18	[	[	X
ajlm-2375	16	19	32/59	32/59	NUM
ajlm-2375	16	20	]	]	PUNCT
ajlm-2375	16	21	)	)	PUNCT
ajlm-2375	16	22	.	.	PUNCT
ajlm-2375	17	1	for	for	ADP
ajlm-2375	17	2	rs2070788	rs2070788	NOUN
ajlm-2375	17	3	,	,	PUNCT
ajlm-2375	17	4	the	the	DET
ajlm-2375	17	5	aa	aa	PROPN
ajlm-2375	17	6	genotype	genotype	NOUN
ajlm-2375	17	7	was	be	AUX
ajlm-2375	17	8	the	the	DET
ajlm-2375	17	9	most	most	ADV
ajlm-2375	17	10	frequent	frequent	ADJ
ajlm-2375	17	11	among	among	ADP
ajlm-2375	17	12	all	all	DET
ajlm-2375	17	13	patients	patient	NOUN
ajlm-2375	17	14	(	(	PUNCT
ajlm-2375	17	15	46	46	NUM
ajlm-2375	17	16	%	%	NOUN
ajlm-2375	18	1	[	[	X
ajlm-2375	18	2	46/100	46/100	NUM
ajlm-2375	18	3	]	]	PUNCT
ajlm-2375	18	4	)	)	PUNCT
ajlm-2375	18	5	.	.	PUNCT
ajlm-2375	19	1	no	no	DET
ajlm-2375	19	2	rs2285666	rs2285666	ADJ
ajlm-2375	19	3	or	or	CCONJ
ajlm-2375	19	4	rs2070788	rs2070788	ADJ
ajlm-2375	19	5	genotypes	genotype	NOUN
ajlm-2375	19	6	or	or	CCONJ
ajlm-2375	19	7	allele	allele	NOUN
ajlm-2375	19	8	frequencies	frequency	NOUN
ajlm-2375	19	9	had	have	VERB
ajlm-2375	19	10	significant	significant	ADJ
ajlm-2375	19	11	associations	association	NOUN
ajlm-2375	19	12	with	with	ADP
ajlm-2375	19	13	either	either	CCONJ
ajlm-2375	19	14	severity	severity	NOUN
ajlm-2375	19	15	or	or	CCONJ
ajlm-2375	19	16	outcomes	outcome	NOUN
ajlm-2375	19	17	of	of	ADP
ajlm-2375	19	18	patients	patient	NOUN
ajlm-2375	19	19	.	.	PUNCT
ajlm-2375	20	1	conclusion	conclusion	NOUN
ajlm-2375	20	2	:	:	PUNCT
ajlm-2375	20	3	this	this	DET
ajlm-2375	20	4	study	study	NOUN
ajlm-2375	20	5	found	find	VERB
ajlm-2375	20	6	no	no	DET
ajlm-2375	20	7	significant	significant	ADJ
ajlm-2375	20	8	associations	association	NOUN
ajlm-2375	20	9	of	of	ADP
ajlm-2375	20	10	covid-19	covid-19	PROPN
ajlm-2375	20	11	severity	severity	NOUN
ajlm-2375	20	12	or	or	CCONJ
ajlm-2375	20	13	outcomes	outcome	NOUN
ajlm-2375	20	14	of	of	ADP
ajlm-2375	20	15	patients	patient	NOUN
ajlm-2375	20	16	with	with	ADP
ajlm-2375	20	17	genotypes	genotype	NOUN
ajlm-2375	20	18	or	or	CCONJ
ajlm-2375	20	19	allele	allele	NOUN
ajlm-2375	20	20	frequencies	frequency	NOUN
ajlm-2375	20	21	of	of	ADP
ajlm-2375	20	22	the	the	DET
ajlm-2375	20	23	rs2285666	rs2285666	NOUN
ajlm-2375	20	24	snp	snp	NOUN
ajlm-2375	20	25	in	in	ADP
ajlm-2375	20	26	the	the	DET
ajlm-2375	20	27	ace2	ace2	NOUN
ajlm-2375	20	28	gene	gene	NOUN
ajlm-2375	20	29	or	or	CCONJ
ajlm-2375	20	30	the	the	DET
ajlm-2375	20	31	rs2070788	rs2070788	NOUN
ajlm-2375	20	32	snp	snp	NOUN
ajlm-2375	20	33	of	of	ADP
ajlm-2375	20	34	the	the	DET
ajlm-2375	20	35	tmprss2	tmprss2	ADJ
ajlm-2375	20	36	gene	gene	NOUN
ajlm-2375	20	37	.	.	PUNCT
ajlm-2375	21	1	the	the	DET
ajlm-2375	21	2	search	search	NOUN
ajlm-2375	21	3	for	for	ADP
ajlm-2375	21	4	other	other	ADJ
ajlm-2375	21	5	genetic	genetic	ADJ
ajlm-2375	21	6	associations	association	NOUN
ajlm-2375	21	7	with	with	ADP
ajlm-2375	21	8	covid-19	covid-19	PROPN
ajlm-2375	21	9	infection	infection	NOUN
ajlm-2375	21	10	is	be	AUX
ajlm-2375	21	11	still	still	ADV
ajlm-2375	21	12	required	require	VERB
ajlm-2375	21	13	.	.	PUNCT
ajlm-2375	22	1	what	what	PRON
ajlm-2375	22	2	this	this	DET
ajlm-2375	22	3	study	study	NOUN
ajlm-2375	22	4	adds	add	VERB
ajlm-2375	22	5	:	:	PUNCT
ajlm-2375	22	6	the	the	DET
ajlm-2375	22	7	study	study	NOUN
ajlm-2375	22	8	reveals	reveal	VERB
ajlm-2375	22	9	that	that	SCONJ
ajlm-2375	22	10	host	host	NOUN
ajlm-2375	22	11	genetics	genetic	NOUN
ajlm-2375	22	12	explain	explain	VERB
ajlm-2375	22	13	the	the	DET
ajlm-2375	22	14	variation	variation	NOUN
ajlm-2375	22	15	observed	observe	VERB
ajlm-2375	22	16	in	in	ADP
ajlm-2375	22	17	the	the	DET
ajlm-2375	22	18	disease	disease	NOUN
ajlm-2375	22	19	.	.	PUNCT
ajlm-2375	23	1	specific	specific	ADJ
ajlm-2375	23	2	genetic	genetic	ADJ
ajlm-2375	23	3	variants	variant	NOUN
ajlm-2375	23	4	can	can	AUX
ajlm-2375	23	5	confer	confer	VERB
ajlm-2375	23	6	either	either	CCONJ
ajlm-2375	23	7	increased	increase	VERB
ajlm-2375	23	8	susceptibility	susceptibility	NOUN
ajlm-2375	23	9	or	or	CCONJ
ajlm-2375	23	10	resistance	resistance	NOUN
ajlm-2375	23	11	to	to	ADP
ajlm-2375	23	12	the	the	DET
ajlm-2375	23	13	disease	disease	NOUN
ajlm-2375	23	14	.	.	PUNCT
ajlm-2375	24	1	keywords	keyword	NOUN
ajlm-2375	24	2	:	:	PUNCT
ajlm-2375	24	3	ace2	ace2	PROPN
ajlm-2375	24	4	gene	gene	NOUN
ajlm-2375	24	5	;	;	PUNCT
ajlm-2375	24	6	tmprss2	tmprss2	ADP
ajlm-2375	24	7	gene	gene	NOUN
ajlm-2375	24	8	;	;	PUNCT
ajlm-2375	24	9	single	single	ADJ
ajlm-2375	24	10	nucleotide	nucleotide	NOUN
ajlm-2375	24	11	polymorphisms	polymorphism	NOUN
ajlm-2375	24	12	;	;	PUNCT
ajlm-2375	24	13	covid-19	covid-19	PROPN
ajlm-2375	24	14	;	;	PUNCT
ajlm-2375	24	15	severity	severity	NOUN
ajlm-2375	24	16	;	;	PUNCT
ajlm-2375	24	17	outcome	outcome	NOUN
ajlm-2375	24	18	.	.	PUNCT
ajlm-2375	25	1	introduction	introduction	NOUN
ajlm-2375	25	2	coronavirus	coronavirus	NOUN
ajlm-2375	25	3	disease	disease	NOUN
ajlm-2375	25	4	2019	2019	NUM
ajlm-2375	25	5	(	(	PUNCT
ajlm-2375	25	6	covid-19	covid-19	PROPN
ajlm-2375	25	7	)	)	PUNCT
ajlm-2375	25	8	,	,	PUNCT
ajlm-2375	25	9	which	which	PRON
ajlm-2375	25	10	is	be	AUX
ajlm-2375	25	11	caused	cause	VERB
ajlm-2375	25	12	by	by	ADP
ajlm-2375	25	13	the	the	DET
ajlm-2375	25	14	severe	severe	ADJ
ajlm-2375	25	15	acute	acute	ADJ
ajlm-2375	25	16	respiratory	respiratory	ADJ
ajlm-2375	25	17	syndrome	syndrome	NOUN
ajlm-2375	25	18	coronavirus	coronavirus	NOUN
ajlm-2375	25	19	2	2	NUM
ajlm-2375	25	20	(	(	PUNCT
ajlm-2375	25	21	sars	sar	NOUN
ajlm-2375	25	22	-	-	PUNCT
ajlm-2375	25	23	cov-2	cov-2	NOUN
ajlm-2375	25	24	)	)	PUNCT
ajlm-2375	25	25	,	,	PUNCT
ajlm-2375	25	26	has	have	AUX
ajlm-2375	25	27	resulted	result	VERB
ajlm-2375	25	28	in	in	ADP
ajlm-2375	25	29	more	more	ADJ
ajlm-2375	25	30	than	than	ADP
ajlm-2375	25	31	6	6	NUM
ajlm-2375	25	32	million	million	NUM
ajlm-2375	25	33	fatalities	fatality	NOUN
ajlm-2375	25	34	and	and	CCONJ
ajlm-2375	25	35	603	603	NUM
ajlm-2375	25	36	million	million	NUM
ajlm-2375	25	37	confirmed	confirm	VERB
ajlm-2375	25	38	cases	case	NOUN
ajlm-2375	25	39	since	since	SCONJ
ajlm-2375	25	40	its	its	PRON
ajlm-2375	25	41	identification	identification	NOUN
ajlm-2375	25	42	in	in	ADP
ajlm-2375	25	43	2019	2019	NUM
ajlm-2375	25	44	until	until	ADP
ajlm-2375	25	45	07	07	NUM
ajlm-2375	25	46	september	september	PROPN
ajlm-2375	25	47	2022.1	2022.1	NUM
ajlm-2375	25	48	the	the	DET
ajlm-2375	25	49	clinical	clinical	ADJ
ajlm-2375	25	50	presentations	presentation	NOUN
ajlm-2375	25	51	of	of	ADP
ajlm-2375	25	52	the	the	DET
ajlm-2375	25	53	covid-19	covid-19	PROPN
ajlm-2375	25	54	infection	infection	NOUN
ajlm-2375	25	55	showed	show	VERB
ajlm-2375	25	56	significant	significant	ADJ
ajlm-2375	25	57	variation	variation	NOUN
ajlm-2375	25	58	,	,	PUNCT
ajlm-2375	25	59	ranging	range	VERB
ajlm-2375	25	60	from	from	ADP
ajlm-2375	25	61	asymptomatic	asymptomatic	ADJ
ajlm-2375	25	62	cases	case	NOUN
ajlm-2375	25	63	to	to	ADP
ajlm-2375	25	64	mortality	mortality	NOUN
ajlm-2375	25	65	resulting	result	VERB
ajlm-2375	25	66	from	from	ADP
ajlm-2375	25	67	severe	severe	ADJ
ajlm-2375	25	68	pneumonia	pneumonia	NOUN
ajlm-2375	25	69	.	.	PUNCT
ajlm-2375	26	1	host	host	NOUN
ajlm-2375	26	2	genetics	genetic	NOUN
ajlm-2375	26	3	can	can	AUX
ajlm-2375	26	4	account	account	VERB
ajlm-2375	26	5	for	for	ADP
ajlm-2375	26	6	part	part	NOUN
ajlm-2375	26	7	of	of	ADP
ajlm-2375	26	8	this	this	DET
ajlm-2375	26	9	variation	variation	NOUN
ajlm-2375	26	10	,	,	PUNCT
ajlm-2375	26	11	as	as	SCONJ
ajlm-2375	26	12	some	some	DET
ajlm-2375	26	13	genetic	genetic	ADJ
ajlm-2375	26	14	variants	variant	NOUN
ajlm-2375	26	15	can	can	AUX
ajlm-2375	26	16	confer	confer	VERB
ajlm-2375	26	17	either	either	CCONJ
ajlm-2375	26	18	increased	increase	VERB
ajlm-2375	26	19	susceptibility	susceptibility	NOUN
ajlm-2375	26	20	or	or	CCONJ
ajlm-2375	26	21	resistance	resistance	NOUN
ajlm-2375	26	22	to	to	ADP
ajlm-2375	26	23	the	the	DET
ajlm-2375	26	24	disease.2	disease.2	PROPN
ajlm-2375	26	25	similar	similar	ADJ
ajlm-2375	26	26	to	to	ADP
ajlm-2375	26	27	all	all	DET
ajlm-2375	26	28	viruses	virus	NOUN
ajlm-2375	26	29	,	,	PUNCT
ajlm-2375	26	30	sars	sar	NOUN
ajlm-2375	26	31	-	-	PUNCT
ajlm-2375	26	32	cov-2	cov-2	NOUN
ajlm-2375	26	33	undergoes	undergo	VERB
ajlm-2375	26	34	genetic	genetic	ADJ
ajlm-2375	26	35	mutations	mutation	NOUN
ajlm-2375	26	36	over	over	ADP
ajlm-2375	26	37	time	time	NOUN
ajlm-2375	26	38	,	,	PUNCT
ajlm-2375	26	39	which	which	PRON
ajlm-2375	26	40	can	can	AUX
ajlm-2375	26	41	potentially	potentially	ADV
ajlm-2375	26	42	affect	affect	VERB
ajlm-2375	26	43	various	various	ADJ
ajlm-2375	26	44	aspects	aspect	NOUN
ajlm-2375	26	45	of	of	ADP
ajlm-2375	26	46	the	the	DET
ajlm-2375	26	47	virus	virus	NOUN
ajlm-2375	26	48	,	,	PUNCT
ajlm-2375	26	49	including	include	VERB
ajlm-2375	26	50	its	its	PRON
ajlm-2375	26	51	ability	ability	NOUN
ajlm-2375	26	52	to	to	PART
ajlm-2375	26	53	spread	spread	VERB
ajlm-2375	26	54	and	and	CCONJ
ajlm-2375	26	55	infect	infect	VERB
ajlm-2375	26	56	,	,	PUNCT
ajlm-2375	26	57	the	the	DET
ajlm-2375	26	58	severity	severity	NOUN
ajlm-2375	26	59	of	of	ADP
ajlm-2375	26	60	symptoms	symptom	NOUN
ajlm-2375	26	61	and	and	CCONJ
ajlm-2375	26	62	disease	disease	NOUN
ajlm-2375	26	63	,	,	PUNCT
ajlm-2375	26	64	the	the	DET
ajlm-2375	26	65	efficacy	efficacy	NOUN
ajlm-2375	26	66	of	of	ADP
ajlm-2375	26	67	vaccines	vaccine	NOUN
ajlm-2375	26	68	,	,	PUNCT
ajlm-2375	26	69	diagnostic	diagnostic	ADJ
ajlm-2375	26	70	methods	method	NOUN
ajlm-2375	26	71	,	,	PUNCT
ajlm-2375	26	72	and	and	CCONJ
ajlm-2375	26	73	other	other	ADJ
ajlm-2375	26	74	public	public	ADJ
ajlm-2375	26	75	health	health	NOUN
ajlm-2375	26	76	interventions	intervention	NOUN
ajlm-2375	26	77	.	.	PUNCT
ajlm-2375	27	1	since	since	SCONJ
ajlm-2375	27	2	the	the	DET
ajlm-2375	27	3	outbreak	outbreak	NOUN
ajlm-2375	27	4	of	of	ADP
ajlm-2375	27	5	the	the	DET
ajlm-2375	27	6	pandemic	pandemic	ADJ
ajlm-2375	27	7	,	,	PUNCT
ajlm-2375	27	8	sars	sar	NOUN
ajlm-2375	27	9	-	-	PUNCT
ajlm-2375	27	10	cov-2	cov-2	PART
ajlm-2375	27	11	has	have	AUX
ajlm-2375	27	12	been	be	AUX
ajlm-2375	27	13	undergoing	undergo	VERB
ajlm-2375	27	14	continuous	continuous	ADJ
ajlm-2375	27	15	evolution	evolution	NOUN
ajlm-2375	27	16	.	.	PUNCT
ajlm-2375	28	1	omicron	omicron	PROPN
ajlm-2375	28	2	,	,	PUNCT
ajlm-2375	28	3	the	the	DET
ajlm-2375	28	4	most	most	ADV
ajlm-2375	28	5	divergent	divergent	ADJ
ajlm-2375	28	6	variant	variant	NOUN
ajlm-2375	28	7	of	of	ADP
ajlm-2375	28	8	concern	concern	NOUN
ajlm-2375	28	9	,	,	PUNCT
ajlm-2375	28	10	is	be	AUX
ajlm-2375	28	11	still	still	ADV
ajlm-2375	28	12	evolving	evolve	VERB
ajlm-2375	28	13	,	,	PUNCT
ajlm-2375	28	14	both	both	CCONJ
ajlm-2375	28	15	genetically	genetically	ADV
ajlm-2375	28	16	and	and	CCONJ
ajlm-2375	28	17	antigenically	antigenically	ADV
ajlm-2375	28	18	.	.	PUNCT
ajlm-2375	29	1	there	there	PRON
ajlm-2375	29	2	is	be	VERB
ajlm-2375	29	3	a	a	DET
ajlm-2375	29	4	possibility	possibility	NOUN
ajlm-2375	29	5	that	that	SCONJ
ajlm-2375	29	6	it	it	PRON
ajlm-2375	29	7	may	may	AUX
ajlm-2375	29	8	be	be	AUX
ajlm-2375	29	9	able	able	ADJ
ajlm-2375	29	10	to	to	PART
ajlm-2375	29	11	evade	evade	VERB
ajlm-2375	29	12	the	the	DET
ajlm-2375	29	13	existing	exist	VERB
ajlm-2375	29	14	population	population	NOUN
ajlm-2375	29	15	immunity	immunity	NOUN
ajlm-2375	29	16	compared	compare	VERB
ajlm-2375	29	17	with	with	ADP
ajlm-2375	29	18	the	the	DET
ajlm-2375	29	19	pre	pre	ADJ
ajlm-2375	29	20	-	-	ADJ
ajlm-2375	29	21	omicron	omicron	ADJ
ajlm-2375	29	22	strains	strain	NOUN
ajlm-2375	29	23	.	.	PUNCT
ajlm-2375	30	1	also	also	ADV
ajlm-2375	30	2	,	,	PUNCT
ajlm-2375	30	3	omicron	omicron	PROPN
ajlm-2375	30	4	prefers	prefer	VERB
ajlm-2375	30	5	to	to	PART
ajlm-2375	30	6	involve	involve	VERB
ajlm-2375	30	7	the	the	DET
ajlm-2375	30	8	upper	upper	ADJ
ajlm-2375	30	9	rather	rather	ADV
ajlm-2375	30	10	than	than	ADP
ajlm-2375	30	11	the	the	DET
ajlm-2375	30	12	lower	low	ADJ
ajlm-2375	30	13	respiratory	respiratory	ADJ
ajlm-2375	30	14	tract	tract	NOUN
ajlm-2375	30	15	;	;	PUNCT
ajlm-2375	30	16	therefore	therefore	ADV
ajlm-2375	30	17	,	,	PUNCT
ajlm-2375	30	18	ongoing	ongoing	ADJ
ajlm-2375	30	19	research	research	NOUN
ajlm-2375	30	20	on	on	ADP
ajlm-2375	30	21	the	the	DET
ajlm-2375	30	22	sars	sar	NOUN
ajlm-2375	30	23	-	-	PUNCT
ajlm-2375	30	24	cov-2	cov-2	PART
ajlm-2375	30	25	virus	virus	NOUN
ajlm-2375	30	26	is	be	AUX
ajlm-2375	30	27	still	still	ADV
ajlm-2375	30	28	required.3	required.3	PROPN
ajlm-2375	30	29	the	the	DET
ajlm-2375	30	30	sars	sar	NOUN
ajlm-2375	30	31	-	-	PUNCT
ajlm-2375	30	32	cov-2	cov-2	PART
ajlm-2375	30	33	virus	virus	NOUN
ajlm-2375	30	34	binds	bind	VERB
ajlm-2375	30	35	to	to	ADP
ajlm-2375	30	36	host	host	NOUN
ajlm-2375	30	37	cell	cell	NOUN
ajlm-2375	30	38	surface	surface	NOUN
ajlm-2375	30	39	receptors	receptor	NOUN
ajlm-2375	30	40	by	by	ADP
ajlm-2375	30	41	utilising	utilise	VERB
ajlm-2375	30	42	spike	spike	NOUN
ajlm-2375	30	43	(	(	PUNCT
ajlm-2375	30	44	s	s	NOUN
ajlm-2375	30	45	)	)	PUNCT
ajlm-2375	30	46	protein	protein	NOUN
ajlm-2375	30	47	to	to	PART
ajlm-2375	30	48	mediate	mediate	VERB
ajlm-2375	30	49	the	the	DET
ajlm-2375	30	50	fusion	fusion	NOUN
ajlm-2375	30	51	of	of	ADP
ajlm-2375	30	52	the	the	DET
ajlm-2375	30	53	viral	viral	ADJ
ajlm-2375	30	54	envelope	envelope	NOUN
ajlm-2375	30	55	with	with	ADP
ajlm-2375	30	56	the	the	DET
ajlm-2375	30	57	cell	cell	NOUN
ajlm-2375	30	58	membrane	membrane	NOUN
ajlm-2375	30	59	.	.	PUNCT
ajlm-2375	31	1	the	the	DET
ajlm-2375	31	2	s	s	NOUN
ajlm-2375	31	3	protein	protein	NOUN
ajlm-2375	31	4	is	be	AUX
ajlm-2375	31	5	composed	compose	VERB
ajlm-2375	31	6	of	of	ADP
ajlm-2375	31	7	s1	s1	NOUN
ajlm-2375	31	8	and	and	CCONJ
ajlm-2375	31	9	s2	s2	NOUN
ajlm-2375	31	10	subunits	subunit	NOUN
ajlm-2375	31	11	.	.	PUNCT
ajlm-2375	32	1	the	the	DET
ajlm-2375	32	2	subunit	subunit	NOUN
ajlm-2375	32	3	s1	s1	PROPN
ajlm-2375	32	4	contains	contain	VERB
ajlm-2375	32	5	the	the	DET
ajlm-2375	32	6	receptor	receptor	NOUN
ajlm-2375	32	7	-	-	PUNCT
ajlm-2375	32	8	binding	bind	VERB
ajlm-2375	32	9	domain	domain	NOUN
ajlm-2375	32	10	,	,	PUNCT
ajlm-2375	32	11	that	that	PRON
ajlm-2375	32	12	interacts	interact	VERB
ajlm-2375	32	13	with	with	ADP
ajlm-2375	32	14	the	the	DET
ajlm-2375	32	15	peptidase	peptidase	NOUN
ajlm-2375	32	16	domain	domain	NOUN
ajlm-2375	32	17	of	of	ADP
ajlm-2375	32	18	the	the	DET
ajlm-2375	32	19	angiotensin	angiotensin	NOUN
ajlm-2375	32	20	-	-	PUNCT
ajlm-2375	32	21	converting	convert	VERB
ajlm-2375	32	22	enzyme	enzyme	NOUN
ajlm-2375	32	23	2	2	NUM
ajlm-2375	32	24	(	(	PUNCT
ajlm-2375	32	25	ace2	ace2	NOUN
ajlm-2375	32	26	)	)	PUNCT
ajlm-2375	32	27	protein	protein	NOUN
ajlm-2375	32	28	.	.	PUNCT
ajlm-2375	33	1	this	this	DET
ajlm-2375	33	2	step	step	NOUN
ajlm-2375	33	3	is	be	AUX
ajlm-2375	33	4	critical	critical	ADJ
ajlm-2375	33	5	for	for	ADP
ajlm-2375	33	6	the	the	DET
ajlm-2375	33	7	viral	viral	ADJ
ajlm-2375	33	8	entry	entry	NOUN
ajlm-2375	33	9	into	into	ADP
ajlm-2375	33	10	the	the	DET
ajlm-2375	33	11	cell	cell	NOUN
ajlm-2375	33	12	.	.	PUNCT
ajlm-2375	34	1	the	the	DET
ajlm-2375	34	2	ace2	ace2	PROPN
ajlm-2375	34	3	protein	protein	NOUN
ajlm-2375	34	4	is	be	AUX
ajlm-2375	34	5	a	a	DET
ajlm-2375	34	6	well	well	ADV
ajlm-2375	34	7	-	-	PUNCT
ajlm-2375	34	8	characterised	characterise	VERB
ajlm-2375	34	9	negative	negative	ADJ
ajlm-2375	34	10	regulator	regulator	NOUN
ajlm-2375	34	11	of	of	ADP
ajlm-2375	34	12	the	the	DET
ajlm-2375	34	13	renin	renin	ADJ
ajlm-2375	34	14	-	-	PUNCT
ajlm-2375	34	15	angiotensin	angiotensin	NOUN
ajlm-2375	34	16	system	system	NOUN
ajlm-2375	34	17	,	,	PUNCT
ajlm-2375	34	18	which	which	PRON
ajlm-2375	34	19	catalyses	catalyse	VERB
ajlm-2375	34	20	the	the	DET
ajlm-2375	34	21	conversion	conversion	NOUN
ajlm-2375	34	22	of	of	ADP
ajlm-2375	34	23	angiotensin	angiotensin	PROPN
ajlm-2375	34	24	ii	ii	PROPN
ajlm-2375	34	25	to	to	ADP
ajlm-2375	34	26	the	the	DET
ajlm-2375	34	27	heptapeptide	heptapeptide	PROPN
ajlm-2375	34	28	angiotensin	angiotensin	PROPN
ajlm-2375	34	29	(	(	PUNCT
ajlm-2375	34	30	1–7	1–7	NUM
ajlm-2375	34	31	)	)	PUNCT
ajlm-2375	34	32	,	,	PUNCT
ajlm-2375	34	33	which	which	PRON
ajlm-2375	34	34	produces	produce	VERB
ajlm-2375	34	35	the	the	DET
ajlm-2375	34	36	opposite	opposite	ADJ
ajlm-2375	34	37	effect	effect	NOUN
ajlm-2375	34	38	to	to	ADP
ajlm-2375	34	39	that	that	PRON
ajlm-2375	34	40	of	of	ADP
ajlm-2375	34	41	angiotensin	angiotensin	NOUN
ajlm-2375	34	42	ii.4	ii.4	PROPN
ajlm-2375	34	43	the	the	DET
ajlm-2375	34	44	ace2	ace2	NOUN
ajlm-2375	34	45	protein	protein	NOUN
ajlm-2375	34	46	plays	play	VERB
ajlm-2375	34	47	two	two	NUM
ajlm-2375	34	48	opposing	oppose	VERB
ajlm-2375	34	49	roles	role	NOUN
ajlm-2375	34	50	in	in	ADP
ajlm-2375	34	51	covid-19	covid-19	PROPN
ajlm-2375	34	52	infection	infection	NOUN
ajlm-2375	34	53	.	.	PUNCT
ajlm-2375	35	1	firstly	firstly	ADV
ajlm-2375	35	2	,	,	PUNCT
ajlm-2375	35	3	it	it	PRON
ajlm-2375	35	4	acts	act	VERB
ajlm-2375	35	5	as	as	ADP
ajlm-2375	35	6	a	a	DET
ajlm-2375	35	7	potent	potent	ADJ
ajlm-2375	35	8	receptor	receptor	NOUN
ajlm-2375	35	9	for	for	ADP
ajlm-2375	35	10	the	the	DET
ajlm-2375	35	11	virus	virus	NOUN
ajlm-2375	35	12	to	to	PART
ajlm-2375	35	13	enter	enter	VERB
ajlm-2375	35	14	the	the	DET
ajlm-2375	35	15	cell	cell	NOUN
ajlm-2375	35	16	.	.	PUNCT
ajlm-2375	36	1	secondly	secondly	ADV
ajlm-2375	36	2	,	,	PUNCT
ajlm-2375	36	3	it	it	PRON
ajlm-2375	36	4	has	have	VERB
ajlm-2375	36	5	a	a	DET
ajlm-2375	36	6	protective	protective	ADJ
ajlm-2375	36	7	function	function	NOUN
ajlm-2375	36	8	in	in	ADP
ajlm-2375	36	9	maintaining	maintain	VERB
ajlm-2375	36	10	the	the	DET
ajlm-2375	36	11	balance	balance	NOUN
ajlm-2375	36	12	of	of	ADP
ajlm-2375	36	13	angiotensin	angiotensin	PROPN
ajlm-2375	36	14	ii	ii	PROPN
ajlm-2375	36	15	,	,	PUNCT
ajlm-2375	36	16	a	a	DET
ajlm-2375	36	17	hormone	hormone	NOUN
ajlm-2375	36	18	involved	involve	VERB
ajlm-2375	36	19	in	in	ADP
ajlm-2375	36	20	regulating	regulate	VERB
ajlm-2375	36	21	blood	blood	NOUN
ajlm-2375	36	22	pressure	pressure	NOUN
ajlm-2375	36	23	.	.	PUNCT
ajlm-2375	37	1	however	however	ADV
ajlm-2375	37	2	,	,	PUNCT
ajlm-2375	37	3	when	when	SCONJ
ajlm-2375	37	4	there	there	PRON
ajlm-2375	37	5	is	be	VERB
ajlm-2375	37	6	an	an	DET
ajlm-2375	37	7	excessive	excessive	ADJ
ajlm-2375	37	8	buildup	buildup	NOUN
ajlm-2375	37	9	of	of	ADP
ajlm-2375	37	10	angiotensin	angiotensin	PROPN
ajlm-2375	37	11	ii	ii	PROPN
ajlm-2375	37	12	,	,	PUNCT
ajlm-2375	37	13	it	it	PRON
ajlm-2375	37	14	can	can	AUX
ajlm-2375	37	15	lead	lead	VERB
ajlm-2375	37	16	to	to	ADP
ajlm-2375	37	17	the	the	DET
ajlm-2375	37	18	release	release	NOUN
ajlm-2375	37	19	of	of	ADP
ajlm-2375	37	20	large	large	ADJ
ajlm-2375	37	21	amounts	amount	NOUN
ajlm-2375	37	22	of	of	ADP
ajlm-2375	37	23	cytokines	cytokine	NOUN
ajlm-2375	37	24	,	,	PUNCT
ajlm-2375	37	25	causing	cause	VERB
ajlm-2375	37	26	a	a	DET
ajlm-2375	37	27	cytokine	cytokine	ADJ
ajlm-2375	37	28	storm	storm	NOUN
ajlm-2375	37	29	and	and	CCONJ
ajlm-2375	37	30	subsequent	subsequent	ADJ
ajlm-2375	37	31	tissue	tissue	NOUN
ajlm-2375	37	32	damage.5	damage.5	VERB
ajlm-2375	37	33	the	the	DET
ajlm-2375	37	34	interaction	interaction	NOUN
ajlm-2375	37	35	between	between	ADP
ajlm-2375	37	36	sars	sar	NOUN
ajlm-2375	37	37	-	-	PUNCT
ajlm-2375	37	38	cov-2	cov-2	PART
ajlm-2375	37	39	and	and	CCONJ
ajlm-2375	37	40	ace2	ace2	NOUN
ajlm-2375	37	41	protein	protein	NOUN
ajlm-2375	37	42	receptors	receptor	NOUN
ajlm-2375	37	43	results	result	VERB
ajlm-2375	37	44	in	in	ADP
ajlm-2375	37	45	a	a	DET
ajlm-2375	37	46	decrease	decrease	NOUN
ajlm-2375	37	47	in	in	ADP
ajlm-2375	37	48	ace2	ace2	NOUN
ajlm-2375	37	49	protein	protein	NOUN
ajlm-2375	37	50	expression	expression	NOUN
ajlm-2375	37	51	and	and	CCONJ
ajlm-2375	37	52	a	a	DET
ajlm-2375	37	53	reduction	reduction	NOUN
ajlm-2375	37	54	in	in	ADP
ajlm-2375	37	55	its	its	PRON
ajlm-2375	37	56	protective	protective	ADJ
ajlm-2375	37	57	function	function	NOUN
ajlm-2375	37	58	on	on	ADP
ajlm-2375	37	59	the	the	DET
ajlm-2375	37	60	angiotensin	angiotensin	NOUN
ajlm-2375	37	61	ii	ii	PROPN
ajlm-2375	37	62	pathway	pathway	NOUN
ajlm-2375	37	63	.	.	PUNCT
ajlm-2375	38	1	therefore	therefore	ADV
ajlm-2375	38	2	,	,	PUNCT
ajlm-2375	38	3	the	the	DET
ajlm-2375	38	4	activation	activation	NOUN
ajlm-2375	38	5	of	of	ADP
ajlm-2375	38	6	ace2	ace2	NOUN
ajlm-2375	38	7	has	have	AUX
ajlm-2375	38	8	been	be	AUX
ajlm-2375	38	9	proposed	propose	VERB
ajlm-2375	38	10	as	as	ADP
ajlm-2375	38	11	a	a	DET
ajlm-2375	38	12	potential	potential	ADJ
ajlm-2375	38	13	therapy	therapy	NOUN
ajlm-2375	38	14	for	for	ADP
ajlm-2375	38	15	covid-19	covid-19	PROPN
ajlm-2375	38	16	.	.	PUNCT
ajlm-2375	39	1	this	this	PRON
ajlm-2375	39	2	emphasises	emphasise	VERB
ajlm-2375	39	3	the	the	DET
ajlm-2375	39	4	significance	significance	NOUN
ajlm-2375	39	5	of	of	ADP
ajlm-2375	39	6	ongoing	ongoing	ADJ
ajlm-2375	39	7	research	research	NOUN
ajlm-2375	39	8	on	on	ADP
ajlm-2375	39	9	ace2	ace2	NOUN
ajlm-2375	39	10	gene	gene	NOUN
ajlm-2375	39	11	polymorphisms	polymorphism	NOUN
ajlm-2375	39	12	and	and	CCONJ
ajlm-2375	39	13	their	their	PRON
ajlm-2375	39	14	functional	functional	ADJ
ajlm-2375	39	15	impacts	impact	NOUN
ajlm-2375	39	16	.	.	PUNCT
ajlm-2375	40	1	this	this	PRON
ajlm-2375	40	2	is	be	AUX
ajlm-2375	40	3	important	important	ADJ
ajlm-2375	40	4	not	not	PART
ajlm-2375	40	5	only	only	ADV
ajlm-2375	40	6	because	because	SCONJ
ajlm-2375	40	7	the	the	DET
ajlm-2375	40	8	ace2	ace2	NOUN
ajlm-2375	40	9	protein	protein	NOUN
ajlm-2375	40	10	receptor	receptor	NOUN
ajlm-2375	40	11	is	be	AUX
ajlm-2375	40	12	involved	involve	VERB
ajlm-2375	40	13	in	in	ADP
ajlm-2375	40	14	the	the	DET
ajlm-2375	40	15	development	development	NOUN
ajlm-2375	40	16	of	of	ADP
ajlm-2375	40	17	infections	infection	NOUN
ajlm-2375	40	18	,	,	PUNCT
ajlm-2375	40	19	but	but	CCONJ
ajlm-2375	40	20	also	also	ADV
ajlm-2375	40	21	because	because	SCONJ
ajlm-2375	40	22	it	it	PRON
ajlm-2375	40	23	is	be	AUX
ajlm-2375	40	24	suggested	suggest	VERB
ajlm-2375	40	25	to	to	PART
ajlm-2375	40	26	be	be	AUX
ajlm-2375	40	27	a	a	DET
ajlm-2375	40	28	potential	potential	ADJ
ajlm-2375	40	29	target	target	NOUN
ajlm-2375	40	30	for	for	ADP
ajlm-2375	40	31	therapy.6	therapy.6	PROPN
ajlm-2375	40	32	the	the	DET
ajlm-2375	40	33	ace2	ace2	PROPN
ajlm-2375	40	34	gene	gene	NOUN
ajlm-2375	40	35	is	be	AUX
ajlm-2375	40	36	located	locate	VERB
ajlm-2375	40	37	on	on	ADP
ajlm-2375	40	38	chromosome	chromosome	NOUN
ajlm-2375	40	39	xp22	xp22	PROPN
ajlm-2375	40	40	;	;	PUNCT
ajlm-2375	40	41	a	a	DET
ajlm-2375	40	42	functional	functional	ADJ
ajlm-2375	40	43	single	single	ADJ
ajlm-2375	40	44	nucleotide	nucleotide	NOUN
ajlm-2375	40	45	polymorphism	polymorphism	NOUN
ajlm-2375	40	46	(	(	PUNCT
ajlm-2375	40	47	snp	snp	PROPN
ajlm-2375	40	48	)	)	PUNCT
ajlm-2375	40	49	in	in	ADP
ajlm-2375	40	50	the	the	DET
ajlm-2375	40	51	ace2	ace2	PROPN
ajlm-2375	40	52	gene	gene	NOUN
ajlm-2375	40	53	‘	'	PUNCT
ajlm-2375	40	54	g8790a	g8790a	PROPN
ajlm-2375	40	55	(	(	PUNCT
ajlm-2375	40	56	rs2285666	rs2285666	NOUN
ajlm-2375	40	57	)	)	PUNCT
ajlm-2375	40	58	’	'	PUNCT
ajlm-2375	40	59	in	in	ADP
ajlm-2375	40	60	intron	intron	ADJ
ajlm-2375	40	61	3	3	NUM
ajlm-2375	40	62	could	could	AUX
ajlm-2375	40	63	alter	alter	VERB
ajlm-2375	40	64	mrna	mrna	PROPN
ajlm-2375	40	65	splicing	splicing	NOUN
ajlm-2375	40	66	and	and	CCONJ
ajlm-2375	40	67	so	so	ADV
ajlm-2375	40	68	affect	affect	VERB
ajlm-2375	40	69	ace2	ace2	NOUN
ajlm-2375	40	70	gene	gene	NOUN
ajlm-2375	40	71	expression.7	expression.7	PROPN
ajlm-2375	40	72	in	in	ADP
ajlm-2375	40	73	addition	addition	NOUN
ajlm-2375	40	74	,	,	PUNCT
ajlm-2375	40	75	rs2285666	rs2285666	PROPN
ajlm-2375	40	76	is	be	AUX
ajlm-2375	40	77	suggested	suggest	VERB
ajlm-2375	40	78	to	to	PART
ajlm-2375	40	79	alter	alter	VERB
ajlm-2375	40	80	the	the	DET
ajlm-2375	40	81	binding	bind	VERB
ajlm-2375	40	82	affinity	affinity	NOUN
ajlm-2375	40	83	of	of	ADP
ajlm-2375	40	84	the	the	DET
ajlm-2375	40	85	ace2	ace2	NOUN
ajlm-2375	40	86	protein	protein	NOUN
ajlm-2375	40	87	receptor	receptor	NOUN
ajlm-2375	40	88	for	for	ADP
ajlm-2375	40	89	sars	sar	NOUN
ajlm-2375	40	90	-	-	PUNCT
ajlm-2375	40	91	cov-2.8	cov-2.8	NOUN
ajlm-2375	40	92	receptor	receptor	NOUN
ajlm-2375	40	93	binding	binding	NOUN
ajlm-2375	40	94	is	be	AUX
ajlm-2375	40	95	facilitated	facilitate	VERB
ajlm-2375	40	96	by	by	ADP
ajlm-2375	40	97	the	the	DET
ajlm-2375	40	98	human	human	ADJ
ajlm-2375	40	99	enzyme	enzyme	NOUN
ajlm-2375	40	100	transmembrane	transmembrane	ADJ
ajlm-2375	40	101	protease	protease	NOUN
ajlm-2375	40	102	serine	serine	NOUN
ajlm-2375	40	103	2	2	NUM
ajlm-2375	40	104	(	(	PUNCT
ajlm-2375	40	105	tmprss2),9	tmprss2),9	PROPN
ajlm-2375	40	106	a	a	DET
ajlm-2375	40	107	family	family	NOUN
ajlm-2375	40	108	of	of	ADP
ajlm-2375	40	109	membrane	membrane	NOUN
ajlm-2375	40	110	-	-	PUNCT
ajlm-2375	40	111	anchored	anchor	VERB
ajlm-2375	40	112	proteases	protease	NOUN
ajlm-2375	40	113	expressed	express	VERB
ajlm-2375	40	114	on	on	ADP
ajlm-2375	40	115	the	the	DET
ajlm-2375	40	116	airway	airway	NOUN
ajlm-2375	40	117	epithelial	epithelial	ADJ
ajlm-2375	40	118	cell	cell	NOUN
ajlm-2375	40	119	surface	surface	NOUN
ajlm-2375	40	120	.	.	PUNCT
ajlm-2375	41	1	it	it	PRON
ajlm-2375	41	2	acts	act	VERB
ajlm-2375	41	3	as	as	ADP
ajlm-2375	41	4	a	a	DET
ajlm-2375	41	5	viral	viral	ADJ
ajlm-2375	41	6	entry	entry	NOUN
ajlm-2375	41	7	cofactor	cofactor	NOUN
ajlm-2375	41	8	by	by	ADP
ajlm-2375	41	9	cleavage	cleavage	NOUN
ajlm-2375	41	10	of	of	ADP
ajlm-2375	41	11	the	the	DET
ajlm-2375	41	12	viral	viral	ADJ
ajlm-2375	41	13	spike	spike	NOUN
ajlm-2375	41	14	s	s	PART
ajlm-2375	41	15	protein	protein	NOUN
ajlm-2375	41	16	to	to	ADP
ajlm-2375	41	17	s1	s1	NOUN
ajlm-2375	41	18	and	and	CCONJ
ajlm-2375	41	19	s2	s2	PROPN
ajlm-2375	41	20	subunits	subunit	NOUN
ajlm-2375	41	21	to	to	PART
ajlm-2375	41	22	facilitate	facilitate	VERB
ajlm-2375	41	23	the	the	DET
ajlm-2375	41	24	interaction	interaction	NOUN
ajlm-2375	41	25	with	with	ADP
ajlm-2375	41	26	the	the	DET
ajlm-2375	41	27	ace2	ace2	NOUN
ajlm-2375	41	28	protein	protein	NOUN
ajlm-2375	41	29	receptor	receptor	NOUN
ajlm-2375	41	30	’s	’s	PART
ajlm-2375	41	31	extracellular	extracellular	ADJ
ajlm-2375	41	32	domain.10	domain.10	NOUN
ajlm-2375	41	33	therefore	therefore	ADV
ajlm-2375	41	34	,	,	PUNCT
ajlm-2375	41	35	genetic	genetic	ADJ
ajlm-2375	41	36	variations	variation	NOUN
ajlm-2375	41	37	in	in	ADP
ajlm-2375	41	38	ace2	ace2	PROPN
ajlm-2375	41	39	and	and	CCONJ
ajlm-2375	41	40	tmprss2	tmprss2	SCONJ
ajlm-2375	41	41	nucleotide	nucleotide	NOUN
ajlm-2375	41	42	sequences	sequence	NOUN
ajlm-2375	41	43	may	may	AUX
ajlm-2375	41	44	change	change	VERB
ajlm-2375	41	45	the	the	DET
ajlm-2375	41	46	interaction	interaction	NOUN
ajlm-2375	41	47	of	of	ADP
ajlm-2375	41	48	receptor	receptor	NOUN
ajlm-2375	41	49	-	-	PUNCT
ajlm-2375	41	50	binding	bind	VERB
ajlm-2375	41	51	domain	domain	NOUN
ajlm-2375	41	52	and	and	CCONJ
ajlm-2375	41	53	peptidase	peptidase	NOUN
ajlm-2375	41	54	domains	domain	NOUN
ajlm-2375	41	55	,	,	PUNCT
ajlm-2375	41	56	altering	alter	VERB
ajlm-2375	41	57	the	the	DET
ajlm-2375	41	58	host	host	NOUN
ajlm-2375	41	59	’s	’s	PART
ajlm-2375	41	60	susceptibility	susceptibility	NOUN
ajlm-2375	41	61	to	to	ADP
ajlm-2375	41	62	the	the	DET
ajlm-2375	41	63	virus	virus	NOUN
ajlm-2375	41	64	and	and	CCONJ
ajlm-2375	41	65	influencing	influence	VERB
ajlm-2375	41	66	the	the	DET
ajlm-2375	41	67	disease	disease	NOUN
ajlm-2375	41	68	’s	’s	PART
ajlm-2375	41	69	severity	severity	NOUN
ajlm-2375	41	70	and	and	CCONJ
ajlm-2375	41	71	outcome	outcome	NOUN
ajlm-2375	41	72	.	.	PUNCT
ajlm-2375	42	1	the	the	DET
ajlm-2375	42	2	tmprss2	tmprss2	ADJ
ajlm-2375	42	3	gene	gene	NOUN
ajlm-2375	42	4	is	be	AUX
ajlm-2375	42	5	located	locate	VERB
ajlm-2375	42	6	on	on	ADP
ajlm-2375	42	7	chromosome	chromosome	NOUN
ajlm-2375	42	8	21q22	21q22	NUM
ajlm-2375	42	9	.	.	PUNCT
ajlm-2375	43	1	rs2070788	rs2070788	NOUN
ajlm-2375	43	2	is	be	AUX
ajlm-2375	43	3	a	a	DET
ajlm-2375	43	4	g	g	NOUN
ajlm-2375	43	5	to	to	ADP
ajlm-2375	43	6	a	a	DET
ajlm-2375	43	7	transition	transition	NOUN
ajlm-2375	43	8	snp	snp	NOUN
ajlm-2375	43	9	located	locate	VERB
ajlm-2375	43	10	in	in	ADP
ajlm-2375	43	11	intron	intron	ADJ
ajlm-2375	43	12	11–12	11–12	NUM
ajlm-2375	43	13	of	of	ADP
ajlm-2375	43	14	the	the	DET
ajlm-2375	43	15	tmprss2	tmprss2	ADJ
ajlm-2375	43	16	gene	gene	NOUN
ajlm-2375	43	17	and	and	CCONJ
ajlm-2375	43	18	was	be	AUX
ajlm-2375	43	19	found	find	VERB
ajlm-2375	43	20	to	to	PART
ajlm-2375	43	21	be	be	AUX
ajlm-2375	43	22	associated	associate	VERB
ajlm-2375	43	23	with	with	ADP
ajlm-2375	43	24	reduced	reduced	ADJ
ajlm-2375	43	25	tmprss2	tmprss2	SCONJ
ajlm-2375	43	26	gene	gene	NOUN
ajlm-2375	43	27	expression.11	expression.11	NOUN
ajlm-2375	43	28	based	base	VERB
ajlm-2375	43	29	on	on	ADP
ajlm-2375	43	30	that	that	PRON
ajlm-2375	43	31	,	,	PUNCT
ajlm-2375	43	32	it	it	PRON
ajlm-2375	43	33	was	be	AUX
ajlm-2375	43	34	proposed	propose	VERB
ajlm-2375	43	35	that	that	SCONJ
ajlm-2375	43	36	the	the	DET
ajlm-2375	43	37	aforementioned	aforementioned	ADJ
ajlm-2375	43	38	snps	snps	PROPN
ajlm-2375	43	39	can	can	AUX
ajlm-2375	43	40	influence	influence	VERB
ajlm-2375	43	41	the	the	DET
ajlm-2375	43	42	course	course	NOUN
ajlm-2375	43	43	of	of	ADP
ajlm-2375	43	44	covid-19	covid-19	PROPN
ajlm-2375	43	45	infection	infection	NOUN
ajlm-2375	43	46	.	.	PUNCT
ajlm-2375	44	1	this	this	DET
ajlm-2375	44	2	work	work	NOUN
ajlm-2375	44	3	was	be	AUX
ajlm-2375	44	4	performed	perform	VERB
ajlm-2375	44	5	to	to	PART
ajlm-2375	44	6	evaluate	evaluate	VERB
ajlm-2375	44	7	the	the	DET
ajlm-2375	44	8	possible	possible	ADJ
ajlm-2375	44	9	association	association	NOUN
ajlm-2375	44	10	between	between	ADP
ajlm-2375	44	11	the	the	DET
ajlm-2375	44	12	ace2	ace2	PROPN
ajlm-2375	44	13	(	(	PUNCT
ajlm-2375	44	14	rs2285666	rs2285666	NOUN
ajlm-2375	44	15	)	)	PUNCT
ajlm-2375	44	16	and	and	CCONJ
ajlm-2375	44	17	tmprss2	tmprss2	ADV
ajlm-2375	44	18	(	(	PUNCT
ajlm-2375	44	19	rs2070788	rs2070788	PROPN
ajlm-2375	44	20	)	)	PUNCT
ajlm-2375	44	21	snps	snps	NOUN
ajlm-2375	44	22	and	and	CCONJ
ajlm-2375	44	23	clinical	clinical	ADJ
ajlm-2375	44	24	severity	severity	NOUN
ajlm-2375	44	25	and	and	CCONJ
ajlm-2375	44	26	outcomes	outcome	NOUN
ajlm-2375	44	27	among	among	ADP
ajlm-2375	44	28	covid-19	covid-19	PROPN
ajlm-2375	44	29	patients	patient	NOUN
ajlm-2375	44	30	.	.	PUNCT
ajlm-2375	45	1	methods	method	NOUN
ajlm-2375	45	2	ethical	ethical	ADJ
ajlm-2375	45	3	considerations	consideration	NOUN
ajlm-2375	45	4	the	the	DET
ajlm-2375	45	5	institutional	institutional	ADJ
ajlm-2375	45	6	review	review	NOUN
ajlm-2375	45	7	board	board	NOUN
ajlm-2375	45	8	of	of	ADP
ajlm-2375	45	9	the	the	DET
ajlm-2375	45	10	faculty	faculty	NOUN
ajlm-2375	45	11	of	of	ADP
ajlm-2375	45	12	medicine	medicine	NOUN
ajlm-2375	45	13	,	,	PUNCT
ajlm-2375	45	14	zagazig	zagazig	PROPN
ajlm-2375	45	15	university	university	PROPN
ajlm-2375	45	16	,	,	PUNCT
ajlm-2375	45	17	approved	approve	VERB
ajlm-2375	45	18	this	this	DET
ajlm-2375	45	19	work	work	NOUN
ajlm-2375	45	20	(	(	PUNCT
ajlm-2375	45	21	zu	zu	NOUN
ajlm-2375	45	22	-	-	PUNCT
ajlm-2375	45	23	irb#6775	irb#6775	NOUN
ajlm-2375	45	24	)	)	PUNCT
ajlm-2375	45	25	.	.	PUNCT
ajlm-2375	46	1	participants	participant	NOUN
ajlm-2375	46	2	voluntarily	voluntarily	ADV
ajlm-2375	46	3	signed	sign	VERB
ajlm-2375	46	4	a	a	DET
ajlm-2375	46	5	written	write	VERB
ajlm-2375	46	6	informed	inform	VERB
ajlm-2375	46	7	consent	consent	NOUN
ajlm-2375	46	8	.	.	PUNCT
ajlm-2375	47	1	procedures	procedure	NOUN
ajlm-2375	47	2	were	be	AUX
ajlm-2375	47	3	carried	carry	VERB
ajlm-2375	47	4	out	out	ADP
ajlm-2375	47	5	in	in	ADP
ajlm-2375	47	6	agreement	agreement	NOUN
ajlm-2375	47	7	with	with	ADP
ajlm-2375	47	8	the	the	DET
ajlm-2375	47	9	declaration	declaration	NOUN
ajlm-2375	47	10	of	of	ADP
ajlm-2375	47	11	helsinki	helsinki	PROPN
ajlm-2375	47	12	.	.	PUNCT
ajlm-2375	48	1	patients	patient	NOUN
ajlm-2375	48	2	’	’	PART
ajlm-2375	48	3	data	datum	NOUN
ajlm-2375	48	4	files	file	NOUN
ajlm-2375	48	5	and	and	CCONJ
ajlm-2375	48	6	sample	sample	NOUN
ajlm-2375	48	7	tubes	tube	NOUN
ajlm-2375	48	8	were	be	AUX
ajlm-2375	48	9	coded	code	VERB
ajlm-2375	48	10	,	,	PUNCT
ajlm-2375	48	11	so	so	SCONJ
ajlm-2375	48	12	laboratory	laboratory	NOUN
ajlm-2375	48	13	workers	worker	NOUN
ajlm-2375	48	14	were	be	AUX
ajlm-2375	48	15	blinded	blind	VERB
ajlm-2375	48	16	to	to	ADP
ajlm-2375	48	17	patients	patient	NOUN
ajlm-2375	48	18	’	'	PUNCT
ajlm-2375	48	19	information	information	NOUN
ajlm-2375	48	20	.	.	PUNCT
ajlm-2375	49	1	study	study	NOUN
ajlm-2375	49	2	design	design	NOUN
ajlm-2375	49	3	and	and	CCONJ
ajlm-2375	49	4	patient	patient	ADJ
ajlm-2375	49	5	criteria	criterion	NOUN
ajlm-2375	49	6	this	this	DET
ajlm-2375	49	7	prospective	prospective	ADJ
ajlm-2375	49	8	cohort	cohort	NOUN
ajlm-2375	49	9	study	study	NOUN
ajlm-2375	49	10	was	be	AUX
ajlm-2375	49	11	performed	perform	VERB
ajlm-2375	49	12	in	in	ADP
ajlm-2375	49	13	the	the	DET
ajlm-2375	49	14	biochemistry	biochemistry	NOUN
ajlm-2375	49	15	and	and	CCONJ
ajlm-2375	49	16	clinical	clinical	ADJ
ajlm-2375	49	17	pathology	pathology	NOUN
ajlm-2375	49	18	departments	department	NOUN
ajlm-2375	49	19	in	in	ADP
ajlm-2375	49	20	collaboration	collaboration	NOUN
ajlm-2375	49	21	with	with	ADP
ajlm-2375	49	22	the	the	DET
ajlm-2375	49	23	scientific	scientific	ADJ
ajlm-2375	49	24	and	and	CCONJ
ajlm-2375	49	25	medical	medical	ADJ
ajlm-2375	49	26	research	research	NOUN
ajlm-2375	49	27	center	center	NOUN
ajlm-2375	49	28	,	,	PUNCT
ajlm-2375	49	29	faculty	faculty	NOUN
ajlm-2375	49	30	of	of	ADP
ajlm-2375	49	31	medicine	medicine	NOUN
ajlm-2375	49	32	,	,	PUNCT
ajlm-2375	49	33	zagazig	zagazig	PROPN
ajlm-2375	49	34	university	university	PROPN
ajlm-2375	49	35	,	,	PUNCT
ajlm-2375	49	36	zagazig	zagazig	PROPN
ajlm-2375	49	37	,	,	PUNCT
ajlm-2375	49	38	egypt	egypt	PROPN
ajlm-2375	49	39	,	,	PUNCT
ajlm-2375	49	40	from	from	ADP
ajlm-2375	49	41	01	01	NUM
ajlm-2375	49	42	july	july	PROPN
ajlm-2375	49	43	2021	2021	NUM
ajlm-2375	49	44	to	to	ADP
ajlm-2375	49	45	30	30	NUM
ajlm-2375	49	46	november	november	PROPN
ajlm-2375	49	47	2021	2021	NUM
ajlm-2375	49	48	.	.	PUNCT
ajlm-2375	50	1	the	the	DET
ajlm-2375	50	2	study	study	NOUN
ajlm-2375	50	3	included	include	VERB
ajlm-2375	50	4	100	100	NUM
ajlm-2375	50	5	consecutive	consecutive	ADJ
ajlm-2375	50	6	patients	patient	NOUN
ajlm-2375	50	7	,	,	PUNCT
ajlm-2375	50	8	≥	≥	NOUN
ajlm-2375	50	9	18	18	NUM
ajlm-2375	50	10	years	year	NOUN
ajlm-2375	50	11	old	old	ADJ
ajlm-2375	50	12	,	,	PUNCT
ajlm-2375	50	13	from	from	ADP
ajlm-2375	50	14	both	both	DET
ajlm-2375	50	15	genders	gender	NOUN
ajlm-2375	50	16	and	and	CCONJ
ajlm-2375	50	17	the	the	DET
ajlm-2375	50	18	same	same	ADJ
ajlm-2375	50	19	ethnicity	ethnicity	NOUN
ajlm-2375	50	20	,	,	PUNCT
ajlm-2375	50	21	admitted	admit	VERB
ajlm-2375	50	22	to	to	ADP
ajlm-2375	50	23	the	the	DET
ajlm-2375	50	24	covid-19	covid-19	PROPN
ajlm-2375	50	25	clinic	clinic	NOUN
ajlm-2375	50	26	,	,	PUNCT
ajlm-2375	50	27	isolation	isolation	NOUN
ajlm-2375	50	28	and	and	CCONJ
ajlm-2375	50	29	intensive	intensive	ADJ
ajlm-2375	50	30	care	care	NOUN
ajlm-2375	50	31	units	unit	NOUN
ajlm-2375	50	32	of	of	ADP
ajlm-2375	50	33	the	the	DET
ajlm-2375	50	34	zagazig	zagazig	PROPN
ajlm-2375	50	35	university	university	PROPN
ajlm-2375	50	36	hospitals	hospital	NOUN
ajlm-2375	50	37	,	,	PUNCT
ajlm-2375	50	38	zagazig	zagazig	PROPN
ajlm-2375	50	39	,	,	PUNCT
ajlm-2375	50	40	egypt	egypt	PROPN
ajlm-2375	50	41	.	.	PUNCT
ajlm-2375	51	1	patients	patient	NOUN
ajlm-2375	51	2	who	who	PRON
ajlm-2375	51	3	refused	refuse	VERB
ajlm-2375	51	4	to	to	PART
ajlm-2375	51	5	participate	participate	VERB
ajlm-2375	51	6	were	be	AUX
ajlm-2375	51	7	excluded	exclude	VERB
ajlm-2375	51	8	from	from	ADP
ajlm-2375	51	9	the	the	DET
ajlm-2375	51	10	study	study	NOUN
ajlm-2375	51	11	.	.	PUNCT
ajlm-2375	52	1	diagnosis	diagnosis	NOUN
ajlm-2375	52	2	and	and	CCONJ
ajlm-2375	52	3	routine	routine	ADJ
ajlm-2375	52	4	investigations	investigation	NOUN
ajlm-2375	52	5	patients	patient	NOUN
ajlm-2375	52	6	were	be	AUX
ajlm-2375	52	7	selected	select	VERB
ajlm-2375	52	8	based	base	VERB
ajlm-2375	52	9	on	on	ADP
ajlm-2375	52	10	the	the	DET
ajlm-2375	52	11	covid-19	covid-19	PROPN
ajlm-2375	52	12	case	case	NOUN
ajlm-2375	52	13	definition	definition	NOUN
ajlm-2375	52	14	provided	provide	VERB
ajlm-2375	52	15	by	by	ADP
ajlm-2375	52	16	the	the	DET
ajlm-2375	52	17	world	world	NOUN
ajlm-2375	52	18	health	health	NOUN
ajlm-2375	52	19	organization.12	organization.12	NOUN
ajlm-2375	52	20	nasopharyngeal	nasopharyngeal	ADJ
ajlm-2375	52	21	and	and	CCONJ
ajlm-2375	52	22	oropharyngeal	oropharyngeal	ADJ
ajlm-2375	52	23	swabs	swab	NOUN
ajlm-2375	52	24	were	be	AUX
ajlm-2375	52	25	collected	collect	VERB
ajlm-2375	52	26	and	and	CCONJ
ajlm-2375	52	27	processed	process	VERB
ajlm-2375	52	28	according	accord	VERB
ajlm-2375	52	29	to	to	ADP
ajlm-2375	52	30	the	the	DET
ajlm-2375	52	31	centres	centre	NOUN
ajlm-2375	52	32	for	for	ADP
ajlm-2375	52	33	disease	disease	NOUN
ajlm-2375	52	34	control	control	NOUN
ajlm-2375	52	35	guidelines.13	guidelines.13	VERB
ajlm-2375	52	36	the	the	DET
ajlm-2375	52	37	diagnosis	diagnosis	NOUN
ajlm-2375	52	38	of	of	ADP
ajlm-2375	52	39	covid-19	covid-19	PROPN
ajlm-2375	52	40	patients	patient	NOUN
ajlm-2375	52	41	was	be	AUX
ajlm-2375	52	42	made	make	VERB
ajlm-2375	52	43	by	by	ADP
ajlm-2375	52	44	real	real	ADJ
ajlm-2375	52	45	-	-	PUNCT
ajlm-2375	52	46	time	time	NOUN
ajlm-2375	52	47	polymerase	polymerase	NOUN
ajlm-2375	52	48	chain	chain	NOUN
ajlm-2375	52	49	reaction	reaction	NOUN
ajlm-2375	52	50	(	(	PUNCT
ajlm-2375	52	51	pcr	pcr	NOUN
ajlm-2375	52	52	)	)	PUNCT
ajlm-2375	52	53	of	of	ADP
ajlm-2375	52	54	the	the	DET
ajlm-2375	52	55	collected	collect	VERB
ajlm-2375	52	56	swabs	swab	NOUN
ajlm-2375	52	57	,	,	PUNCT
ajlm-2375	52	58	at	at	ADP
ajlm-2375	52	59	the	the	DET
ajlm-2375	52	60	scientific	scientific	ADJ
ajlm-2375	52	61	and	and	CCONJ
ajlm-2375	52	62	medical	medical	ADJ
ajlm-2375	52	63	research	research	NOUN
ajlm-2375	52	64	centre	centre	NOUN
ajlm-2375	52	65	according	accord	VERB
ajlm-2375	52	66	to	to	ADP
ajlm-2375	52	67	the	the	DET
ajlm-2375	52	68	guidelines	guideline	NOUN
ajlm-2375	52	69	of	of	ADP
ajlm-2375	52	70	the	the	DET
ajlm-2375	52	71	egyptian	egyptian	PROPN
ajlm-2375	52	72	ministry	ministry	PROPN
ajlm-2375	52	73	of	of	ADP
ajlm-2375	52	74	health	health	PROPN
ajlm-2375	52	75	and	and	CCONJ
ajlm-2375	52	76	as	as	SCONJ
ajlm-2375	52	77	described	describe	VERB
ajlm-2375	52	78	previously.14	previously.14	NOUN
ajlm-2375	52	79	cycle	cycle	NOUN
ajlm-2375	52	80	threshold	threshold	NOUN
ajlm-2375	52	81	values	value	NOUN
ajlm-2375	52	82	were	be	AUX
ajlm-2375	52	83	used	use	VERB
ajlm-2375	52	84	as	as	ADP
ajlm-2375	52	85	an	an	DET
ajlm-2375	52	86	indicator	indicator	NOUN
ajlm-2375	52	87	of	of	ADP
ajlm-2375	52	88	viral	viral	ADJ
ajlm-2375	52	89	load.15	load.15	NOUN
ajlm-2375	52	90	routine	routine	ADJ
ajlm-2375	52	91	laboratory	laboratory	NOUN
ajlm-2375	52	92	workup	workup	PROPN
ajlm-2375	52	93	data	datum	NOUN
ajlm-2375	52	94	including	include	VERB
ajlm-2375	52	95	full	full	ADJ
ajlm-2375	52	96	blood	blood	NOUN
ajlm-2375	52	97	counts	count	NOUN
ajlm-2375	52	98	,	,	PUNCT
ajlm-2375	52	99	liver	liver	NOUN
ajlm-2375	52	100	,	,	PUNCT
ajlm-2375	52	101	kidney	kidney	NOUN
ajlm-2375	52	102	function	function	NOUN
ajlm-2375	52	103	tests	test	NOUN
ajlm-2375	52	104	,	,	PUNCT
ajlm-2375	52	105	c	c	NOUN
ajlm-2375	52	106	reactive	reactive	ADJ
ajlm-2375	52	107	protein	protein	NOUN
ajlm-2375	52	108	(	(	PUNCT
ajlm-2375	52	109	crp	crp	PROPN
ajlm-2375	52	110	)	)	PUNCT
ajlm-2375	52	111	,	,	PUNCT
ajlm-2375	52	112	lactate	lactate	NOUN
ajlm-2375	52	113	dehydrogenase	dehydrogenase	NOUN
ajlm-2375	52	114	,	,	PUNCT
ajlm-2375	52	115	plasma	plasma	NOUN
ajlm-2375	52	116	ferritin	ferritin	NOUN
ajlm-2375	52	117	,	,	PUNCT
ajlm-2375	52	118	troponin	troponin	PROPN
ajlm-2375	52	119	t	t	PROPN
ajlm-2375	52	120	,	,	PUNCT
ajlm-2375	52	121	and	and	CCONJ
ajlm-2375	52	122	d	d	X
ajlm-2375	52	123	dimer	dimer	NOUN
ajlm-2375	52	124	were	be	AUX
ajlm-2375	52	125	collected	collect	VERB
ajlm-2375	52	126	from	from	ADP
ajlm-2375	52	127	patients	patient	NOUN
ajlm-2375	52	128	’	'	PUNCT
ajlm-2375	52	129	files	file	NOUN
ajlm-2375	52	130	.	.	PUNCT
ajlm-2375	53	1	additionally	additionally	ADV
ajlm-2375	53	2	,	,	PUNCT
ajlm-2375	53	3	all	all	DET
ajlm-2375	53	4	patients	patient	NOUN
ajlm-2375	53	5	underwent	undergo	VERB
ajlm-2375	53	6	routine	routine	ADJ
ajlm-2375	53	7	chest	chest	NOUN
ajlm-2375	53	8	computed	compute	VERB
ajlm-2375	53	9	tomography	tomography	NOUN
ajlm-2375	53	10	scans	scan	NOUN
ajlm-2375	53	11	;	;	PUNCT
ajlm-2375	53	12	results	result	NOUN
ajlm-2375	53	13	were	be	AUX
ajlm-2375	53	14	collected	collect	VERB
ajlm-2375	53	15	from	from	ADP
ajlm-2375	53	16	patients	patient	NOUN
ajlm-2375	53	17	’	'	PUNCT
ajlm-2375	53	18	files	file	NOUN
ajlm-2375	53	19	after	after	ADP
ajlm-2375	53	20	obtaining	obtain	VERB
ajlm-2375	53	21	the	the	DET
ajlm-2375	53	22	required	required	ADJ
ajlm-2375	53	23	permissions	permission	NOUN
ajlm-2375	53	24	.	.	PUNCT
ajlm-2375	54	1	the	the	DET
ajlm-2375	54	2	egyptian	egyptian	PROPN
ajlm-2375	54	3	ministry	ministry	PROPN
ajlm-2375	54	4	of	of	ADP
ajlm-2375	54	5	health	health	PROPN
ajlm-2375	54	6	and	and	CCONJ
ajlm-2375	54	7	population	population	NOUN
ajlm-2375	54	8	management	management	NOUN
ajlm-2375	54	9	roles	role	NOUN
ajlm-2375	54	10	were	be	AUX
ajlm-2375	54	11	applied	apply	VERB
ajlm-2375	54	12	to	to	PART
ajlm-2375	54	13	stratify	stratify	VERB
ajlm-2375	54	14	confirmed	confirm	VERB
ajlm-2375	54	15	patients	patient	NOUN
ajlm-2375	54	16	based	base	VERB
ajlm-2375	54	17	on	on	ADP
ajlm-2375	54	18	severity	severity	NOUN
ajlm-2375	54	19	.	.	PUNCT
ajlm-2375	55	1	mild	mild	ADJ
ajlm-2375	55	2	cases	case	NOUN
ajlm-2375	55	3	include	include	VERB
ajlm-2375	55	4	all	all	DET
ajlm-2375	55	5	symptomatic	symptomatic	ADJ
ajlm-2375	55	6	patients	patient	NOUN
ajlm-2375	55	7	with	with	ADP
ajlm-2375	55	8	no	no	DET
ajlm-2375	55	9	radiological	radiological	ADJ
ajlm-2375	55	10	signs	sign	NOUN
ajlm-2375	55	11	of	of	ADP
ajlm-2375	55	12	pneumonia	pneumonia	NOUN
ajlm-2375	55	13	.	.	PUNCT
ajlm-2375	56	1	moderate	moderate	ADJ
ajlm-2375	56	2	cases	case	NOUN
ajlm-2375	56	3	are	be	AUX
ajlm-2375	56	4	those	those	PRON
ajlm-2375	56	5	with	with	ADP
ajlm-2375	56	6	pneumonia	pneumonia	NOUN
ajlm-2375	56	7	manifestation	manifestation	NOUN
ajlm-2375	56	8	with	with	ADP
ajlm-2375	56	9	positive	positive	ADJ
ajlm-2375	56	10	radiological	radiological	ADJ
ajlm-2375	56	11	signs	sign	NOUN
ajlm-2375	56	12	and	and	CCONJ
ajlm-2375	56	13	do	do	AUX
ajlm-2375	56	14	not	not	PART
ajlm-2375	56	15	meet	meet	VERB
ajlm-2375	56	16	the	the	DET
ajlm-2375	56	17	criteria	criterion	NOUN
ajlm-2375	56	18	of	of	ADP
ajlm-2375	56	19	severe	severe	ADJ
ajlm-2375	56	20	cases	case	NOUN
ajlm-2375	56	21	.	.	PUNCT
ajlm-2375	57	1	severe	severe	ADJ
ajlm-2375	57	2	cases	case	NOUN
ajlm-2375	57	3	are	be	AUX
ajlm-2375	57	4	those	those	PRON
ajlm-2375	57	5	with	with	ADP
ajlm-2375	57	6	a	a	DET
ajlm-2375	57	7	respiratory	respiratory	ADJ
ajlm-2375	57	8	rate	rate	NOUN
ajlm-2375	57	9	>	>	X
ajlm-2375	57	10	30	30	NUM
ajlm-2375	57	11	,	,	PUNCT
ajlm-2375	57	12	oxygen	oxygen	NOUN
ajlm-2375	57	13	saturation	saturation	NOUN
ajlm-2375	57	14	at	at	ADP
ajlm-2375	57	15	room	room	NOUN
ajlm-2375	57	16	air	air	NOUN
ajlm-2375	57	17	<	<	X
ajlm-2375	57	18	92	92	NUM
ajlm-2375	57	19	,	,	PUNCT
ajlm-2375	57	20	and	and	CCONJ
ajlm-2375	57	21	chest	chest	NOUN
ajlm-2375	57	22	imaging	imaging	NOUN
ajlm-2375	57	23	showing	show	VERB
ajlm-2375	57	24	>	>	X
ajlm-2375	57	25	50	50	NUM
ajlm-2375	57	26	%	%	NOUN
ajlm-2375	57	27	lesions	lesion	NOUN
ajlm-2375	57	28	or	or	CCONJ
ajlm-2375	57	29	progressive	progressive	ADJ
ajlm-2375	57	30	lesions	lesion	NOUN
ajlm-2375	57	31	within	within	ADP
ajlm-2375	57	32	1	1	NUM
ajlm-2375	57	33	day	day	NOUN
ajlm-2375	57	34	or	or	CCONJ
ajlm-2375	57	35	2	2	NUM
ajlm-2375	57	36	days	day	NOUN
ajlm-2375	57	37	,	,	PUNCT
ajlm-2375	57	38	while	while	SCONJ
ajlm-2375	57	39	critically	critically	ADV
ajlm-2375	57	40	ill	ill	ADJ
ajlm-2375	57	41	patients	patient	NOUN
ajlm-2375	57	42	are	be	AUX
ajlm-2375	57	43	severe	severe	ADJ
ajlm-2375	57	44	patients	patient	NOUN
ajlm-2375	57	45	who	who	PRON
ajlm-2375	57	46	still	still	ADV
ajlm-2375	57	47	have	have	VERB
ajlm-2375	57	48	oxygen	oxygen	NOUN
ajlm-2375	57	49	saturation	saturation	NOUN
ajlm-2375	57	50	at	at	ADP
ajlm-2375	57	51	room	room	NOUN
ajlm-2375	57	52	air	air	NOUN
ajlm-2375	57	53	<	<	X
ajlm-2375	57	54	92	92	NUM
ajlm-2375	57	55	or	or	CCONJ
ajlm-2375	57	56	respiratory	respiratory	ADJ
ajlm-2375	57	57	rate	rate	NOUN
ajlm-2375	57	58	>	>	X
ajlm-2375	57	59	30	30	NUM
ajlm-2375	57	60	,	,	PUNCT
ajlm-2375	57	61	despite	despite	SCONJ
ajlm-2375	57	62	receiving	receive	VERB
ajlm-2375	57	63	oxygen	oxygen	NOUN
ajlm-2375	57	64	therapy.14	therapy.14	PROPN
ajlm-2375	57	65	asymptomatic	asymptomatic	ADJ
ajlm-2375	57	66	,	,	PUNCT
ajlm-2375	57	67	mild	mild	ADJ
ajlm-2375	57	68	,	,	PUNCT
ajlm-2375	57	69	and	and	CCONJ
ajlm-2375	57	70	moderate	moderate	ADJ
ajlm-2375	57	71	cases	case	NOUN
ajlm-2375	57	72	without	without	ADP
ajlm-2375	57	73	risk	risk	NOUN
ajlm-2375	57	74	were	be	AUX
ajlm-2375	57	75	referred	refer	VERB
ajlm-2375	57	76	to	to	ADP
ajlm-2375	57	77	home	home	NOUN
ajlm-2375	57	78	isolation	isolation	NOUN
ajlm-2375	57	79	with	with	ADP
ajlm-2375	57	80	close	close	ADJ
ajlm-2375	57	81	follow	follow	NOUN
ajlm-2375	57	82	-	-	PUNCT
ajlm-2375	57	83	up	up	NOUN
ajlm-2375	57	84	.	.	PUNCT
ajlm-2375	58	1	conversely	conversely	ADV
ajlm-2375	58	2	,	,	PUNCT
ajlm-2375	58	3	moderate	moderate	ADJ
ajlm-2375	58	4	cases	case	NOUN
ajlm-2375	58	5	were	be	AUX
ajlm-2375	58	6	hospitalized	hospitalize	VERB
ajlm-2375	58	7	in	in	ADP
ajlm-2375	58	8	covid-19	covid-19	PROPN
ajlm-2375	58	9	areas	area	NOUN
ajlm-2375	58	10	,	,	PUNCT
ajlm-2375	58	11	severe	severe	ADJ
ajlm-2375	58	12	cases	case	NOUN
ajlm-2375	58	13	were	be	AUX
ajlm-2375	58	14	hospitalized	hospitalize	VERB
ajlm-2375	58	15	in	in	ADP
ajlm-2375	58	16	intermediate	intermediate	ADJ
ajlm-2375	58	17	care	care	NOUN
ajlm-2375	58	18	units	unit	NOUN
ajlm-2375	58	19	,	,	PUNCT
ajlm-2375	58	20	while	while	SCONJ
ajlm-2375	58	21	critically	critically	ADV
ajlm-2375	58	22	ill	ill	ADJ
ajlm-2375	58	23	patients	patient	NOUN
ajlm-2375	58	24	were	be	AUX
ajlm-2375	58	25	hospitalized	hospitalize	VERB
ajlm-2375	58	26	in	in	ADP
ajlm-2375	58	27	intensive	intensive	ADJ
ajlm-2375	58	28	care	care	NOUN
ajlm-2375	58	29	units	unit	NOUN
ajlm-2375	58	30	.	.	PUNCT
ajlm-2375	59	1	therapy	therapy	NOUN
ajlm-2375	59	2	was	be	AUX
ajlm-2375	59	3	carried	carry	VERB
ajlm-2375	59	4	out	out	ADP
ajlm-2375	59	5	according	accord	VERB
ajlm-2375	59	6	to	to	ADP
ajlm-2375	59	7	the	the	DET
ajlm-2375	59	8	aforementioned	aforementioned	ADJ
ajlm-2375	59	9	guidelines	guideline	NOUN
ajlm-2375	59	10	.	.	PUNCT
ajlm-2375	60	1	routine	routine	ADJ
ajlm-2375	60	2	laboratory	laboratory	NOUN
ajlm-2375	60	3	workup	workup	PROPN
ajlm-2375	60	4	was	be	AUX
ajlm-2375	60	5	performed	perform	VERB
ajlm-2375	60	6	in	in	ADP
ajlm-2375	60	7	the	the	DET
ajlm-2375	60	8	clinical	clinical	ADJ
ajlm-2375	60	9	pathology	pathology	NOUN
ajlm-2375	60	10	department	department	NOUN
ajlm-2375	60	11	laboratories	laboratory	NOUN
ajlm-2375	60	12	.	.	PUNCT
ajlm-2375	61	1	based	base	VERB
ajlm-2375	61	2	on	on	ADP
ajlm-2375	61	3	the	the	DET
ajlm-2375	61	4	severity	severity	NOUN
ajlm-2375	61	5	,	,	PUNCT
ajlm-2375	61	6	patients	patient	NOUN
ajlm-2375	61	7	were	be	AUX
ajlm-2375	61	8	classified	classify	VERB
ajlm-2375	61	9	as	as	ADP
ajlm-2375	61	10	mild	mild	ADJ
ajlm-2375	61	11	,	,	PUNCT
ajlm-2375	61	12	moderate	moderate	ADJ
ajlm-2375	61	13	,	,	PUNCT
ajlm-2375	61	14	or	or	CCONJ
ajlm-2375	61	15	severe	severe	ADJ
ajlm-2375	61	16	cases	case	NOUN
ajlm-2375	61	17	,	,	PUNCT
ajlm-2375	61	18	and	and	CCONJ
ajlm-2375	61	19	based	base	VERB
ajlm-2375	61	20	on	on	ADP
ajlm-2375	61	21	the	the	DET
ajlm-2375	61	22	outcome	outcome	NOUN
ajlm-2375	61	23	patients	patient	NOUN
ajlm-2375	61	24	were	be	AUX
ajlm-2375	61	25	classified	classify	VERB
ajlm-2375	61	26	as	as	SCONJ
ajlm-2375	61	27	survived	survive	VERB
ajlm-2375	61	28	and	and	CCONJ
ajlm-2375	61	29	died	die	VERB
ajlm-2375	61	30	.	.	PUNCT
ajlm-2375	62	1	demographic	demographic	ADJ
ajlm-2375	62	2	criteria	criterion	NOUN
ajlm-2375	62	3	,	,	PUNCT
ajlm-2375	62	4	history	history	NOUN
ajlm-2375	62	5	of	of	ADP
ajlm-2375	62	6	vaccination	vaccination	NOUN
ajlm-2375	62	7	,	,	PUNCT
ajlm-2375	62	8	comorbidities	comorbiditie	NOUN
ajlm-2375	62	9	,	,	PUNCT
ajlm-2375	62	10	occurrence	occurrence	NOUN
ajlm-2375	62	11	of	of	ADP
ajlm-2375	62	12	complications	complication	NOUN
ajlm-2375	62	13	,	,	PUNCT
ajlm-2375	62	14	viral	viral	ADJ
ajlm-2375	62	15	load	load	NOUN
ajlm-2375	62	16	,	,	PUNCT
ajlm-2375	62	17	and	and	CCONJ
ajlm-2375	62	18	laboratory	laboratory	NOUN
ajlm-2375	62	19	results	result	NOUN
ajlm-2375	62	20	were	be	AUX
ajlm-2375	62	21	compared	compare	VERB
ajlm-2375	62	22	in	in	ADP
ajlm-2375	62	23	between	between	ADP
ajlm-2375	62	24	each	each	DET
ajlm-2375	62	25	two	two	NUM
ajlm-2375	62	26	groups	group	NOUN
ajlm-2375	62	27	.	.	PUNCT
ajlm-2375	63	1	according	accord	VERB
ajlm-2375	63	2	to	to	ADP
ajlm-2375	63	3	the	the	DET
ajlm-2375	63	4	guidelines	guideline	NOUN
ajlm-2375	63	5	of	of	ADP
ajlm-2375	63	6	the	the	DET
ajlm-2375	63	7	egyptian	egyptian	PROPN
ajlm-2375	63	8	ministry	ministry	PROPN
ajlm-2375	63	9	of	of	ADP
ajlm-2375	63	10	health	health	PROPN
ajlm-2375	63	11	,	,	PUNCT
ajlm-2375	63	12	parenteral	parenteral	ADJ
ajlm-2375	63	13	prophylactic	prophylactic	ADJ
ajlm-2375	63	14	anticoagulants	anticoagulant	NOUN
ajlm-2375	63	15	were	be	AUX
ajlm-2375	63	16	prescribed	prescribe	VERB
ajlm-2375	63	17	for	for	SCONJ
ajlm-2375	63	18	hospitalised	hospitalise	VERB
ajlm-2375	63	19	patients	patient	NOUN
ajlm-2375	63	20	to	to	PART
ajlm-2375	63	21	guard	guard	VERB
ajlm-2375	63	22	against	against	ADP
ajlm-2375	63	23	cardiovascular	cardiovascular	ADJ
ajlm-2375	63	24	complications	complication	NOUN
ajlm-2375	63	25	.	.	PUNCT
ajlm-2375	64	1	in	in	ADP
ajlm-2375	64	2	case	case	NOUN
ajlm-2375	64	3	of	of	ADP
ajlm-2375	64	4	suspected	suspect	VERB
ajlm-2375	64	5	pulmonary	pulmonary	ADJ
ajlm-2375	64	6	embolism	embolism	NOUN
ajlm-2375	64	7	,	,	PUNCT
ajlm-2375	64	8	as	as	SCONJ
ajlm-2375	64	9	most	most	ADJ
ajlm-2375	64	10	of	of	ADP
ajlm-2375	64	11	these	these	DET
ajlm-2375	64	12	patients	patient	NOUN
ajlm-2375	64	13	are	be	AUX
ajlm-2375	64	14	haemodynamically	haemodynamically	ADV
ajlm-2375	64	15	unstable	unstable	ADJ
ajlm-2375	64	16	,	,	PUNCT
ajlm-2375	64	17	and	and	CCONJ
ajlm-2375	64	18	because	because	SCONJ
ajlm-2375	64	19	of	of	ADP
ajlm-2375	64	20	the	the	DET
ajlm-2375	64	21	risk	risk	NOUN
ajlm-2375	64	22	of	of	ADP
ajlm-2375	64	23	medical	medical	ADJ
ajlm-2375	64	24	staff	staff	NOUN
ajlm-2375	64	25	exposure	exposure	NOUN
ajlm-2375	64	26	to	to	ADP
ajlm-2375	64	27	infection	infection	NOUN
ajlm-2375	64	28	,	,	PUNCT
ajlm-2375	64	29	diagnosis	diagnosis	NOUN
ajlm-2375	64	30	was	be	AUX
ajlm-2375	64	31	based	base	VERB
ajlm-2375	64	32	on	on	ADP
ajlm-2375	64	33	echocardiography	echocardiography	NOUN
ajlm-2375	64	34	and	and	CCONJ
ajlm-2375	64	35	d	d	NOUN
ajlm-2375	64	36	-	-	PUNCT
ajlm-2375	64	37	dimer	dimer	ADJ
ajlm-2375	64	38	level	level	NOUN
ajlm-2375	64	39	rather	rather	ADV
ajlm-2375	64	40	than	than	ADP
ajlm-2375	64	41	ct	ct	PROPN
ajlm-2375	64	42	-	-	PUNCT
ajlm-2375	64	43	angiography.16	angiography.16	PROPN
ajlm-2375	64	44	genotyping	genotyping	NOUN
ajlm-2375	64	45	according	accord	VERB
ajlm-2375	64	46	to	to	ADP
ajlm-2375	64	47	manufacturers	manufacturer	NOUN
ajlm-2375	64	48	’	’	PART
ajlm-2375	64	49	guidelines	guideline	NOUN
ajlm-2375	64	50	,	,	PUNCT
ajlm-2375	64	51	a	a	DET
ajlm-2375	64	52	volume	volume	NOUN
ajlm-2375	64	53	of	of	ADP
ajlm-2375	64	54	2	2	NUM
ajlm-2375	64	55	ml	ml	NOUN
ajlm-2375	64	56	of	of	ADP
ajlm-2375	64	57	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-2375	64	58	acid	acid	NOUN
ajlm-2375	64	59	anti	anti	ADJ
ajlm-2375	64	60	-	-	ADJ
ajlm-2375	64	61	coagulated	coagulated	ADJ
ajlm-2375	64	62	blood	blood	NOUN
ajlm-2375	64	63	was	be	AUX
ajlm-2375	64	64	obtained	obtain	VERB
ajlm-2375	64	65	for	for	ADP
ajlm-2375	64	66	dna	dna	NOUN
ajlm-2375	64	67	extraction	extraction	NOUN
ajlm-2375	64	68	using	use	VERB
ajlm-2375	64	69	the	the	DET
ajlm-2375	64	70	qiaamp	qiaamp	ADJ
ajlm-2375	64	71	blood	blood	NOUN
ajlm-2375	64	72	kit	kit	NOUN
ajlm-2375	64	73	(	(	PUNCT
ajlm-2375	64	74	qiagen	qiagen	PROPN
ajlm-2375	64	75	gmbh	gmbh	PROPN
ajlm-2375	64	76	,	,	PUNCT
ajlm-2375	64	77	hilden	hilden	PROPN
ajlm-2375	64	78	,	,	PUNCT
ajlm-2375	64	79	germany	germany	PROPN
ajlm-2375	64	80	)	)	PUNCT
ajlm-2375	64	81	.	.	PUNCT
ajlm-2375	65	1	for	for	ADP
ajlm-2375	65	2	the	the	DET
ajlm-2375	65	3	ace2	ace2	PROPN
ajlm-2375	65	4	snp	snp	PROPN
ajlm-2375	65	5	,	,	PUNCT
ajlm-2375	65	6	rs2285666	rs2285666	ADJ
ajlm-2375	65	7	,	,	PUNCT
ajlm-2375	65	8	pcr	pcr	NOUN
ajlm-2375	65	9	and	and	CCONJ
ajlm-2375	65	10	restriction	restriction	NOUN
ajlm-2375	65	11	fragment	fragment	NOUN
ajlm-2375	65	12	length	length	NOUN
ajlm-2375	65	13	polymorphism	polymorphism	NOUN
ajlm-2375	65	14	were	be	AUX
ajlm-2375	65	15	used	use	VERB
ajlm-2375	65	16	with	with	ADP
ajlm-2375	65	17	the	the	DET
ajlm-2375	65	18	primers	primer	NOUN
ajlm-2375	65	19	:	:	PUNCT
ajlm-2375	65	20	forward	forward	ADV
ajlm-2375	65	21	5′-cat	5′-cat	NUM
ajlm-2375	65	22	gtg	gtg	PROPN
ajlm-2375	65	23	gtc	gtc	PROPN
ajlm-2375	65	24	aaa	aaa	PROPN
ajlm-2375	65	25	agg	agg	PROPN
ajlm-2375	65	26	ata	ata	PROPN
ajlm-2375	65	27	tct-3′	tct-3′	PROPN
ajlm-2375	65	28	and	and	CCONJ
ajlm-2375	65	29	reverse	reverse	VERB
ajlm-2375	65	30	5′-aaa	5′-aaa	PROPN
ajlm-2375	65	31	gta	gta	PROPN
ajlm-2375	65	32	agg	agg	PROPN
ajlm-2375	65	33	ttg	ttg	PROPN
ajlm-2375	65	34	gca	gca	PROPN
ajlm-2375	65	35	gac	gac	PROPN
ajlm-2375	65	36	at-3′.	at-3′.	PROPN
ajlm-2375	65	37	polymerase	polymerase	NOUN
ajlm-2375	65	38	chain	chain	NOUN
ajlm-2375	65	39	reaction	reaction	NOUN
ajlm-2375	65	40	mixture	mixture	NOUN
ajlm-2375	65	41	included	include	VERB
ajlm-2375	65	42	12.5	12.5	NUM
ajlm-2375	65	43	µl	µl	NOUN
ajlm-2375	65	44	of	of	ADP
ajlm-2375	65	45	dreamtaq	dreamtaq	VERB
ajlm-2375	65	46	green	green	ADJ
ajlm-2375	65	47	pcr	pcr	PROPN
ajlm-2375	65	48	master	master	NOUN
ajlm-2375	65	49	mix	mix	NOUN
ajlm-2375	65	50	(	(	PUNCT
ajlm-2375	65	51	thermo	thermo	NOUN
ajlm-2375	65	52	scientific	scientific	ADJ
ajlm-2375	65	53	™	™	PROPN
ajlm-2375	65	54	,	,	PUNCT
ajlm-2375	65	55	vilnius	vilnius	PROPN
ajlm-2375	65	56	,	,	PUNCT
ajlm-2375	65	57	lithuania	lithuania	PROPN
ajlm-2375	65	58	)	)	PUNCT
ajlm-2375	65	59	,	,	PUNCT
ajlm-2375	65	60	10	10	NUM
ajlm-2375	65	61	pmol	pmol	NOUN
ajlm-2375	65	62	of	of	ADP
ajlm-2375	65	63	forward	forward	ADV
ajlm-2375	65	64	and	and	CCONJ
ajlm-2375	65	65	reverse	reverse	ADJ
ajlm-2375	65	66	primers	primer	NOUN
ajlm-2375	65	67	,	,	PUNCT
ajlm-2375	65	68	100	100	NUM
ajlm-2375	65	69	ng	ng	NOUN
ajlm-2375	65	70	of	of	ADP
ajlm-2375	65	71	extracted	extract	VERB
ajlm-2375	65	72	genomic	genomic	ADJ
ajlm-2375	65	73	dna	dna	NOUN
ajlm-2375	65	74	,	,	PUNCT
ajlm-2375	65	75	and	and	CCONJ
ajlm-2375	65	76	nucleases	nuclease	NOUN
ajlm-2375	65	77	-	-	PUNCT
ajlm-2375	65	78	free	free	ADJ
ajlm-2375	65	79	water	water	NOUN
ajlm-2375	65	80	up	up	ADP
ajlm-2375	65	81	to	to	PART
ajlm-2375	65	82	25	25	NUM
ajlm-2375	65	83	µl	µl	NOUN
ajlm-2375	65	84	.	.	PUNCT
ajlm-2375	66	1	the	the	DET
ajlm-2375	66	2	thermal	thermal	ADJ
ajlm-2375	66	3	cycling	cycling	NOUN
ajlm-2375	66	4	conditions	condition	NOUN
ajlm-2375	66	5	commenced	commence	VERB
ajlm-2375	66	6	with	with	ADP
ajlm-2375	66	7	an	an	DET
ajlm-2375	66	8	initial	initial	ADJ
ajlm-2375	66	9	denaturation	denaturation	NOUN
ajlm-2375	66	10	at	at	ADP
ajlm-2375	66	11	95	95	NUM
ajlm-2375	66	12	°	°	ADP
ajlm-2375	66	13	c	c	NOUN
ajlm-2375	66	14	for	for	ADP
ajlm-2375	66	15	5	5	NUM
ajlm-2375	66	16	min	min	NOUN
ajlm-2375	66	17	,	,	PUNCT
ajlm-2375	66	18	then	then	ADV
ajlm-2375	66	19	25	25	NUM
ajlm-2375	66	20	cycles	cycle	NOUN
ajlm-2375	66	21	(	(	PUNCT
ajlm-2375	66	22	95	95	NUM
ajlm-2375	66	23	°	°	NUM
ajlm-2375	66	24	c	c	NOUN
ajlm-2375	66	25	for	for	ADP
ajlm-2375	66	26	30	30	NUM
ajlm-2375	66	27	s	s	NOUN
ajlm-2375	66	28	,	,	PUNCT
ajlm-2375	66	29	60	60	NUM
ajlm-2375	66	30	°	°	NUM
ajlm-2375	66	31	c	c	NOUN
ajlm-2375	66	32	for	for	ADP
ajlm-2375	66	33	40	40	NUM
ajlm-2375	66	34	s	s	NOUN
ajlm-2375	66	35	,	,	PUNCT
ajlm-2375	66	36	and	and	CCONJ
ajlm-2375	66	37	72	72	NUM
ajlm-2375	66	38	°	°	NOUN
ajlm-2375	66	39	c	c	NOUN
ajlm-2375	66	40	for	for	ADP
ajlm-2375	66	41	30	30	NUM
ajlm-2375	66	42	s	s	NOUN
ajlm-2375	66	43	)	)	PUNCT
ajlm-2375	66	44	,	,	PUNCT
ajlm-2375	66	45	ended	end	VERB
ajlm-2375	66	46	by	by	ADP
ajlm-2375	66	47	a	a	DET
ajlm-2375	66	48	final	final	ADJ
ajlm-2375	66	49	extension	extension	NOUN
ajlm-2375	66	50	for	for	ADP
ajlm-2375	66	51	3	3	NUM
ajlm-2375	66	52	min	min	NOUN
ajlm-2375	66	53	at	at	ADP
ajlm-2375	66	54	72	72	NUM
ajlm-2375	66	55	°	°	NOUN
ajlm-2375	66	56	c	c	NOUN
ajlm-2375	66	57	.	.	PUNCT
ajlm-2375	67	1	the	the	DET
ajlm-2375	67	2	pcr	pcr	ADJ
ajlm-2375	67	3	products	product	NOUN
ajlm-2375	67	4	were	be	AUX
ajlm-2375	67	5	digested	digest	VERB
ajlm-2375	67	6	using	use	VERB
ajlm-2375	67	7	alui	alui	NOUN
ajlm-2375	67	8	(	(	PUNCT
ajlm-2375	67	9	thermo	thermo	PROPN
ajlm-2375	67	10	fisher	fisher	PROPN
ajlm-2375	67	11	scientific	scientific	PROPN
ajlm-2375	67	12	inc	inc	PROPN
ajlm-2375	67	13	.	.	PROPN
ajlm-2375	67	14	,	,	PUNCT
ajlm-2375	67	15	toronto	toronto	PROPN
ajlm-2375	67	16	,	,	PUNCT
ajlm-2375	67	17	ontario	ontario	PROPN
ajlm-2375	67	18	,	,	PUNCT
ajlm-2375	67	19	canada	canada	PROPN
ajlm-2375	67	20	)	)	PUNCT
ajlm-2375	67	21	at	at	ADP
ajlm-2375	67	22	37	37	NUM
ajlm-2375	67	23	°	°	ADP
ajlm-2375	67	24	c	c	NOUN
ajlm-2375	67	25	for	for	ADP
ajlm-2375	67	26	3	3	NUM
ajlm-2375	67	27	h.17	h.17	PROPN
ajlm-2375	67	28	the	the	DET
ajlm-2375	67	29	amplified	amplify	VERB
ajlm-2375	67	30	and	and	CCONJ
ajlm-2375	67	31	digested	digested	ADJ
ajlm-2375	67	32	products	product	NOUN
ajlm-2375	67	33	were	be	AUX
ajlm-2375	67	34	examined	examine	VERB
ajlm-2375	67	35	using	use	VERB
ajlm-2375	67	36	2	2	NUM
ajlm-2375	67	37	%	%	NOUN
ajlm-2375	67	38	agarose	agarose	NOUN
ajlm-2375	67	39	gel	gel	NOUN
ajlm-2375	67	40	electrophoresis	electrophoresis	NOUN
ajlm-2375	67	41	for	for	ADP
ajlm-2375	67	42	30	30	NUM
ajlm-2375	67	43	min	min	NOUN
ajlm-2375	67	44	and	and	CCONJ
ajlm-2375	67	45	visualized	visualize	VERB
ajlm-2375	67	46	utilising	utilise	VERB
ajlm-2375	67	47	an	an	DET
ajlm-2375	67	48	ultraviolet	ultraviolet	ADJ
ajlm-2375	67	49	transilluminator	transilluminator	NOUN
ajlm-2375	67	50	.	.	PUNCT
ajlm-2375	68	1	the	the	DET
ajlm-2375	68	2	amplicon	amplicon	NOUN
ajlm-2375	68	3	size	size	NOUN
ajlm-2375	68	4	was	be	AUX
ajlm-2375	68	5	817	817	NUM
ajlm-2375	68	6	bp	bp	NOUN
ajlm-2375	68	7	,	,	PUNCT
ajlm-2375	68	8	after	after	ADP
ajlm-2375	68	9	restriction	restriction	NOUN
ajlm-2375	68	10	;	;	PUNCT
ajlm-2375	68	11	the	the	DET
ajlm-2375	68	12	g	g	PROPN
ajlm-2375	68	13	allele	allele	PROPN
ajlm-2375	68	14	appears	appear	VERB
ajlm-2375	68	15	as	as	ADP
ajlm-2375	68	16	one	one	NUM
ajlm-2375	68	17	band	band	NOUN
ajlm-2375	68	18	at	at	ADP
ajlm-2375	68	19	817	817	NUM
ajlm-2375	68	20	bp	bp	NOUN
ajlm-2375	68	21	,	,	PUNCT
ajlm-2375	68	22	and	and	CCONJ
ajlm-2375	68	23	the	the	DET
ajlm-2375	68	24	a	a	DET
ajlm-2375	68	25	allele	allele	NOUN
ajlm-2375	68	26	appears	appear	VERB
ajlm-2375	68	27	as	as	ADP
ajlm-2375	68	28	two	two	NUM
ajlm-2375	68	29	bands	band	NOUN
ajlm-2375	68	30	at	at	ADP
ajlm-2375	68	31	589	589	NUM
ajlm-2375	68	32	bp	bp	NOUN
ajlm-2375	68	33	and	and	CCONJ
ajlm-2375	68	34	228	228	NUM
ajlm-2375	68	35	bp	bp	PROPN
ajlm-2375	68	36	.	.	PUNCT
ajlm-2375	69	1	in	in	ADP
ajlm-2375	69	2	women	woman	NOUN
ajlm-2375	69	3	,	,	PUNCT
ajlm-2375	69	4	the	the	DET
ajlm-2375	69	5	ag	ag	PROPN
ajlm-2375	69	6	genotype	genotype	NOUN
ajlm-2375	69	7	appears	appear	VERB
ajlm-2375	69	8	as	as	SCONJ
ajlm-2375	69	9	three	three	NUM
ajlm-2375	69	10	bands	band	NOUN
ajlm-2375	69	11	at	at	ADP
ajlm-2375	69	12	817	817	NUM
ajlm-2375	69	13	bp	bp	NOUN
ajlm-2375	69	14	,	,	PUNCT
ajlm-2375	69	15	589	589	NUM
ajlm-2375	69	16	bp	bp	NOUN
ajlm-2375	69	17	,	,	PUNCT
ajlm-2375	69	18	and	and	CCONJ
ajlm-2375	69	19	228	228	NUM
ajlm-2375	69	20	bp.18	bp.18	NOUN
ajlm-2375	69	21	for	for	ADP
ajlm-2375	69	22	the	the	DET
ajlm-2375	69	23	tmprss2	tmprss2	ADJ
ajlm-2375	69	24	snp	snp	ADJ
ajlm-2375	69	25	,	,	PUNCT
ajlm-2375	69	26	rs2070788	rs2070788	NOUN
ajlm-2375	69	27	,	,	PUNCT
ajlm-2375	69	28	a	a	DET
ajlm-2375	69	29	real	real	ADJ
ajlm-2375	69	30	-	-	PUNCT
ajlm-2375	69	31	time	time	NOUN
ajlm-2375	69	32	polymerase	polymerase	NOUN
ajlm-2375	69	33	chain	chain	NOUN
ajlm-2375	69	34	reaction	reaction	NOUN
ajlm-2375	69	35	assay	assay	PROPN
ajlm-2375	69	36	was	be	AUX
ajlm-2375	69	37	performed	perform	VERB
ajlm-2375	69	38	,	,	PUNCT
ajlm-2375	69	39	snp	snp	ADJ
ajlm-2375	69	40	genotyping	genotype	VERB
ajlm-2375	69	41	assay	assay	NOUN
ajlm-2375	69	42	that	that	PRON
ajlm-2375	69	43	contains	contain	VERB
ajlm-2375	69	44	the	the	DET
ajlm-2375	69	45	specific	specific	ADJ
ajlm-2375	69	46	primer	primer	NOUN
ajlm-2375	69	47	-	-	PUNCT
ajlm-2375	69	48	probe	probe	NOUN
ajlm-2375	69	49	mixture	mixture	NOUN
ajlm-2375	69	50	and	and	CCONJ
ajlm-2375	69	51	taqman	taqman	NOUN
ajlm-2375	69	52	universal	universal	ADJ
ajlm-2375	69	53	pcr	pcr	PROPN
ajlm-2375	69	54	master	master	NOUN
ajlm-2375	69	55	mix	mix	NOUN
ajlm-2375	69	56	were	be	AUX
ajlm-2375	69	57	purchased	purchase	VERB
ajlm-2375	69	58	from	from	ADP
ajlm-2375	69	59	thermo	thermo	PROPN
ajlm-2375	69	60	fisher	fisher	PROPN
ajlm-2375	69	61	scientific	scientific	PROPN
ajlm-2375	69	62	inc	inc	PROPN
ajlm-2375	69	63	.	.	PROPN
ajlm-2375	70	1	(	(	PUNCT
ajlm-2375	70	2	vilnius	vilnius	PROPN
ajlm-2375	70	3	,	,	PUNCT
ajlm-2375	70	4	lithuania	lithuania	PROPN
ajlm-2375	70	5	)	)	PUNCT
ajlm-2375	70	6	,	,	PUNCT
ajlm-2375	70	7	amplification	amplification	NOUN
ajlm-2375	70	8	and	and	CCONJ
ajlm-2375	70	9	detection	detection	NOUN
ajlm-2375	70	10	were	be	AUX
ajlm-2375	70	11	carried	carry	VERB
ajlm-2375	70	12	out	out	ADP
ajlm-2375	70	13	on	on	ADP
ajlm-2375	70	14	quantstdiotm5	quantstdiotm5	ADJ
ajlm-2375	70	15	real	real	ADJ
ajlm-2375	70	16	-	-	PUNCT
ajlm-2375	70	17	time	time	NOUN
ajlm-2375	70	18	polymerase	polymerase	NOUN
ajlm-2375	70	19	chain	chain	NOUN
ajlm-2375	70	20	reaction	reaction	NOUN
ajlm-2375	70	21	system	system	NOUN
ajlm-2375	70	22	(	(	PUNCT
ajlm-2375	70	23	applied	apply	VERB
ajlm-2375	70	24	biosystems	biosystem	NOUN
ajlm-2375	70	25	,	,	PUNCT
ajlm-2375	70	26	siemens	siemens	PROPN
ajlm-2375	70	27	healthcare	healthcare	PROPN
ajlm-2375	70	28	diagnostics	diagnostics	PROPN
ajlm-2375	70	29	inc	inc	PROPN
ajlm-2375	70	30	,	,	PUNCT
ajlm-2375	70	31	singapore	singapore	PROPN
ajlm-2375	70	32	)	)	PUNCT
ajlm-2375	70	33	;	;	PUNCT
ajlm-2375	70	34	all	all	DET
ajlm-2375	70	35	procedures	procedure	NOUN
ajlm-2375	70	36	were	be	AUX
ajlm-2375	70	37	carried	carry	VERB
ajlm-2375	70	38	out	out	ADP
ajlm-2375	70	39	according	accord	VERB
ajlm-2375	70	40	to	to	ADP
ajlm-2375	70	41	manufacturers	manufacturer	NOUN
ajlm-2375	70	42	’	’	PART
ajlm-2375	70	43	guidelines	guideline	NOUN
ajlm-2375	70	44	.	.	PUNCT
ajlm-2375	71	1	the	the	DET
ajlm-2375	71	2	reaction	reaction	NOUN
ajlm-2375	71	3	mixture	mixture	NOUN
ajlm-2375	71	4	was	be	AUX
ajlm-2375	71	5	as	as	SCONJ
ajlm-2375	71	6	follows	follow	VERB
ajlm-2375	71	7	:	:	PUNCT
ajlm-2375	71	8	10	10	NUM
ajlm-2375	71	9	µl	µl	NOUN
ajlm-2375	71	10	of	of	ADP
ajlm-2375	71	11	(	(	PUNCT
ajlm-2375	71	12	2x	2x	NUM
ajlm-2375	71	13	)	)	PUNCT
ajlm-2375	71	14	taqman	taqman	NOUN
ajlm-2375	71	15	universal	universal	ADJ
ajlm-2375	71	16	pcr	pcr	PROPN
ajlm-2375	71	17	master	master	NOUN
ajlm-2375	71	18	mix	mix	NOUN
ajlm-2375	71	19	,	,	PUNCT
ajlm-2375	71	20	20	20	NUM
ajlm-2375	71	21	units	unit	NOUN
ajlm-2375	71	22	(	(	PUNCT
ajlm-2375	71	23	0.5	0.5	NUM
ajlm-2375	71	24	µl	µl	NOUN
ajlm-2375	71	25	)	)	PUNCT
ajlm-2375	71	26	of	of	ADP
ajlm-2375	71	27	the	the	DET
ajlm-2375	71	28	primer	primer	NOUN
ajlm-2375	71	29	-	-	PUNCT
ajlm-2375	71	30	probe	probe	NOUN
ajlm-2375	71	31	assay	assay	NOUN
ajlm-2375	71	32	,	,	PUNCT
ajlm-2375	71	33	1	1	NUM
ajlm-2375	71	34	µl	µl	NOUN
ajlm-2375	71	35	of	of	ADP
ajlm-2375	71	36	the	the	DET
ajlm-2375	71	37	extracted	extract	VERB
ajlm-2375	71	38	genomic	genomic	ADJ
ajlm-2375	71	39	dna	dna	NOUN
ajlm-2375	71	40	,	,	PUNCT
ajlm-2375	71	41	and	and	CCONJ
ajlm-2375	71	42	8.5	8.5	NUM
ajlm-2375	71	43	µl	µl	ADP
ajlm-2375	71	44	nuclease	nuclease	NOUN
ajlm-2375	71	45	-	-	PUNCT
ajlm-2375	71	46	free	free	ADJ
ajlm-2375	71	47	water	water	NOUN
ajlm-2375	71	48	making	make	VERB
ajlm-2375	71	49	the	the	DET
ajlm-2375	71	50	final	final	ADJ
ajlm-2375	71	51	volume	volume	NOUN
ajlm-2375	71	52	of	of	ADP
ajlm-2375	71	53	the	the	DET
ajlm-2375	71	54	mixture	mixture	NOUN
ajlm-2375	71	55	20	20	NUM
ajlm-2375	71	56	µl	µl	NOUN
ajlm-2375	71	57	.	.	PUNCT
ajlm-2375	72	1	the	the	DET
ajlm-2375	72	2	real	real	ADJ
ajlm-2375	72	3	-	-	PUNCT
ajlm-2375	72	4	time	time	NOUN
ajlm-2375	72	5	polymerase	polymerase	NOUN
ajlm-2375	72	6	chain	chain	NOUN
ajlm-2375	72	7	reaction	reaction	NOUN
ajlm-2375	72	8	cycling	cycling	NOUN
ajlm-2375	72	9	conditions	condition	NOUN
ajlm-2375	72	10	were	be	AUX
ajlm-2375	72	11	60	60	NUM
ajlm-2375	72	12	°	°	ADP
ajlm-2375	72	13	c	c	NOUN
ajlm-2375	72	14	for	for	ADP
ajlm-2375	72	15	2	2	NUM
ajlm-2375	72	16	min	min	NOUN
ajlm-2375	72	17	,	,	PUNCT
ajlm-2375	72	18	initial	initial	ADJ
ajlm-2375	72	19	denaturation	denaturation	NOUN
ajlm-2375	72	20	at	at	ADP
ajlm-2375	72	21	95	95	NUM
ajlm-2375	72	22	°	°	ADP
ajlm-2375	72	23	c	c	NOUN
ajlm-2375	72	24	for	for	ADP
ajlm-2375	72	25	10	10	NUM
ajlm-2375	72	26	min	min	NOUN
ajlm-2375	72	27	then	then	ADV
ajlm-2375	72	28	40	40	NUM
ajlm-2375	72	29	cycles	cycle	NOUN
ajlm-2375	72	30	of	of	ADP
ajlm-2375	72	31	denaturation	denaturation	NOUN
ajlm-2375	72	32	at	at	ADP
ajlm-2375	72	33	95	95	NUM
ajlm-2375	72	34	°	°	ADP
ajlm-2375	72	35	c	c	NOUN
ajlm-2375	72	36	for	for	ADP
ajlm-2375	72	37	15	15	NUM
ajlm-2375	72	38	s	s	NOUN
ajlm-2375	72	39	,	,	PUNCT
ajlm-2375	72	40	and	and	CCONJ
ajlm-2375	72	41	annealing	anneal	VERB
ajlm-2375	72	42	-extension	-extension	NOUN
ajlm-2375	72	43	at	at	ADP
ajlm-2375	72	44	60	60	NUM
ajlm-2375	72	45	°	°	ADP
ajlm-2375	72	46	c	c	NOUN
ajlm-2375	72	47	for	for	ADP
ajlm-2375	72	48	1	1	NUM
ajlm-2375	72	49	min.19	min.19	NOUN
ajlm-2375	72	50	data	datum	NOUN
ajlm-2375	72	51	analysis	analysis	NOUN
ajlm-2375	72	52	and	and	CCONJ
ajlm-2375	72	53	results	result	VERB
ajlm-2375	72	54	interpretation	interpretation	NOUN
ajlm-2375	72	55	were	be	AUX
ajlm-2375	72	56	carried	carry	VERB
ajlm-2375	72	57	out	out	ADP
ajlm-2375	72	58	automatically	automatically	ADV
ajlm-2375	72	59	by	by	ADP
ajlm-2375	72	60	the	the	DET
ajlm-2375	72	61	instrument	instrument	NOUN
ajlm-2375	72	62	’s	’s	PART
ajlm-2375	72	63	software	software	NOUN
ajlm-2375	72	64	based	base	VERB
ajlm-2375	72	65	on	on	ADP
ajlm-2375	72	66	the	the	DET
ajlm-2375	72	67	default	default	NOUN
ajlm-2375	72	68	cycle	cycle	NOUN
ajlm-2375	72	69	threshold	threshold	NOUN
ajlm-2375	72	70	cutoff	cutoff	NOUN
ajlm-2375	72	71	.	.	PUNCT
ajlm-2375	73	1	data	datum	NOUN
ajlm-2375	73	2	analysis	analysis	NOUN
ajlm-2375	73	3	the	the	DET
ajlm-2375	73	4	spss	spss	ADJ
ajlm-2375	73	5	®	®	NOUN
ajlm-2375	73	6	statistical	statistical	ADJ
ajlm-2375	73	7	software	software	NOUN
ajlm-2375	73	8	version	version	NOUN
ajlm-2375	73	9	22	22	NUM
ajlm-2375	73	10	(	(	PUNCT
ajlm-2375	73	11	ibm	ibm	PROPN
ajlm-2375	73	12	corp	corp	PROPN
ajlm-2375	73	13	.	.	PROPN
ajlm-2375	73	14	,	,	PUNCT
ajlm-2375	73	15	armonk	armonk	PROPN
ajlm-2375	73	16	,	,	PUNCT
ajlm-2375	73	17	new	new	PROPN
ajlm-2375	73	18	york	york	PROPN
ajlm-2375	73	19	,	,	PUNCT
ajlm-2375	73	20	united	united	PROPN
ajlm-2375	73	21	states	states	PROPN
ajlm-2375	73	22	)	)	PUNCT
ajlm-2375	73	23	was	be	AUX
ajlm-2375	73	24	used	use	VERB
ajlm-2375	73	25	for	for	ADP
ajlm-2375	73	26	data	datum	NOUN
ajlm-2375	73	27	analysis	analysis	NOUN
ajlm-2375	73	28	.	.	PUNCT
ajlm-2375	74	1	numeric	numeric	ADJ
ajlm-2375	74	2	values	value	NOUN
ajlm-2375	74	3	are	be	AUX
ajlm-2375	74	4	presented	present	VERB
ajlm-2375	74	5	as	as	ADP
ajlm-2375	74	6	mean	mean	NOUN
ajlm-2375	74	7	±	±	NUM
ajlm-2375	74	8	standard	standard	ADJ
ajlm-2375	74	9	deviation	deviation	NOUN
ajlm-2375	74	10	if	if	SCONJ
ajlm-2375	74	11	it	it	PRON
ajlm-2375	74	12	was	be	AUX
ajlm-2375	74	13	normally	normally	ADV
ajlm-2375	74	14	distributed	distribute	VERB
ajlm-2375	74	15	(	(	PUNCT
ajlm-2375	74	16	age	age	NOUN
ajlm-2375	74	17	,	,	PUNCT
ajlm-2375	74	18	haemoglobin	haemoglobin	NOUN
ajlm-2375	74	19	concentration	concentration	NOUN
ajlm-2375	74	20	,	,	PUNCT
ajlm-2375	74	21	and	and	CCONJ
ajlm-2375	74	22	platelet	platelet	NOUN
ajlm-2375	74	23	counts	count	NOUN
ajlm-2375	74	24	)	)	PUNCT
ajlm-2375	74	25	,	,	PUNCT
ajlm-2375	74	26	while	while	SCONJ
ajlm-2375	74	27	for	for	ADP
ajlm-2375	74	28	not	not	PART
ajlm-2375	74	29	-	-	PUNCT
ajlm-2375	74	30	normally	normally	ADV
ajlm-2375	74	31	distributed	distribute	VERB
ajlm-2375	74	32	data	datum	NOUN
ajlm-2375	74	33	(	(	PUNCT
ajlm-2375	74	34	total	total	ADJ
ajlm-2375	74	35	and	and	CCONJ
ajlm-2375	74	36	differential	differential	ADJ
ajlm-2375	74	37	leukocyte	leukocyte	NOUN
ajlm-2375	74	38	counts	count	NOUN
ajlm-2375	74	39	,	,	PUNCT
ajlm-2375	74	40	prothrombin	prothrombin	ADJ
ajlm-2375	74	41	time	time	NOUN
ajlm-2375	74	42	,	,	PUNCT
ajlm-2375	74	43	kidney	kidney	NOUN
ajlm-2375	74	44	function	function	NOUN
ajlm-2375	74	45	tests	test	NOUN
ajlm-2375	74	46	,	,	PUNCT
ajlm-2375	74	47	liver	liver	NOUN
ajlm-2375	74	48	enzymes	enzyme	NOUN
ajlm-2375	74	49	,	,	PUNCT
ajlm-2375	74	50	lactate	lactate	NOUN
ajlm-2375	74	51	dehydrogenase	dehydrogenase	NOUN
ajlm-2375	74	52	,	,	PUNCT
ajlm-2375	74	53	ferritin	ferritin	ADJ
ajlm-2375	74	54	,	,	PUNCT
ajlm-2375	74	55	crp	crp	PROPN
ajlm-2375	74	56	,	,	PUNCT
ajlm-2375	74	57	and	and	CCONJ
ajlm-2375	74	58	cycle	cycle	NOUN
ajlm-2375	74	59	threshold	threshold	NOUN
ajlm-2375	74	60	value	value	NOUN
ajlm-2375	74	61	)	)	PUNCT
ajlm-2375	74	62	the	the	DET
ajlm-2375	74	63	median	median	NOUN
ajlm-2375	74	64	(	(	PUNCT
ajlm-2375	74	65	range	range	NOUN
ajlm-2375	74	66	)	)	PUNCT
ajlm-2375	74	67	was	be	AUX
ajlm-2375	74	68	used	use	VERB
ajlm-2375	74	69	.	.	PUNCT
ajlm-2375	75	1	student	student	NOUN
ajlm-2375	75	2	’s	’s	PART
ajlm-2375	75	3	t	t	PROPN
ajlm-2375	75	4	-	-	PUNCT
ajlm-2375	75	5	test	test	NOUN
ajlm-2375	75	6	and	and	CCONJ
ajlm-2375	75	7	one	one	NUM
ajlm-2375	75	8	-	-	PUNCT
ajlm-2375	75	9	way	way	NOUN
ajlm-2375	75	10	analysis	analysis	NOUN
ajlm-2375	75	11	of	of	ADP
ajlm-2375	75	12	variance	variance	NOUN
ajlm-2375	75	13	with	with	SCONJ
ajlm-2375	75	14	least	least	ADJ
ajlm-2375	75	15	significant	significant	ADJ
ajlm-2375	75	16	differences	difference	NOUN
ajlm-2375	75	17	post	post	X
ajlm-2375	75	18	hoc	hoc	X
ajlm-2375	75	19	test	test	NOUN
ajlm-2375	75	20	were	be	AUX
ajlm-2375	75	21	used	use	VERB
ajlm-2375	75	22	to	to	PART
ajlm-2375	75	23	compare	compare	VERB
ajlm-2375	75	24	means	mean	NOUN
ajlm-2375	75	25	;	;	PUNCT
ajlm-2375	75	26	mann	mann	PROPN
ajlm-2375	75	27	-	-	PUNCT
ajlm-2375	75	28	whitney	whitney	PROPN
ajlm-2375	75	29	u	u	PROPN
ajlm-2375	75	30	test	test	NOUN
ajlm-2375	75	31	and	and	CCONJ
ajlm-2375	75	32	krusskal	krusskal	PROPN
ajlm-2375	75	33	-	-	PUNCT
ajlm-2375	75	34	wallis	wallis	PROPN
ajlm-2375	75	35	with	with	ADP
ajlm-2375	75	36	bonferroni	bonferroni	PROPN
ajlm-2375	75	37	post	post	X
ajlm-2375	75	38	hoc	hoc	X
ajlm-2375	75	39	tests	test	NOUN
ajlm-2375	75	40	were	be	AUX
ajlm-2375	75	41	used	use	VERB
ajlm-2375	75	42	for	for	ADP
ajlm-2375	75	43	medians	median	NOUN
ajlm-2375	75	44	comparison	comparison	NOUN
ajlm-2375	75	45	.	.	PUNCT
ajlm-2375	76	1	frequencies	frequency	NOUN
ajlm-2375	76	2	were	be	AUX
ajlm-2375	76	3	expressed	express	VERB
ajlm-2375	76	4	as	as	ADP
ajlm-2375	76	5	numbers	number	NOUN
ajlm-2375	76	6	(	(	PUNCT
ajlm-2375	76	7	percentages	percentage	NOUN
ajlm-2375	76	8	)	)	PUNCT
ajlm-2375	76	9	.	.	PUNCT
ajlm-2375	77	1	chi	chi	ADJ
ajlm-2375	77	2	-	-	PUNCT
ajlm-2375	77	3	square	square	NOUN
ajlm-2375	77	4	test	test	NOUN
ajlm-2375	77	5	and	and	CCONJ
ajlm-2375	77	6	the	the	DET
ajlm-2375	77	7	two	two	NUM
ajlm-2375	77	8	-	-	PUNCT
ajlm-2375	77	9	tailed	tail	VERB
ajlm-2375	77	10	fisher	fisher	NOUN
ajlm-2375	77	11	’s	’s	PART
ajlm-2375	77	12	exact	exact	ADJ
ajlm-2375	77	13	test	test	NOUN
ajlm-2375	77	14	for	for	ADP
ajlm-2375	77	15	results	result	NOUN
ajlm-2375	77	16	≤	≤	NUM
ajlm-2375	77	17	5	5	NUM
ajlm-2375	77	18	were	be	AUX
ajlm-2375	77	19	used	use	VERB
ajlm-2375	77	20	to	to	PART
ajlm-2375	77	21	compare	compare	VERB
ajlm-2375	77	22	frequencies	frequency	NOUN
ajlm-2375	77	23	.	.	PUNCT
ajlm-2375	78	1	p	p	X
ajlm-2375	78	2	-	-	PUNCT
ajlm-2375	78	3	values	value	NOUN
ajlm-2375	78	4	<	<	X
ajlm-2375	78	5	0.05	0.05	NUM
ajlm-2375	78	6	were	be	AUX
ajlm-2375	78	7	considered	consider	VERB
ajlm-2375	78	8	statistically	statistically	ADV
ajlm-2375	78	9	significant	significant	ADJ
ajlm-2375	78	10	differences	difference	NOUN
ajlm-2375	78	11	.	.	PUNCT
ajlm-2375	79	1	after	after	ADP
ajlm-2375	79	2	comparing	compare	VERB
ajlm-2375	79	3	all	all	DET
ajlm-2375	79	4	variables	variable	NOUN
ajlm-2375	79	5	either	either	CCONJ
ajlm-2375	79	6	qualitatively	qualitatively	ADV
ajlm-2375	79	7	or	or	CCONJ
ajlm-2375	79	8	quantitatively	quantitatively	ADV
ajlm-2375	79	9	between	between	ADP
ajlm-2375	79	10	different	different	ADJ
ajlm-2375	79	11	groups	group	NOUN
ajlm-2375	79	12	,	,	PUNCT
ajlm-2375	79	13	all	all	DET
ajlm-2375	79	14	variables	variable	NOUN
ajlm-2375	79	15	that	that	PRON
ajlm-2375	79	16	have	have	VERB
ajlm-2375	79	17	p	p	X
ajlm-2375	79	18	<	<	X
ajlm-2375	79	19	0.1	0.1	NUM
ajlm-2375	79	20	were	be	AUX
ajlm-2375	79	21	tested	test	VERB
ajlm-2375	79	22	by	by	ADP
ajlm-2375	79	23	the	the	DET
ajlm-2375	79	24	multivariate	multivariate	NOUN
ajlm-2375	79	25	logistic	logistic	ADJ
ajlm-2375	79	26	regression	regression	NOUN
ajlm-2375	79	27	,	,	PUNCT
ajlm-2375	79	28	and	and	CCONJ
ajlm-2375	79	29	significant	significant	ADJ
ajlm-2375	79	30	results	result	NOUN
ajlm-2375	79	31	are	be	AUX
ajlm-2375	79	32	presented	present	VERB
ajlm-2375	79	33	as	as	ADP
ajlm-2375	79	34	p	p	NOUN
ajlm-2375	79	35	-	-	PUNCT
ajlm-2375	79	36	value	value	NOUN
ajlm-2375	79	37	,	,	PUNCT
ajlm-2375	79	38	odds	odd	NOUN
ajlm-2375	79	39	ratio	ratio	NOUN
ajlm-2375	79	40	and	and	CCONJ
ajlm-2375	79	41	95	95	NUM
ajlm-2375	79	42	%	%	NOUN
ajlm-2375	79	43	confidence	confidence	NOUN
ajlm-2375	79	44	interval	interval	NOUN
ajlm-2375	79	45	.	.	PUNCT
ajlm-2375	80	1	because	because	SCONJ
ajlm-2375	80	2	ace2	ace2	PROPN
ajlm-2375	80	3	is	be	AUX
ajlm-2375	80	4	an	an	DET
ajlm-2375	80	5	x	x	ADV
ajlm-2375	80	6	-	-	PUNCT
ajlm-2375	80	7	linked	link	VERB
ajlm-2375	80	8	gene	gene	NOUN
ajlm-2375	80	9	,	,	PUNCT
ajlm-2375	80	10	ace2	ace2	PROPN
ajlm-2375	80	11	g8790a	g8790a	NOUN
ajlm-2375	80	12	genotypes	genotype	NOUN
ajlm-2375	80	13	were	be	AUX
ajlm-2375	80	14	analysed	analyse	VERB
ajlm-2375	80	15	separately	separately	ADV
ajlm-2375	80	16	in	in	ADP
ajlm-2375	80	17	female	female	ADJ
ajlm-2375	80	18	and	and	CCONJ
ajlm-2375	80	19	male	male	ADJ
ajlm-2375	80	20	patients	patient	NOUN
ajlm-2375	80	21	.	.	PUNCT
ajlm-2375	81	1	results	result	VERB
ajlm-2375	81	2	this	this	DET
ajlm-2375	81	3	study	study	NOUN
ajlm-2375	81	4	included	include	VERB
ajlm-2375	81	5	100	100	NUM
ajlm-2375	81	6	patients	patient	NOUN
ajlm-2375	81	7	with	with	ADP
ajlm-2375	81	8	covid-19	covid-19	PROPN
ajlm-2375	81	9	admitted	admit	VERB
ajlm-2375	81	10	to	to	ADP
ajlm-2375	81	11	zagazig	zagazig	PROPN
ajlm-2375	81	12	university	university	NOUN
ajlm-2375	81	13	hospitals	hospital	NOUN
ajlm-2375	81	14	;	;	PUNCT
ajlm-2375	81	15	their	their	PRON
ajlm-2375	81	16	ages	age	NOUN
ajlm-2375	81	17	ranged	range	VERB
ajlm-2375	81	18	from	from	ADP
ajlm-2375	81	19	35	35	NUM
ajlm-2375	81	20	years	year	NOUN
ajlm-2375	81	21	to	to	ADP
ajlm-2375	81	22	80	80	NUM
ajlm-2375	81	23	years	year	NOUN
ajlm-2375	81	24	,	,	PUNCT
ajlm-2375	81	25	59	59	NUM
ajlm-2375	81	26	%	%	NOUN
ajlm-2375	81	27	(	(	PUNCT
ajlm-2375	81	28	59/100	59/100	NUM
ajlm-2375	81	29	)	)	PUNCT
ajlm-2375	81	30	of	of	ADP
ajlm-2375	81	31	them	they	PRON
ajlm-2375	81	32	were	be	AUX
ajlm-2375	81	33	male	male	ADJ
ajlm-2375	81	34	patients	patient	NOUN
ajlm-2375	81	35	,	,	PUNCT
ajlm-2375	81	36	and	and	CCONJ
ajlm-2375	81	37	41	41	NUM
ajlm-2375	81	38	%	%	NOUN
ajlm-2375	81	39	(	(	PUNCT
ajlm-2375	81	40	41/100	41/100	NOUN
ajlm-2375	81	41	)	)	PUNCT
ajlm-2375	81	42	were	be	AUX
ajlm-2375	81	43	female	female	ADJ
ajlm-2375	81	44	patients	patient	NOUN
ajlm-2375	81	45	.	.	PUNCT
ajlm-2375	82	1	apart	apart	ADV
ajlm-2375	82	2	from	from	ADP
ajlm-2375	82	3	smoking	smoking	NOUN
ajlm-2375	82	4	(	(	PUNCT
ajlm-2375	82	5	36	36	NUM
ajlm-2375	82	6	%	%	NOUN
ajlm-2375	82	7	)	)	PUNCT
ajlm-2375	82	8	,	,	PUNCT
ajlm-2375	82	9	no	no	DET
ajlm-2375	82	10	other	other	ADJ
ajlm-2375	82	11	substance	substance	NOUN
ajlm-2375	82	12	abuse	abuse	NOUN
ajlm-2375	82	13	,	,	PUNCT
ajlm-2375	82	14	including	include	VERB
ajlm-2375	82	15	alcohol	alcohol	NOUN
ajlm-2375	82	16	,	,	PUNCT
ajlm-2375	82	17	has	have	AUX
ajlm-2375	82	18	been	be	AUX
ajlm-2375	82	19	reported	report	VERB
ajlm-2375	82	20	;	;	PUNCT
ajlm-2375	82	21	56	56	NUM
ajlm-2375	82	22	%	%	NOUN
ajlm-2375	82	23	of	of	ADP
ajlm-2375	82	24	patients	patient	NOUN
ajlm-2375	82	25	had	have	VERB
ajlm-2375	82	26	history	history	NOUN
ajlm-2375	82	27	of	of	ADP
ajlm-2375	82	28	other	other	ADJ
ajlm-2375	82	29	medical	medical	ADJ
ajlm-2375	82	30	diseases	disease	NOUN
ajlm-2375	82	31	including	include	VERB
ajlm-2375	82	32	hypertension	hypertension	NOUN
ajlm-2375	82	33	(	(	PUNCT
ajlm-2375	82	34	31	31	NUM
ajlm-2375	82	35	%	%	NOUN
ajlm-2375	82	36	)	)	PUNCT
ajlm-2375	82	37	,	,	PUNCT
ajlm-2375	82	38	diabetes	diabetes	NOUN
ajlm-2375	82	39	mellitus	mellitus	NOUN
ajlm-2375	82	40	(	(	PUNCT
ajlm-2375	82	41	19	19	NUM
ajlm-2375	82	42	%	%	NOUN
ajlm-2375	82	43	)	)	PUNCT
ajlm-2375	82	44	,	,	PUNCT
ajlm-2375	82	45	cardiovascular	cardiovascular	ADJ
ajlm-2375	82	46	diseases	disease	NOUN
ajlm-2375	82	47	(	(	PUNCT
ajlm-2375	82	48	14	14	NUM
ajlm-2375	82	49	%	%	NOUN
ajlm-2375	82	50	)	)	PUNCT
ajlm-2375	82	51	,	,	PUNCT
ajlm-2375	82	52	chronic	chronic	ADJ
ajlm-2375	82	53	obstructive	obstructive	ADJ
ajlm-2375	82	54	lung	lung	NOUN
ajlm-2375	82	55	diseases	disease	NOUN
ajlm-2375	82	56	(	(	PUNCT
ajlm-2375	82	57	8	8	NUM
ajlm-2375	82	58	%	%	NOUN
ajlm-2375	82	59	)	)	PUNCT
ajlm-2375	82	60	and	and	CCONJ
ajlm-2375	82	61	malignancies	malignancy	NOUN
ajlm-2375	82	62	(	(	PUNCT
ajlm-2375	82	63	6	6	NUM
ajlm-2375	82	64	%	%	NOUN
ajlm-2375	82	65	)	)	PUNCT
ajlm-2375	82	66	(	(	PUNCT
ajlm-2375	82	67	table	table	NOUN
ajlm-2375	82	68	1	1	NUM
ajlm-2375	82	69	)	)	PUNCT
ajlm-2375	82	70	.	.	PUNCT
ajlm-2375	83	1	prior	prior	ADV
ajlm-2375	83	2	to	to	ADP
ajlm-2375	83	3	the	the	DET
ajlm-2375	83	4	globalisation	globalisation	NOUN
ajlm-2375	83	5	of	of	ADP
ajlm-2375	83	6	the	the	DET
ajlm-2375	83	7	vaccination	vaccination	NOUN
ajlm-2375	83	8	programme	programme	NOUN
ajlm-2375	83	9	in	in	ADP
ajlm-2375	83	10	egypt	egypt	PROPN
ajlm-2375	83	11	,	,	PUNCT
ajlm-2375	83	12	only	only	ADV
ajlm-2375	83	13	14	14	NUM
ajlm-2375	83	14	%	%	NOUN
ajlm-2375	83	15	of	of	ADP
ajlm-2375	83	16	patients	patient	NOUN
ajlm-2375	83	17	had	have	AUX
ajlm-2375	83	18	been	be	AUX
ajlm-2375	83	19	administered	administer	VERB
ajlm-2375	83	20	the	the	DET
ajlm-2375	83	21	sinopharm	sinopharm	NOUN
ajlm-2375	83	22	vaccine	vaccine	NOUN
ajlm-2375	83	23	,	,	PUNCT
ajlm-2375	83	24	while	while	SCONJ
ajlm-2375	83	25	2	2	NUM
ajlm-2375	83	26	%	%	NOUN
ajlm-2375	83	27	had	have	AUX
ajlm-2375	83	28	received	receive	VERB
ajlm-2375	83	29	the	the	DET
ajlm-2375	83	30	oxford	oxford	ADJ
ajlm-2375	83	31	astrazeneca	astrazeneca	NOUN
ajlm-2375	83	32	vaccine	vaccine	NOUN
ajlm-2375	83	33	.	.	PUNCT
ajlm-2375	84	1	among	among	ADP
ajlm-2375	84	2	the	the	DET
ajlm-2375	84	3	patients	patient	NOUN
ajlm-2375	84	4	,	,	PUNCT
ajlm-2375	84	5	fever	fever	NOUN
ajlm-2375	84	6	was	be	AUX
ajlm-2375	84	7	observed	observe	VERB
ajlm-2375	84	8	in	in	ADP
ajlm-2375	84	9	95	95	NUM
ajlm-2375	84	10	%	%	NOUN
ajlm-2375	84	11	of	of	ADP
ajlm-2375	84	12	cases	case	NOUN
ajlm-2375	84	13	,	,	PUNCT
ajlm-2375	84	14	pharyngitis	pharyngitis	NOUN
ajlm-2375	84	15	in	in	ADP
ajlm-2375	84	16	94	94	NUM
ajlm-2375	84	17	%	%	NOUN
ajlm-2375	84	18	of	of	ADP
ajlm-2375	84	19	cases	case	NOUN
ajlm-2375	84	20	,	,	PUNCT
ajlm-2375	84	21	and	and	CCONJ
ajlm-2375	84	22	chest	chest	NOUN
ajlm-2375	84	23	pain	pain	NOUN
ajlm-2375	84	24	in	in	ADP
ajlm-2375	84	25	61	61	NUM
ajlm-2375	84	26	%	%	NOUN
ajlm-2375	84	27	of	of	ADP
ajlm-2375	84	28	cases	case	NOUN
ajlm-2375	84	29	;	;	PUNCT
ajlm-2375	84	30	4	4	NUM
ajlm-2375	84	31	%	%	NOUN
ajlm-2375	84	32	were	be	AUX
ajlm-2375	84	33	diagnosed	diagnose	VERB
ajlm-2375	84	34	by	by	ADP
ajlm-2375	84	35	pcr	pcr	PROPN
ajlm-2375	84	36	before	before	ADP
ajlm-2375	84	37	the	the	DET
ajlm-2375	84	38	appearance	appearance	NOUN
ajlm-2375	84	39	of	of	ADP
ajlm-2375	84	40	symptoms	symptom	NOUN
ajlm-2375	84	41	.	.	PUNCT
ajlm-2375	85	1	concerning	concern	VERB
ajlm-2375	85	2	severity	severity	NOUN
ajlm-2375	85	3	,	,	PUNCT
ajlm-2375	85	4	51	51	NUM
ajlm-2375	85	5	%	%	NOUN
ajlm-2375	85	6	,	,	PUNCT
ajlm-2375	85	7	34	34	NUM
ajlm-2375	85	8	%	%	NOUN
ajlm-2375	85	9	and	and	CCONJ
ajlm-2375	85	10	15	15	NUM
ajlm-2375	85	11	%	%	NOUN
ajlm-2375	85	12	were	be	AUX
ajlm-2375	85	13	severe	severe	ADJ
ajlm-2375	85	14	,	,	PUNCT
ajlm-2375	85	15	moderate	moderate	ADJ
ajlm-2375	85	16	and	and	CCONJ
ajlm-2375	85	17	mild	mild	ADJ
ajlm-2375	85	18	cases	case	NOUN
ajlm-2375	85	19	,	,	PUNCT
ajlm-2375	85	20	while	while	SCONJ
ajlm-2375	85	21	44	44	NUM
ajlm-2375	85	22	%	%	NOUN
ajlm-2375	85	23	died	die	VERB
ajlm-2375	85	24	by	by	ADP
ajlm-2375	85	25	the	the	DET
ajlm-2375	85	26	end	end	NOUN
ajlm-2375	85	27	of	of	ADP
ajlm-2375	85	28	the	the	DET
ajlm-2375	85	29	study	study	NOUN
ajlm-2375	85	30	.	.	PUNCT
ajlm-2375	86	1	nineteen	nineteen	NUM
ajlm-2375	86	2	patients	patient	NOUN
ajlm-2375	86	3	(	(	PUNCT
ajlm-2375	86	4	19	19	NUM
ajlm-2375	86	5	%	%	NOUN
ajlm-2375	86	6	)	)	PUNCT
ajlm-2375	86	7	were	be	AUX
ajlm-2375	86	8	complicated	complicate	VERB
ajlm-2375	86	9	with	with	ADP
ajlm-2375	86	10	secondary	secondary	ADJ
ajlm-2375	86	11	bacterial	bacterial	ADJ
ajlm-2375	86	12	pneumonia	pneumonia	NOUN
ajlm-2375	86	13	;	;	PUNCT
ajlm-2375	86	14	12	12	NUM
ajlm-2375	86	15	(	(	PUNCT
ajlm-2375	86	16	12	12	NUM
ajlm-2375	86	17	%	%	NOUN
ajlm-2375	86	18	)	)	PUNCT
ajlm-2375	86	19	were	be	AUX
ajlm-2375	86	20	infected	infect	VERB
ajlm-2375	86	21	with	with	ADP
ajlm-2375	86	22	methicillin	methicillin	NOUN
ajlm-2375	86	23	-	-	PUNCT
ajlm-2375	86	24	resistant	resistant	ADJ
ajlm-2375	86	25	staphylococcus	staphylococcus	NOUN
ajlm-2375	86	26	aureus	aureus	NOUN
ajlm-2375	86	27	,	,	PUNCT
ajlm-2375	86	28	5	5	NUM
ajlm-2375	86	29	%	%	NOUN
ajlm-2375	86	30	with	with	ADP
ajlm-2375	86	31	klebsiella	klebsiella	NOUN
ajlm-2375	86	32	pneumoniae	pneumoniae	NOUN
ajlm-2375	86	33	,	,	PUNCT
ajlm-2375	86	34	and	and	CCONJ
ajlm-2375	86	35	2	2	NUM
ajlm-2375	86	36	%	%	NOUN
ajlm-2375	86	37	with	with	ADP
ajlm-2375	86	38	acinetobacter	acinetobacter	ADJ
ajlm-2375	86	39	spp	spp	NOUN
ajlm-2375	86	40	.	.	PUNCT
ajlm-2375	87	1	seventeen	seventeen	NUM
ajlm-2375	88	1	(	(	PUNCT
ajlm-2375	88	2	17	17	NUM
ajlm-2375	88	3	%	%	NOUN
ajlm-2375	88	4	)	)	PUNCT
ajlm-2375	89	1	patients	patient	NOUN
ajlm-2375	89	2	had	have	VERB
ajlm-2375	89	3	cardiovascular	cardiovascular	ADJ
ajlm-2375	89	4	complications	complication	NOUN
ajlm-2375	89	5	in	in	ADP
ajlm-2375	89	6	the	the	DET
ajlm-2375	89	7	form	form	NOUN
ajlm-2375	89	8	of	of	ADP
ajlm-2375	89	9	lower	low	ADJ
ajlm-2375	89	10	limb	limb	NOUN
ajlm-2375	89	11	ischaemia	ischaemia	NOUN
ajlm-2375	89	12	(	(	PUNCT
ajlm-2375	89	13	2	2	NUM
ajlm-2375	89	14	%	%	NOUN
ajlm-2375	89	15	)	)	PUNCT
ajlm-2375	89	16	,	,	PUNCT
ajlm-2375	89	17	deep	deep	ADJ
ajlm-2375	89	18	vein	vein	ADJ
ajlm-2375	89	19	thrombosis	thrombosis	NOUN
ajlm-2375	89	20	(	(	PUNCT
ajlm-2375	89	21	7	7	NUM
ajlm-2375	89	22	%	%	NOUN
ajlm-2375	89	23	)	)	PUNCT
ajlm-2375	89	24	,	,	PUNCT
ajlm-2375	89	25	pulmonary	pulmonary	ADJ
ajlm-2375	89	26	embolism	embolism	NOUN
ajlm-2375	89	27	(	(	PUNCT
ajlm-2375	89	28	5	5	NUM
ajlm-2375	89	29	%	%	NOUN
ajlm-2375	89	30	)	)	PUNCT
ajlm-2375	89	31	,	,	PUNCT
ajlm-2375	89	32	and	and	CCONJ
ajlm-2375	89	33	cerebrovascular	cerebrovascular	ADJ
ajlm-2375	89	34	stroke	stroke	NOUN
ajlm-2375	89	35	(	(	PUNCT
ajlm-2375	89	36	3	3	NUM
ajlm-2375	89	37	%	%	NOUN
ajlm-2375	89	38	)	)	PUNCT
ajlm-2375	89	39	.	.	PUNCT
ajlm-2375	90	1	ten	ten	NUM
ajlm-2375	90	2	(	(	PUNCT
ajlm-2375	90	3	19.6	19.6	NUM
ajlm-2375	90	4	%	%	NOUN
ajlm-2375	90	5	)	)	PUNCT
ajlm-2375	90	6	of	of	ADP
ajlm-2375	90	7	the	the	DET
ajlm-2375	90	8	severe	severe	ADJ
ajlm-2375	90	9	patients	patient	NOUN
ajlm-2375	90	10	group	group	NOUN
ajlm-2375	90	11	and	and	CCONJ
ajlm-2375	90	12	7	7	NUM
ajlm-2375	90	13	(	(	PUNCT
ajlm-2375	90	14	14.2	14.2	NUM
ajlm-2375	90	15	%	%	NOUN
ajlm-2375	90	16	)	)	PUNCT
ajlm-2375	90	17	of	of	ADP
ajlm-2375	90	18	the	the	DET
ajlm-2375	90	19	mild	mild	ADJ
ajlm-2375	90	20	or	or	CCONJ
ajlm-2375	90	21	moderate	moderate	ADJ
ajlm-2375	90	22	group	group	NOUN
ajlm-2375	90	23	had	have	VERB
ajlm-2375	90	24	cardiovascular	cardiovascular	ADJ
ajlm-2375	90	25	complications	complication	NOUN
ajlm-2375	90	26	,	,	PUNCT
ajlm-2375	90	27	10	10	NUM
ajlm-2375	90	28	(	(	PUNCT
ajlm-2375	90	29	58.8	58.8	NUM
ajlm-2375	90	30	%	%	NOUN
ajlm-2375	90	31	)	)	PUNCT
ajlm-2375	90	32	of	of	ADP
ajlm-2375	90	33	whom	whom	PRON
ajlm-2375	90	34	had	have	AUX
ajlm-2375	90	35	comorbidities	comorbiditie	NOUN
ajlm-2375	90	36	in	in	ADP
ajlm-2375	90	37	the	the	DET
ajlm-2375	90	38	form	form	NOUN
ajlm-2375	90	39	of	of	ADP
ajlm-2375	90	40	hypertension	hypertension	NOUN
ajlm-2375	90	41	(	(	PUNCT
ajlm-2375	90	42	6/10	6/10	NUM
ajlm-2375	90	43	;	;	PUNCT
ajlm-2375	90	44	60	60	NUM
ajlm-2375	90	45	%	%	NOUN
ajlm-2375	90	46	)	)	PUNCT
ajlm-2375	90	47	,	,	PUNCT
ajlm-2375	90	48	diabetes	diabetes	NOUN
ajlm-2375	90	49	mellitus	mellitus	NOUN
ajlm-2375	90	50	(	(	PUNCT
ajlm-2375	90	51	4/10	4/10	NUM
ajlm-2375	90	52	;	;	PUNCT
ajlm-2375	90	53	40	40	NUM
ajlm-2375	90	54	%	%	NOUN
ajlm-2375	90	55	)	)	PUNCT
ajlm-2375	90	56	,	,	PUNCT
ajlm-2375	90	57	cardiovascular	cardiovascular	ADJ
ajlm-2375	90	58	diseases	disease	NOUN
ajlm-2375	90	59	(	(	PUNCT
ajlm-2375	90	60	3/10	3/10	NUM
ajlm-2375	90	61	;	;	PUNCT
ajlm-2375	90	62	30	30	NUM
ajlm-2375	90	63	%	%	NOUN
ajlm-2375	90	64	)	)	PUNCT
ajlm-2375	90	65	and	and	CCONJ
ajlm-2375	90	66	malignancy	malignancy	NOUN
ajlm-2375	90	67	(	(	PUNCT
ajlm-2375	90	68	1/10	1/10	NUM
ajlm-2375	90	69	;	;	PUNCT
ajlm-2375	90	70	10	10	NUM
ajlm-2375	90	71	%	%	NOUN
ajlm-2375	90	72	)	)	PUNCT
ajlm-2375	90	73	,	,	PUNCT
ajlm-2375	90	74	and	and	CCONJ
ajlm-2375	90	75	7	7	NUM
ajlm-2375	90	76	of	of	ADP
ajlm-2375	90	77	whom	whom	PRON
ajlm-2375	90	78	(	(	PUNCT
ajlm-2375	90	79	41.2	41.2	NUM
ajlm-2375	90	80	%	%	NOUN
ajlm-2375	90	81	)	)	PUNCT
ajlm-2375	90	82	did	do	AUX
ajlm-2375	90	83	not	not	PART
ajlm-2375	90	84	survive	survive	VERB
ajlm-2375	90	85	.	.	PUNCT
ajlm-2375	91	1	table	table	NOUN
ajlm-2375	91	2	1	1	NUM
ajlm-2375	91	3	:	:	PUNCT
ajlm-2375	91	4	 	 	SPACE
ajlm-2375	91	5	patient	patient	ADJ
ajlm-2375	91	6	characteristics	characteristic	NOUN
ajlm-2375	91	7	(	(	PUNCT
ajlm-2375	91	8	n	n	NOUN
ajlm-2375	91	9	=	=	NUM
ajlm-2375	91	10	100	100	NUM
ajlm-2375	91	11	)	)	PUNCT
ajlm-2375	91	12	,	,	PUNCT
ajlm-2375	91	13	faculty	faculty	NOUN
ajlm-2375	91	14	of	of	ADP
ajlm-2375	91	15	medicine	medicine	NOUN
ajlm-2375	91	16	,	,	PUNCT
ajlm-2375	91	17	zagazig	zagazig	PROPN
ajlm-2375	91	18	university	university	PROPN
ajlm-2375	91	19	,	,	PUNCT
ajlm-2375	91	20	zagazig	zagazig	PROPN
ajlm-2375	91	21	,	,	PUNCT
ajlm-2375	91	22	egypt	egypt	PROPN
ajlm-2375	91	23	,	,	PUNCT
ajlm-2375	91	24	01	01	NUM
ajlm-2375	91	25	july	july	PROPN
ajlm-2375	91	26	2021	2021	NUM
ajlm-2375	91	27	–	–	PUNCT
ajlm-2375	91	28	30	30	NUM
ajlm-2375	91	29	november	november	NOUN
ajlm-2375	91	30	2021	2021	NUM
ajlm-2375	91	31	.	.	PUNCT
ajlm-2375	92	1	there	there	PRON
ajlm-2375	92	2	were	be	VERB
ajlm-2375	92	3	statistically	statistically	ADV
ajlm-2375	92	4	significant	significant	ADJ
ajlm-2375	92	5	associations	association	NOUN
ajlm-2375	92	6	between	between	ADP
ajlm-2375	92	7	age	age	NOUN
ajlm-2375	92	8	and	and	CCONJ
ajlm-2375	92	9	severity	severity	NOUN
ajlm-2375	92	10	(	(	PUNCT
ajlm-2375	92	11	p	p	X
ajlm-2375	92	12	=	=	NOUN
ajlm-2375	92	13	0.03	0.03	NUM
ajlm-2375	92	14	)	)	PUNCT
ajlm-2375	92	15	(	(	PUNCT
ajlm-2375	92	16	online	online	ADJ
ajlm-2375	92	17	supplementary	supplementary	ADJ
ajlm-2375	92	18	table	table	NOUN
ajlm-2375	92	19	1	1	NUM
ajlm-2375	92	20	)	)	PUNCT
ajlm-2375	92	21	.	.	PUNCT
ajlm-2375	93	1	complications	complication	NOUN
ajlm-2375	93	2	occurred	occur	VERB
ajlm-2375	93	3	more	more	ADV
ajlm-2375	93	4	frequently	frequently	ADV
ajlm-2375	93	5	among	among	ADP
ajlm-2375	93	6	severe	severe	ADJ
ajlm-2375	93	7	patients	patient	NOUN
ajlm-2375	93	8	(	(	PUNCT
ajlm-2375	93	9	p	p	X
ajlm-2375	93	10	<	<	X
ajlm-2375	93	11	0.001	0.001	NUM
ajlm-2375	93	12	)	)	PUNCT
ajlm-2375	93	13	.	.	PUNCT
ajlm-2375	94	1	statistically	statistically	ADV
ajlm-2375	94	2	significant	significant	ADJ
ajlm-2375	94	3	increases	increase	NOUN
ajlm-2375	94	4	among	among	ADP
ajlm-2375	94	5	severe	severe	ADJ
ajlm-2375	94	6	cases	case	NOUN
ajlm-2375	94	7	were	be	AUX
ajlm-2375	94	8	observed	observe	VERB
ajlm-2375	94	9	for	for	ADP
ajlm-2375	94	10	both	both	DET
ajlm-2375	94	11	kidney	kidney	NOUN
ajlm-2375	94	12	function	function	NOUN
ajlm-2375	94	13	markers	marker	NOUN
ajlm-2375	94	14	(	(	PUNCT
ajlm-2375	94	15	p	p	NOUN
ajlm-2375	94	16	=	=	NOUN
ajlm-2375	94	17	0.03	0.03	NUM
ajlm-2375	94	18	)	)	PUNCT
ajlm-2375	94	19	and	and	CCONJ
ajlm-2375	94	20	crp	crp	PROPN
ajlm-2375	95	1	(	(	PUNCT
ajlm-2375	95	2	p	p	X
ajlm-2375	95	3	<	<	X
ajlm-2375	95	4	0.001	0.001	NUM
ajlm-2375	95	5	)	)	PUNCT
ajlm-2375	95	6	.	.	PUNCT
ajlm-2375	96	1	there	there	PRON
ajlm-2375	96	2	were	be	VERB
ajlm-2375	96	3	no	no	DET
ajlm-2375	96	4	significant	significant	ADJ
ajlm-2375	96	5	associations	association	NOUN
ajlm-2375	96	6	between	between	ADP
ajlm-2375	96	7	either	either	CCONJ
ajlm-2375	96	8	demographic	demographic	ADJ
ajlm-2375	96	9	features	feature	NOUN
ajlm-2375	96	10	or	or	CCONJ
ajlm-2375	96	11	laboratory	laboratory	NOUN
ajlm-2375	96	12	data	datum	NOUN
ajlm-2375	96	13	and	and	CCONJ
ajlm-2375	96	14	patient	patient	ADJ
ajlm-2375	96	15	outcome	outcome	NOUN
ajlm-2375	96	16	(	(	PUNCT
ajlm-2375	96	17	online	online	ADJ
ajlm-2375	96	18	supplementary	supplementary	ADJ
ajlm-2375	96	19	table	table	NOUN
ajlm-2375	96	20	2	2	NUM
ajlm-2375	96	21	)	)	PUNCT
ajlm-2375	96	22	.	.	PUNCT
ajlm-2375	97	1	a	a	DET
ajlm-2375	97	2	statistically	statistically	ADV
ajlm-2375	97	3	significant	significant	ADJ
ajlm-2375	97	4	increase	increase	NOUN
ajlm-2375	97	5	in	in	ADP
ajlm-2375	97	6	mortality	mortality	NOUN
ajlm-2375	97	7	rate	rate	NOUN
ajlm-2375	97	8	was	be	AUX
ajlm-2375	97	9	observed	observe	VERB
ajlm-2375	97	10	in	in	ADP
ajlm-2375	97	11	association	association	NOUN
ajlm-2375	97	12	with	with	ADP
ajlm-2375	97	13	severity	severity	NOUN
ajlm-2375	97	14	(	(	PUNCT
ajlm-2375	97	15	p	p	X
ajlm-2375	97	16	<	<	X
ajlm-2375	97	17	0.001	0.001	NUM
ajlm-2375	97	18	)	)	PUNCT
ajlm-2375	97	19	and	and	CCONJ
ajlm-2375	97	20	the	the	DET
ajlm-2375	97	21	occurrence	occurrence	NOUN
ajlm-2375	97	22	of	of	ADP
ajlm-2375	97	23	complications	complication	NOUN
ajlm-2375	97	24	(	(	PUNCT
ajlm-2375	97	25	p	p	NOUN
ajlm-2375	97	26	=	=	NOUN
ajlm-2375	97	27	0.02	0.02	NUM
ajlm-2375	97	28	)	)	PUNCT
ajlm-2375	97	29	.	.	PUNCT
ajlm-2375	98	1	for	for	ADP
ajlm-2375	98	2	the	the	DET
ajlm-2375	98	3	ace2	ace2	PROPN
ajlm-2375	98	4	snp	snp	PROPN
ajlm-2375	98	5	rs2285666	rs2285666	PROPN
ajlm-2375	98	6	,	,	PUNCT
ajlm-2375	98	7	the	the	DET
ajlm-2375	98	8	ga	ga	PROPN
ajlm-2375	98	9	genotype	genotype	NOUN
ajlm-2375	98	10	was	be	AUX
ajlm-2375	98	11	the	the	DET
ajlm-2375	98	12	most	most	ADV
ajlm-2375	98	13	frequent	frequent	ADJ
ajlm-2375	98	14	among	among	ADP
ajlm-2375	98	15	female	female	ADJ
ajlm-2375	98	16	patients	patient	NOUN
ajlm-2375	98	17	(	(	PUNCT
ajlm-2375	98	18	39	39	NUM
ajlm-2375	98	19	%	%	NOUN
ajlm-2375	98	20	)	)	PUNCT
ajlm-2375	98	21	,	,	PUNCT
ajlm-2375	98	22	while	while	SCONJ
ajlm-2375	98	23	among	among	ADP
ajlm-2375	98	24	male	male	ADJ
ajlm-2375	98	25	patients	patient	NOUN
ajlm-2375	98	26	the	the	DET
ajlm-2375	98	27	a	a	DET
ajlm-2375	98	28	genotype	genotype	NOUN
ajlm-2375	98	29	was	be	AUX
ajlm-2375	98	30	more	more	ADV
ajlm-2375	98	31	prevalent	prevalent	ADJ
ajlm-2375	98	32	(	(	PUNCT
ajlm-2375	98	33	54.2	54.2	NUM
ajlm-2375	98	34	%	%	NOUN
ajlm-2375	98	35	)	)	PUNCT
ajlm-2375	98	36	.	.	PUNCT
ajlm-2375	99	1	for	for	ADP
ajlm-2375	99	2	the	the	DET
ajlm-2375	99	3	tmprss2	tmprss2	ADJ
ajlm-2375	99	4	snp	snp	ADJ
ajlm-2375	99	5	rs2070788	rs2070788	NOUN
ajlm-2375	99	6	,	,	PUNCT
ajlm-2375	99	7	the	the	DET
ajlm-2375	99	8	aa	aa	PROPN
ajlm-2375	99	9	genotype	genotype	NOUN
ajlm-2375	99	10	was	be	AUX
ajlm-2375	99	11	the	the	DET
ajlm-2375	99	12	most	most	ADV
ajlm-2375	99	13	frequent	frequent	ADJ
ajlm-2375	99	14	among	among	ADP
ajlm-2375	99	15	all	all	DET
ajlm-2375	99	16	patients	patient	NOUN
ajlm-2375	99	17	(	(	PUNCT
ajlm-2375	99	18	46	46	NUM
ajlm-2375	99	19	%	%	NOUN
ajlm-2375	99	20	)	)	PUNCT
ajlm-2375	99	21	.	.	PUNCT
ajlm-2375	100	1	ace2	ace2	PROPN
ajlm-2375	100	2	rs2285666	rs2285666	PROPN
ajlm-2375	100	3	and	and	CCONJ
ajlm-2375	100	4	tmprss2	tmprss2	ADP
ajlm-2375	100	5	rs2070788	rs2070788	ADJ
ajlm-2375	100	6	genotypes	genotype	NOUN
ajlm-2375	100	7	and	and	CCONJ
ajlm-2375	100	8	allele	allele	NOUN
ajlm-2375	100	9	frequencies	frequency	NOUN
ajlm-2375	100	10	had	have	VERB
ajlm-2375	100	11	no	no	DET
ajlm-2375	100	12	significant	significant	ADJ
ajlm-2375	100	13	associations	association	NOUN
ajlm-2375	100	14	with	with	ADP
ajlm-2375	100	15	either	either	PRON
ajlm-2375	100	16	disease	disease	NOUN
ajlm-2375	100	17	severity	severity	NOUN
ajlm-2375	100	18	or	or	CCONJ
ajlm-2375	100	19	patient	patient	ADJ
ajlm-2375	100	20	outcomes	outcome	NOUN
ajlm-2375	100	21	,	,	PUNCT
ajlm-2375	100	22	as	as	SCONJ
ajlm-2375	100	23	shown	show	VERB
ajlm-2375	100	24	in	in	ADP
ajlm-2375	100	25	table	table	NOUN
ajlm-2375	100	26	2	2	NUM
ajlm-2375	100	27	and	and	CCONJ
ajlm-2375	100	28	table	table	NOUN
ajlm-2375	100	29	3	3	NUM
ajlm-2375	100	30	.	.	PUNCT
ajlm-2375	100	31	multivariate	multivariate	NOUN
ajlm-2375	100	32	logistic	logistic	ADJ
ajlm-2375	100	33	regression	regression	NOUN
ajlm-2375	100	34	revealed	reveal	VERB
ajlm-2375	100	35	that	that	SCONJ
ajlm-2375	100	36	crp	crp	PROPN
ajlm-2375	100	37	level	level	NOUN
ajlm-2375	100	38	was	be	AUX
ajlm-2375	100	39	the	the	DET
ajlm-2375	100	40	only	only	ADJ
ajlm-2375	100	41	independent	independent	ADJ
ajlm-2375	100	42	predictor	predictor	NOUN
ajlm-2375	100	43	of	of	ADP
ajlm-2375	100	44	covid-19	covid-19	PROPN
ajlm-2375	100	45	severity	severity	NOUN
ajlm-2375	100	46	in	in	ADP
ajlm-2375	100	47	this	this	DET
ajlm-2375	100	48	cohort	cohort	NOUN
ajlm-2375	100	49	:	:	PUNCT
ajlm-2375	100	50	p	p	X
ajlm-2375	100	51	=	=	NOUN
ajlm-2375	100	52	0.001	0.001	NUM
ajlm-2375	100	53	,	,	PUNCT
ajlm-2375	100	54	odds	odd	NOUN
ajlm-2375	100	55	ratio	ratio	NOUN
ajlm-2375	100	56	(	(	PUNCT
ajlm-2375	100	57	95	95	NUM
ajlm-2375	100	58	%	%	NOUN
ajlm-2375	100	59	confidence	confidence	NOUN
ajlm-2375	100	60	interval	interval	NOUN
ajlm-2375	100	61	)	)	PUNCT
ajlm-2375	100	62	were	be	AUX
ajlm-2375	100	63	1.1	1.1	NUM
ajlm-2375	100	64	(	(	PUNCT
ajlm-2375	100	65	1.0–1.2	1.0–1.2	NOUN
ajlm-2375	100	66	)	)	PUNCT
ajlm-2375	100	67	(	(	PUNCT
ajlm-2375	100	68	data	datum	NOUN
ajlm-2375	100	69	not	not	PART
ajlm-2375	100	70	presented	present	VERB
ajlm-2375	100	71	)	)	PUNCT
ajlm-2375	100	72	.	.	PUNCT
ajlm-2375	101	1	furthermore	furthermore	ADV
ajlm-2375	101	2	,	,	PUNCT
ajlm-2375	101	3	it	it	PRON
ajlm-2375	101	4	was	be	AUX
ajlm-2375	101	5	found	find	VERB
ajlm-2375	101	6	that	that	SCONJ
ajlm-2375	101	7	severity	severity	NOUN
ajlm-2375	101	8	was	be	AUX
ajlm-2375	101	9	an	an	DET
ajlm-2375	101	10	independent	independent	ADJ
ajlm-2375	101	11	predictor	predictor	NOUN
ajlm-2375	101	12	of	of	ADP
ajlm-2375	101	13	outcome	outcome	NOUN
ajlm-2375	101	14	:	:	PUNCT
ajlm-2375	101	15	p	p	X
ajlm-2375	101	16	<	<	X
ajlm-2375	101	17	0.001	0.001	NUM
ajlm-2375	101	18	,	,	PUNCT
ajlm-2375	101	19	odds	odd	NOUN
ajlm-2375	101	20	ratio	ratio	NOUN
ajlm-2375	101	21	(	(	PUNCT
ajlm-2375	101	22	95	95	NUM
ajlm-2375	101	23	%	%	NOUN
ajlm-2375	101	24	confidence	confidence	NOUN
ajlm-2375	101	25	interval	interval	NOUN
ajlm-2375	101	26	)	)	PUNCT
ajlm-2375	101	27	were	be	AUX
ajlm-2375	101	28	46.5	46.5	NUM
ajlm-2375	101	29	(	(	PUNCT
ajlm-2375	101	30	10.2–211.2	10.2–211.2	NUM
ajlm-2375	101	31	)	)	PUNCT
ajlm-2375	101	32	.	.	PUNCT
ajlm-2375	102	1	table	table	NOUN
ajlm-2375	102	2	2	2	NUM
ajlm-2375	102	3	:	:	PUNCT
ajlm-2375	102	4	 	 	SPACE
ajlm-2375	102	5	associations	association	NOUN
ajlm-2375	102	6	between	between	ADP
ajlm-2375	102	7	covid-19	covid-19	PROPN
ajlm-2375	102	8	severity	severity	NOUN
ajlm-2375	102	9	and	and	CCONJ
ajlm-2375	102	10	single	single	ADJ
ajlm-2375	102	11	nucleotide	nucleotide	ADJ
ajlm-2375	102	12	polymorphisms	polymorphism	NOUN
ajlm-2375	102	13	of	of	ADP
ajlm-2375	102	14	the	the	DET
ajlm-2375	102	15	ace2	ace2	NOUN
ajlm-2375	102	16	and	and	CCONJ
ajlm-2375	102	17	tmprss2	tmprss2	ADP
ajlm-2375	102	18	genes	gene	NOUN
ajlm-2375	102	19	,	,	PUNCT
ajlm-2375	102	20	faculty	faculty	NOUN
ajlm-2375	102	21	of	of	ADP
ajlm-2375	102	22	medicine	medicine	NOUN
ajlm-2375	102	23	,	,	PUNCT
ajlm-2375	102	24	zagazig	zagazig	PROPN
ajlm-2375	102	25	university	university	PROPN
ajlm-2375	102	26	,	,	PUNCT
ajlm-2375	102	27	zagazig	zagazig	PROPN
ajlm-2375	102	28	,	,	PUNCT
ajlm-2375	102	29	egypt	egypt	PROPN
ajlm-2375	102	30	,	,	PUNCT
ajlm-2375	102	31	01	01	NUM
ajlm-2375	102	32	july	july	PROPN
ajlm-2375	102	33	2021	2021	NUM
ajlm-2375	102	34	–	–	PUNCT
ajlm-2375	102	35	30	30	NUM
ajlm-2375	102	36	november	november	NOUN
ajlm-2375	102	37	2021	2021	NUM
ajlm-2375	102	38	.	.	PUNCT
ajlm-2375	103	1	table	table	NOUN
ajlm-2375	103	2	3	3	NUM
ajlm-2375	103	3	:	:	PUNCT
ajlm-2375	103	4	 	 	SPACE
ajlm-2375	103	5	associations	association	NOUN
ajlm-2375	103	6	between	between	ADP
ajlm-2375	103	7	covid-19	covid-19	PROPN
ajlm-2375	103	8	outcomes	outcome	NOUN
ajlm-2375	103	9	and	and	CCONJ
ajlm-2375	103	10	single	single	ADJ
ajlm-2375	103	11	nucleotide	nucleotide	ADJ
ajlm-2375	103	12	polymorphisms	polymorphism	NOUN
ajlm-2375	103	13	of	of	ADP
ajlm-2375	103	14	the	the	DET
ajlm-2375	103	15	ace2	ace2	NOUN
ajlm-2375	103	16	and	and	CCONJ
ajlm-2375	103	17	tmprss2	tmprss2	ADP
ajlm-2375	103	18	genes	gene	NOUN
ajlm-2375	103	19	,	,	PUNCT
ajlm-2375	103	20	faculty	faculty	NOUN
ajlm-2375	103	21	of	of	ADP
ajlm-2375	103	22	medicine	medicine	NOUN
ajlm-2375	103	23	,	,	PUNCT
ajlm-2375	103	24	zagazig	zagazig	PROPN
ajlm-2375	103	25	university	university	PROPN
ajlm-2375	103	26	,	,	PUNCT
ajlm-2375	103	27	zagazig	zagazig	PROPN
ajlm-2375	103	28	,	,	PUNCT
ajlm-2375	103	29	egypt	egypt	PROPN
ajlm-2375	103	30	,	,	PUNCT
ajlm-2375	103	31	01	01	NUM
ajlm-2375	103	32	july	july	PROPN
ajlm-2375	103	33	2021	2021	NUM
ajlm-2375	103	34	–	–	PUNCT
ajlm-2375	103	35	30	30	NUM
ajlm-2375	103	36	november	november	NOUN
ajlm-2375	103	37	2021	2021	NUM
ajlm-2375	103	38	.	.	PUNCT
ajlm-2375	104	1	discussion	discussion	NOUN
ajlm-2375	104	2	the	the	DET
ajlm-2375	104	3	mean	mean	ADJ
ajlm-2375	104	4	age	age	NOUN
ajlm-2375	104	5	of	of	ADP
ajlm-2375	104	6	patients	patient	NOUN
ajlm-2375	104	7	who	who	PRON
ajlm-2375	104	8	developed	develop	VERB
ajlm-2375	104	9	severe	severe	ADJ
ajlm-2375	104	10	disease	disease	NOUN
ajlm-2375	104	11	was	be	AUX
ajlm-2375	104	12	significantly	significantly	ADV
ajlm-2375	104	13	higher	high	ADJ
ajlm-2375	104	14	than	than	ADP
ajlm-2375	104	15	mild	mild	ADJ
ajlm-2375	104	16	or	or	CCONJ
ajlm-2375	104	17	moderate	moderate	ADJ
ajlm-2375	104	18	cases	case	NOUN
ajlm-2375	104	19	.	.	PUNCT
ajlm-2375	105	1	this	this	PRON
ajlm-2375	105	2	aligns	align	VERB
ajlm-2375	105	3	with	with	ADP
ajlm-2375	105	4	many	many	ADJ
ajlm-2375	105	5	previous	previous	ADJ
ajlm-2375	105	6	findings	finding	NOUN
ajlm-2375	105	7	that	that	SCONJ
ajlm-2375	105	8	age	age	NOUN
ajlm-2375	105	9	is	be	AUX
ajlm-2375	105	10	a	a	DET
ajlm-2375	105	11	major	major	ADJ
ajlm-2375	105	12	risk	risk	NOUN
ajlm-2375	105	13	factor	factor	NOUN
ajlm-2375	105	14	for	for	ADP
ajlm-2375	105	15	covid-19	covid-19	PROPN
ajlm-2375	105	16	,	,	PUNCT
ajlm-2375	105	17	and	and	CCONJ
ajlm-2375	105	18	the	the	DET
ajlm-2375	105	19	most	most	ADV
ajlm-2375	105	20	unfavourable	unfavourable	ADJ
ajlm-2375	105	21	outcomes	outcome	NOUN
ajlm-2375	105	22	are	be	AUX
ajlm-2375	105	23	attributed	attribute	VERB
ajlm-2375	105	24	to	to	ADP
ajlm-2375	105	25	age	age	NOUN
ajlm-2375	105	26	-	-	PUNCT
ajlm-2375	105	27	related	relate	VERB
ajlm-2375	105	28	comorbidities	comorbiditie	NOUN
ajlm-2375	105	29	and	and	CCONJ
ajlm-2375	105	30	immunocompromising	immunocompromise	VERB
ajlm-2375	105	31	status.20	status.20	NOUN
ajlm-2375	105	32	patients	patient	NOUN
ajlm-2375	105	33	with	with	ADP
ajlm-2375	105	34	severe	severe	ADJ
ajlm-2375	105	35	disease	disease	NOUN
ajlm-2375	105	36	showed	show	VERB
ajlm-2375	105	37	a	a	DET
ajlm-2375	105	38	slight	slight	ADJ
ajlm-2375	105	39	but	but	CCONJ
ajlm-2375	105	40	significant	significant	ADJ
ajlm-2375	105	41	increase	increase	NOUN
ajlm-2375	105	42	in	in	ADP
ajlm-2375	105	43	serum	serum	NOUN
ajlm-2375	105	44	urea	urea	NOUN
ajlm-2375	105	45	and	and	CCONJ
ajlm-2375	105	46	creatinine	creatinine	NOUN
ajlm-2375	105	47	.	.	PUNCT
ajlm-2375	106	1	hachim	hachim	PROPN
ajlm-2375	106	2	et	et	PROPN
ajlm-2375	106	3	al.21	al.21	PROPN
ajlm-2375	106	4	studied	study	VERB
ajlm-2375	106	5	the	the	DET
ajlm-2375	106	6	kidney	kidney	NOUN
ajlm-2375	106	7	function	function	NOUN
ajlm-2375	106	8	in	in	ADP
ajlm-2375	106	9	250	250	NUM
ajlm-2375	106	10	covid-19	covid-19	PROPN
ajlm-2375	106	11	patients	patient	NOUN
ajlm-2375	106	12	in	in	ADP
ajlm-2375	106	13	the	the	DET
ajlm-2375	106	14	middle	middle	PROPN
ajlm-2375	106	15	east	east	PROPN
ajlm-2375	106	16	region	region	NOUN
ajlm-2375	106	17	.	.	PUNCT
ajlm-2375	107	1	the	the	DET
ajlm-2375	107	2	study	study	NOUN
ajlm-2375	107	3	reported	report	VERB
ajlm-2375	107	4	an	an	DET
ajlm-2375	107	5	association	association	NOUN
ajlm-2375	107	6	between	between	ADP
ajlm-2375	107	7	covid-19	covid-19	PROPN
ajlm-2375	107	8	severity	severity	NOUN
ajlm-2375	107	9	and	and	CCONJ
ajlm-2375	107	10	renal	renal	ADJ
ajlm-2375	107	11	impairment	impairment	NOUN
ajlm-2375	107	12	.	.	PUNCT
ajlm-2375	108	1	additionally	additionally	ADV
ajlm-2375	108	2	,	,	PUNCT
ajlm-2375	108	3	these	these	DET
ajlm-2375	108	4	results	result	NOUN
ajlm-2375	108	5	agree	agree	VERB
ajlm-2375	108	6	with	with	ADP
ajlm-2375	108	7	a	a	DET
ajlm-2375	108	8	study	study	NOUN
ajlm-2375	108	9	conducted	conduct	VERB
ajlm-2375	108	10	by	by	ADP
ajlm-2375	108	11	gabarre	gabarre	NOUN
ajlm-2375	108	12	et	et	PROPN
ajlm-2375	108	13	al	al	PROPN
ajlm-2375	108	14	.	.	PROPN
ajlm-2375	109	1	in	in	ADP
ajlm-2375	109	2	2020	2020	NUM
ajlm-2375	109	3	in	in	ADP
ajlm-2375	109	4	paris	paris	PROPN
ajlm-2375	109	5	,	,	PUNCT
ajlm-2375	109	6	france,22	france,22	NOUN
ajlm-2375	109	7	in	in	ADP
ajlm-2375	109	8	which	which	PRON
ajlm-2375	109	9	42.9	42.9	NUM
ajlm-2375	109	10	%	%	NOUN
ajlm-2375	109	11	of	of	ADP
ajlm-2375	109	12	critically	critically	ADV
ajlm-2375	109	13	ill	ill	ADJ
ajlm-2375	109	14	patients	patient	NOUN
ajlm-2375	109	15	developed	develop	VERB
ajlm-2375	109	16	acute	acute	ADJ
ajlm-2375	109	17	kidney	kidney	NOUN
ajlm-2375	109	18	injury	injury	NOUN
ajlm-2375	109	19	.	.	PUNCT
ajlm-2375	110	1	this	this	DET
ajlm-2375	110	2	finding	finding	NOUN
ajlm-2375	110	3	highlights	highlight	VERB
ajlm-2375	110	4	the	the	DET
ajlm-2375	110	5	value	value	NOUN
ajlm-2375	110	6	of	of	ADP
ajlm-2375	110	7	evaluating	evaluate	VERB
ajlm-2375	110	8	kidney	kidney	NOUN
ajlm-2375	110	9	function	function	NOUN
ajlm-2375	110	10	tests	test	NOUN
ajlm-2375	110	11	in	in	ADP
ajlm-2375	110	12	patient	patient	ADJ
ajlm-2375	110	13	monitoring	monitoring	NOUN
ajlm-2375	110	14	.	.	PUNCT
ajlm-2375	111	1	although	although	SCONJ
ajlm-2375	111	2	it	it	PRON
ajlm-2375	111	3	was	be	AUX
ajlm-2375	111	4	elevated	elevate	VERB
ajlm-2375	111	5	in	in	ADP
ajlm-2375	111	6	94	94	NUM
ajlm-2375	111	7	%	%	NOUN
ajlm-2375	111	8	of	of	ADP
ajlm-2375	111	9	patients	patient	NOUN
ajlm-2375	111	10	,	,	PUNCT
ajlm-2375	111	11	crp	crp	PROPN
ajlm-2375	111	12	showed	show	VERB
ajlm-2375	111	13	a	a	DET
ajlm-2375	111	14	sharp	sharp	ADJ
ajlm-2375	111	15	increase	increase	NOUN
ajlm-2375	111	16	in	in	ADP
ajlm-2375	111	17	severe	severe	ADJ
ajlm-2375	111	18	cases	case	NOUN
ajlm-2375	111	19	,	,	PUNCT
ajlm-2375	111	20	and	and	CCONJ
ajlm-2375	111	21	it	it	PRON
ajlm-2375	111	22	was	be	AUX
ajlm-2375	111	23	the	the	DET
ajlm-2375	111	24	only	only	ADJ
ajlm-2375	111	25	independent	independent	ADJ
ajlm-2375	111	26	predictor	predictor	NOUN
ajlm-2375	111	27	for	for	ADP
ajlm-2375	111	28	patients	patient	NOUN
ajlm-2375	111	29	’	'	PUNCT
ajlm-2375	111	30	severity	severity	NOUN
ajlm-2375	111	31	in	in	ADP
ajlm-2375	111	32	this	this	DET
ajlm-2375	111	33	work	work	NOUN
ajlm-2375	111	34	.	.	PUNCT
ajlm-2375	112	1	these	these	DET
ajlm-2375	112	2	results	result	NOUN
ajlm-2375	112	3	go	go	VERB
ajlm-2375	112	4	with	with	ADP
ajlm-2375	112	5	those	those	PRON
ajlm-2375	112	6	of	of	ADP
ajlm-2375	112	7	wang	wang	PROPN
ajlm-2375	112	8	et	et	PROPN
ajlm-2375	112	9	al	al	PROPN
ajlm-2375	112	10	.	.	PROPN
ajlm-2375	112	11	in	in	ADP
ajlm-2375	112	12	2020	2020	NUM
ajlm-2375	112	13	in	in	ADP
ajlm-2375	112	14	china,23	china,23	NOUN
ajlm-2375	112	15	who	who	PRON
ajlm-2375	112	16	reported	report	VERB
ajlm-2375	112	17	that	that	SCONJ
ajlm-2375	112	18	all	all	DET
ajlm-2375	112	19	patients	patient	NOUN
ajlm-2375	112	20	who	who	PRON
ajlm-2375	112	21	developed	develop	VERB
ajlm-2375	112	22	severe	severe	ADJ
ajlm-2375	112	23	diseases	disease	NOUN
ajlm-2375	112	24	displayed	display	VERB
ajlm-2375	112	25	elevated	elevated	ADJ
ajlm-2375	112	26	crp	crp	NOUN
ajlm-2375	112	27	results	result	NOUN
ajlm-2375	112	28	and	and	CCONJ
ajlm-2375	112	29	that	that	SCONJ
ajlm-2375	112	30	crp	crp	PROPN
ajlm-2375	112	31	was	be	AUX
ajlm-2375	112	32	the	the	DET
ajlm-2375	112	33	only	only	ADJ
ajlm-2375	112	34	independent	independent	ADJ
ajlm-2375	112	35	predictor	predictor	NOUN
ajlm-2375	112	36	of	of	ADP
ajlm-2375	112	37	severity	severity	NOUN
ajlm-2375	112	38	.	.	PUNCT
ajlm-2375	113	1	potempa	potempa	NOUN
ajlm-2375	113	2	et	et	PROPN
ajlm-2375	113	3	al.24	al.24	PROPN
ajlm-2375	113	4	revealed	reveal	VERB
ajlm-2375	113	5	that	that	SCONJ
ajlm-2375	113	6	crp	crp	PROPN
ajlm-2375	113	7	was	be	AUX
ajlm-2375	113	8	a	a	DET
ajlm-2375	113	9	reproducible	reproducible	ADJ
ajlm-2375	113	10	,	,	PUNCT
ajlm-2375	113	11	rapid	rapid	ADJ
ajlm-2375	113	12	,	,	PUNCT
ajlm-2375	113	13	and	and	CCONJ
ajlm-2375	113	14	cost	cost	NOUN
ajlm-2375	113	15	-	-	PUNCT
ajlm-2375	113	16	effective	effective	ADJ
ajlm-2375	113	17	marker	marker	NOUN
ajlm-2375	113	18	to	to	PART
ajlm-2375	113	19	evaluate	evaluate	VERB
ajlm-2375	113	20	the	the	DET
ajlm-2375	113	21	extent	extent	NOUN
ajlm-2375	113	22	of	of	ADP
ajlm-2375	113	23	tissue	tissue	NOUN
ajlm-2375	113	24	damage	damage	NOUN
ajlm-2375	113	25	and	and	CCONJ
ajlm-2375	113	26	inflammatory	inflammatory	ADJ
ajlm-2375	113	27	process	process	NOUN
ajlm-2375	113	28	in	in	ADP
ajlm-2375	113	29	covid-19	covid-19	PROPN
ajlm-2375	113	30	patients	patient	NOUN
ajlm-2375	113	31	.	.	PUNCT
ajlm-2375	114	1	the	the	DET
ajlm-2375	114	2	viral	viral	ADJ
ajlm-2375	114	3	load	load	NOUN
ajlm-2375	114	4	did	do	AUX
ajlm-2375	114	5	not	not	PART
ajlm-2375	114	6	significantly	significantly	ADV
ajlm-2375	114	7	influence	influence	VERB
ajlm-2375	114	8	disease	disease	NOUN
ajlm-2375	114	9	severity	severity	NOUN
ajlm-2375	114	10	.	.	PUNCT
ajlm-2375	115	1	prior	prior	ADJ
ajlm-2375	115	2	research	research	NOUN
ajlm-2375	115	3	has	have	AUX
ajlm-2375	115	4	demonstrated	demonstrate	VERB
ajlm-2375	115	5	conflicting	conflicting	ADJ
ajlm-2375	115	6	findings	finding	NOUN
ajlm-2375	115	7	on	on	ADP
ajlm-2375	115	8	this	this	DET
ajlm-2375	115	9	topic	topic	NOUN
ajlm-2375	115	10	,	,	PUNCT
ajlm-2375	115	11	cho	cho	PROPN
ajlm-2375	115	12	et	et	PROPN
ajlm-2375	115	13	al	al	PROPN
ajlm-2375	115	14	.	.	PROPN
ajlm-2375	116	1	in	in	ADP
ajlm-2375	116	2	2020	2020	NUM
ajlm-2375	116	3	in	in	ADP
ajlm-2375	116	4	hong	hong	PROPN
ajlm-2375	116	5	kong	kong	PROPN
ajlm-2375	116	6	,	,	PUNCT
ajlm-2375	116	7	china,25	china,25	PROPN
ajlm-2375	116	8	reported	report	VERB
ajlm-2375	116	9	that	that	SCONJ
ajlm-2375	116	10	viral	viral	ADJ
ajlm-2375	116	11	load	load	NOUN
ajlm-2375	116	12	is	be	AUX
ajlm-2375	116	13	not	not	PART
ajlm-2375	116	14	associated	associate	VERB
ajlm-2375	116	15	with	with	ADP
ajlm-2375	116	16	either	either	CCONJ
ajlm-2375	116	17	severity	severity	NOUN
ajlm-2375	116	18	or	or	CCONJ
ajlm-2375	116	19	outcome	outcome	NOUN
ajlm-2375	116	20	.	.	PUNCT
ajlm-2375	117	1	abdulrahman	abdulrahman	NOUN
ajlm-2375	117	2	et	et	PROPN
ajlm-2375	117	3	al.26	al.26	PROPN
ajlm-2375	117	4	explain	explain	VERB
ajlm-2375	117	5	that	that	SCONJ
ajlm-2375	117	6	the	the	DET
ajlm-2375	117	7	correlation	correlation	NOUN
ajlm-2375	117	8	between	between	ADP
ajlm-2375	117	9	disease	disease	NOUN
ajlm-2375	117	10	severity	severity	NOUN
ajlm-2375	117	11	and	and	CCONJ
ajlm-2375	117	12	crp	crp	NOUN
ajlm-2375	117	13	level	level	NOUN
ajlm-2375	117	14	,	,	PUNCT
ajlm-2375	117	15	rather	rather	ADV
ajlm-2375	117	16	than	than	ADP
ajlm-2375	117	17	viral	viral	ADJ
ajlm-2375	117	18	load	load	NOUN
ajlm-2375	117	19	,	,	PUNCT
ajlm-2375	117	20	can	can	AUX
ajlm-2375	117	21	be	be	AUX
ajlm-2375	117	22	attributed	attribute	VERB
ajlm-2375	117	23	to	to	ADP
ajlm-2375	117	24	the	the	DET
ajlm-2375	117	25	influence	influence	NOUN
ajlm-2375	117	26	of	of	ADP
ajlm-2375	117	27	host	host	NOUN
ajlm-2375	117	28	factors	factor	NOUN
ajlm-2375	117	29	on	on	ADP
ajlm-2375	117	30	disease	disease	NOUN
ajlm-2375	117	31	progression	progression	NOUN
ajlm-2375	117	32	and	and	CCONJ
ajlm-2375	117	33	the	the	DET
ajlm-2375	117	34	contribution	contribution	NOUN
ajlm-2375	117	35	of	of	ADP
ajlm-2375	117	36	pro	pro	ADJ
ajlm-2375	117	37	-	-	ADJ
ajlm-2375	117	38	inflammatory	inflammatory	ADJ
ajlm-2375	117	39	cytokines	cytokine	NOUN
ajlm-2375	117	40	to	to	ADP
ajlm-2375	117	41	the	the	DET
ajlm-2375	117	42	severity	severity	NOUN
ajlm-2375	117	43	of	of	ADP
ajlm-2375	117	44	the	the	DET
ajlm-2375	117	45	disease	disease	NOUN
ajlm-2375	117	46	.	.	PUNCT
ajlm-2375	118	1	the	the	DET
ajlm-2375	118	2	mortality	mortality	NOUN
ajlm-2375	118	3	rate	rate	NOUN
ajlm-2375	118	4	was	be	AUX
ajlm-2375	118	5	higher	high	ADJ
ajlm-2375	118	6	in	in	ADP
ajlm-2375	118	7	severe	severe	ADJ
ajlm-2375	118	8	cases	case	NOUN
ajlm-2375	118	9	than	than	ADP
ajlm-2375	118	10	in	in	ADP
ajlm-2375	118	11	mild	mild	ADJ
ajlm-2375	118	12	or	or	CCONJ
ajlm-2375	118	13	moderate	moderate	ADJ
ajlm-2375	118	14	cases	case	NOUN
ajlm-2375	118	15	,	,	PUNCT
ajlm-2375	118	16	particularly	particularly	ADV
ajlm-2375	118	17	in	in	ADP
ajlm-2375	118	18	those	those	PRON
ajlm-2375	118	19	who	who	PRON
ajlm-2375	118	20	encountered	encounter	VERB
ajlm-2375	118	21	complications	complication	NOUN
ajlm-2375	118	22	during	during	ADP
ajlm-2375	118	23	the	the	DET
ajlm-2375	118	24	disease	disease	NOUN
ajlm-2375	118	25	course	course	NOUN
ajlm-2375	118	26	.	.	PUNCT
ajlm-2375	119	1	this	this	DET
ajlm-2375	119	2	result	result	NOUN
ajlm-2375	119	3	agrees	agree	VERB
ajlm-2375	119	4	with	with	ADP
ajlm-2375	119	5	previous	previous	ADJ
ajlm-2375	119	6	studies	study	NOUN
ajlm-2375	119	7	in	in	ADP
ajlm-2375	119	8	egypt	egypt	PROPN
ajlm-2375	119	9	and	and	CCONJ
ajlm-2375	119	10	worldwide	worldwide	ADV
ajlm-2375	119	11	.	.	PUNCT
ajlm-2375	120	1	gaber	gaber	PROPN
ajlm-2375	120	2	et	et	PROPN
ajlm-2375	120	3	al	al	PROPN
ajlm-2375	120	4	.	.	PROPN
ajlm-2375	120	5	,	,	PUNCT
ajlm-2375	120	6	in	in	ADP
ajlm-2375	120	7	2022	2022	NUM
ajlm-2375	120	8	in	in	ADP
ajlm-2375	120	9	egypt,27	egypt,27	NOUN
ajlm-2375	120	10	reported	report	VERB
ajlm-2375	120	11	that	that	SCONJ
ajlm-2375	120	12	oxygen	oxygen	NOUN
ajlm-2375	120	13	saturation	saturation	NOUN
ajlm-2375	120	14	and	and	CCONJ
ajlm-2375	120	15	chest	chest	NOUN
ajlm-2375	120	16	computed	compute	VERB
ajlm-2375	120	17	tomography	tomography	NOUN
ajlm-2375	120	18	severity	severity	NOUN
ajlm-2375	120	19	score	score	NOUN
ajlm-2375	120	20	are	be	AUX
ajlm-2375	120	21	predictors	predictor	NOUN
ajlm-2375	120	22	of	of	ADP
ajlm-2375	120	23	mortality	mortality	NOUN
ajlm-2375	120	24	.	.	PUNCT
ajlm-2375	121	1	furthermore	furthermore	ADV
ajlm-2375	121	2	,	,	PUNCT
ajlm-2375	121	3	assal	assal	VERB
ajlm-2375	121	4	et	et	PROPN
ajlm-2375	121	5	al	al	PROPN
ajlm-2375	121	6	.	.	PROPN
ajlm-2375	121	7	,	,	PUNCT
ajlm-2375	121	8	in	in	ADP
ajlm-2375	121	9	2022	2022	NUM
ajlm-2375	121	10	in	in	ADP
ajlm-2375	121	11	egypt,28	egypt,28	NOUN
ajlm-2375	121	12	found	find	VERB
ajlm-2375	121	13	that	that	SCONJ
ajlm-2375	121	14	the	the	DET
ajlm-2375	121	15	need	need	NOUN
ajlm-2375	121	16	for	for	ADP
ajlm-2375	121	17	mechanical	mechanical	ADJ
ajlm-2375	121	18	ventilation	ventilation	NOUN
ajlm-2375	121	19	and	and	CCONJ
ajlm-2375	121	20	the	the	DET
ajlm-2375	121	21	occurrence	occurrence	NOUN
ajlm-2375	121	22	of	of	ADP
ajlm-2375	121	23	secondary	secondary	ADJ
ajlm-2375	121	24	bacterial	bacterial	ADJ
ajlm-2375	121	25	infections	infection	NOUN
ajlm-2375	121	26	are	be	AUX
ajlm-2375	121	27	associated	associate	VERB
ajlm-2375	121	28	with	with	ADP
ajlm-2375	121	29	higher	high	ADJ
ajlm-2375	121	30	mortality	mortality	NOUN
ajlm-2375	121	31	.	.	PUNCT
ajlm-2375	122	1	additionally	additionally	ADV
ajlm-2375	122	2	,	,	PUNCT
ajlm-2375	122	3	mahendra	mahendra	PROPN
ajlm-2375	122	4	et	et	PROPN
ajlm-2375	122	5	al	al	PROPN
ajlm-2375	122	6	.	.	PROPN
ajlm-2375	122	7	,	,	PUNCT
ajlm-2375	122	8	in	in	ADP
ajlm-2375	122	9	2021	2021	NUM
ajlm-2375	122	10	in	in	ADP
ajlm-2375	122	11	india,29	india,29	NOUN
ajlm-2375	122	12	indicated	indicate	VERB
ajlm-2375	122	13	that	that	SCONJ
ajlm-2375	122	14	severe	severe	ADJ
ajlm-2375	122	15	pneumonia	pneumonia	NOUN
ajlm-2375	122	16	is	be	AUX
ajlm-2375	122	17	associated	associate	VERB
ajlm-2375	122	18	with	with	ADP
ajlm-2375	122	19	a	a	DET
ajlm-2375	122	20	higher	high	ADJ
ajlm-2375	122	21	fatality	fatality	NOUN
ajlm-2375	122	22	rate	rate	NOUN
ajlm-2375	122	23	.	.	PUNCT
ajlm-2375	123	1	angiotensin	angiotensin	NOUN
ajlm-2375	123	2	-	-	PUNCT
ajlm-2375	123	3	converting	convert	VERB
ajlm-2375	123	4	enzyme	enzyme	NOUN
ajlm-2375	123	5	2	2	NUM
ajlm-2375	123	6	and	and	CCONJ
ajlm-2375	123	7	tmprss2	tmprss2	SCONJ
ajlm-2375	123	8	gene	gene	NOUN
ajlm-2375	123	9	polymorphisms	polymorphism	NOUN
ajlm-2375	123	10	have	have	AUX
ajlm-2375	123	11	been	be	AUX
ajlm-2375	123	12	implicated	implicate	VERB
ajlm-2375	123	13	previously	previously	ADV
ajlm-2375	123	14	in	in	ADP
ajlm-2375	123	15	altering	alter	VERB
ajlm-2375	123	16	the	the	DET
ajlm-2375	123	17	susceptibility	susceptibility	NOUN
ajlm-2375	123	18	to	to	ADP
ajlm-2375	123	19	covid-19	covid-19	PROPN
ajlm-2375	123	20	infection	infection	NOUN
ajlm-2375	123	21	and	and	CCONJ
ajlm-2375	123	22	influencing	influence	VERB
ajlm-2375	123	23	severity	severity	NOUN
ajlm-2375	123	24	and	and	CCONJ
ajlm-2375	123	25	mortality	mortality	NOUN
ajlm-2375	123	26	rates.30	rates.30	VERB
ajlm-2375	123	27	wang	wang	PROPN
ajlm-2375	123	28	et	et	PROPN
ajlm-2375	123	29	al	al	PROPN
ajlm-2375	123	30	.	.	PROPN
ajlm-2375	123	31	,	,	PUNCT
ajlm-2375	123	32	in	in	ADP
ajlm-2375	123	33	2020	2020	NUM
ajlm-2375	123	34	in	in	ADP
ajlm-2375	123	35	china,31	china,31	NOUN
ajlm-2375	123	36	demonstrated	demonstrate	VERB
ajlm-2375	123	37	that	that	SCONJ
ajlm-2375	123	38	ace2	ace2	PROPN
ajlm-2375	123	39	snps	snps	PROPN
ajlm-2375	123	40	-	-	PUNCT
ajlm-2375	123	41	rs4646116	rs4646116	PROPN
ajlm-2375	123	42	,	,	PUNCT
ajlm-2375	123	43	rs267606406	rs267606406	NOUN
ajlm-2375	123	44	,	,	PUNCT
ajlm-2375	123	45	and	and	CCONJ
ajlm-2375	123	46	rs143936283	rs143936283	PROPN
ajlm-2375	123	47	were	be	AUX
ajlm-2375	123	48	associated	associate	VERB
ajlm-2375	123	49	with	with	ADP
ajlm-2375	123	50	higher	high	ADJ
ajlm-2375	123	51	affinity	affinity	NOUN
ajlm-2375	123	52	to	to	ADP
ajlm-2375	123	53	the	the	DET
ajlm-2375	123	54	receptor	receptor	NOUN
ajlm-2375	123	55	-	-	PUNCT
ajlm-2375	123	56	binding	bind	VERB
ajlm-2375	123	57	domain	domain	NOUN
ajlm-2375	123	58	.	.	PUNCT
ajlm-2375	124	1	in	in	ADP
ajlm-2375	124	2	contrast	contrast	NOUN
ajlm-2375	124	3	,	,	PUNCT
ajlm-2375	124	4	ace2	ace2	PROPN
ajlm-2375	124	5	snps	snps	PROPN
ajlm-2375	124	6	-	-	PUNCT
ajlm-2375	124	7	rs1244687367	rs1244687367	PROPN
ajlm-2375	124	8	,	,	PUNCT
ajlm-2375	124	9	rs146676783	rs146676783	NOUN
ajlm-2375	124	10	,	,	PUNCT
ajlm-2375	124	11	and	and	CCONJ
ajlm-2375	124	12	rs961360700	rs961360700	PROPN
ajlm-2375	124	13	were	be	AUX
ajlm-2375	124	14	associated	associate	VERB
ajlm-2375	124	15	with	with	ADP
ajlm-2375	124	16	lower	low	ADJ
ajlm-2375	124	17	binding	bind	VERB
ajlm-2375	124	18	affinity	affinity	NOUN
ajlm-2375	124	19	and	and	CCONJ
ajlm-2375	124	20	hence	hence	ADV
ajlm-2375	124	21	decreased	decrease	VERB
ajlm-2375	124	22	susceptibility	susceptibility	NOUN
ajlm-2375	124	23	to	to	ADP
ajlm-2375	124	24	covid-19	covid-19	PROPN
ajlm-2375	124	25	infection	infection	NOUN
ajlm-2375	124	26	.	.	PUNCT
ajlm-2375	125	1	also	also	ADV
ajlm-2375	125	2	,	,	PUNCT
ajlm-2375	125	3	tmprss2	tmprss2	SCONJ
ajlm-2375	125	4	gene	gene	NOUN
ajlm-2375	125	5	polymorphisms	polymorphism	NOUN
ajlm-2375	125	6	have	have	AUX
ajlm-2375	125	7	been	be	AUX
ajlm-2375	125	8	associated	associate	VERB
ajlm-2375	125	9	with	with	ADP
ajlm-2375	125	10	susceptibility	susceptibility	NOUN
ajlm-2375	125	11	to	to	ADP
ajlm-2375	125	12	covid-19	covid-19	PROPN
ajlm-2375	125	13	infection	infection	NOUN
ajlm-2375	125	14	and	and	CCONJ
ajlm-2375	125	15	outcome.32	outcome.32	ADJ
ajlm-2375	125	16	in	in	ADP
ajlm-2375	125	17	a	a	DET
ajlm-2375	125	18	study	study	NOUN
ajlm-2375	125	19	on	on	ADP
ajlm-2375	125	20	italian	italian	ADJ
ajlm-2375	125	21	patients	patient	NOUN
ajlm-2375	125	22	in	in	ADP
ajlm-2375	125	23	2020	2020	NUM
ajlm-2375	125	24	,	,	PUNCT
ajlm-2375	125	25	asselta	asselta	PROPN
ajlm-2375	125	26	et	et	PROPN
ajlm-2375	125	27	al	al	PROPN
ajlm-2375	125	28	.	.	PROPN
ajlm-2375	125	29	revealed	reveal	VERB
ajlm-2375	125	30	that	that	SCONJ
ajlm-2375	125	31	tmprss2	tmprss2	SCONJ
ajlm-2375	125	32	snps	snps	NOUN
ajlm-2375	125	33	-	-	PUNCT
ajlm-2375	125	34	rs2070788	rs2070788	NOUN
ajlm-2375	125	35	,	,	PUNCT
ajlm-2375	125	36	rs9974589	rs9974589	PROPN
ajlm-2375	125	37	,	,	PUNCT
ajlm-2375	125	38	and	and	CCONJ
ajlm-2375	125	39	rs7364083	rs7364083	PROPN
ajlm-2375	125	40	were	be	AUX
ajlm-2375	125	41	associated	associate	VERB
ajlm-2375	125	42	with	with	ADP
ajlm-2375	125	43	increased	increase	VERB
ajlm-2375	125	44	severity	severity	NOUN
ajlm-2375	125	45	of	of	ADP
ajlm-2375	125	46	covid-19.32	covid-19.32	PROPN
ajlm-2375	125	47	moreover	moreover	ADV
ajlm-2375	125	48	,	,	PUNCT
ajlm-2375	125	49	fuentes	fuentes	PROPN
ajlm-2375	125	50	et	et	PROPN
ajlm-2375	125	51	al	al	PROPN
ajlm-2375	125	52	.	.	PROPN
ajlm-2375	125	53	reported	report	VERB
ajlm-2375	125	54	that	that	SCONJ
ajlm-2375	125	55	rs61735794	rs61735794	PROPN
ajlm-2375	125	56	and	and	CCONJ
ajlm-2375	125	57	rs61735792	rs61735792	PROPN
ajlm-2375	125	58	were	be	AUX
ajlm-2375	125	59	significantly	significantly	ADV
ajlm-2375	125	60	associated	associate	VERB
ajlm-2375	125	61	with	with	ADP
ajlm-2375	125	62	covid-19	covid-19	PROPN
ajlm-2375	125	63	infection	infection	NOUN
ajlm-2375	125	64	outcome.33	outcome.33	NOUN
ajlm-2375	125	65	in	in	ADP
ajlm-2375	125	66	this	this	DET
ajlm-2375	125	67	work	work	NOUN
ajlm-2375	125	68	,	,	PUNCT
ajlm-2375	125	69	no	no	DET
ajlm-2375	125	70	significant	significant	ADJ
ajlm-2375	125	71	associations	association	NOUN
ajlm-2375	125	72	were	be	AUX
ajlm-2375	125	73	detected	detect	VERB
ajlm-2375	125	74	between	between	ADP
ajlm-2375	125	75	either	either	CCONJ
ajlm-2375	125	76	the	the	DET
ajlm-2375	125	77	ace2	ace2	PROPN
ajlm-2375	125	78	rs2285666	rs2285666	VERB
ajlm-2375	125	79	snp	snp	NOUN
ajlm-2375	125	80	or	or	CCONJ
ajlm-2375	125	81	the	the	DET
ajlm-2375	125	82	tmprss2	tmprss2	ADJ
ajlm-2375	125	83	rs2070788	rs2070788	NOUN
ajlm-2375	125	84	snp	snp	NOUN
ajlm-2375	125	85	and	and	CCONJ
ajlm-2375	125	86	covid-19	covid-19	PROPN
ajlm-2375	125	87	severity	severity	NOUN
ajlm-2375	125	88	and	and	CCONJ
ajlm-2375	125	89	outcome	outcome	NOUN
ajlm-2375	125	90	.	.	PUNCT
ajlm-2375	126	1	the	the	DET
ajlm-2375	126	2	aa	aa	PROPN
ajlm-2375	126	3	genotype	genotype	NOUN
ajlm-2375	126	4	of	of	ADP
ajlm-2375	126	5	rs2285666	rs2285666	PROPN
ajlm-2375	126	6	(	(	PUNCT
ajlm-2375	126	7	g8790a	g8790a	NOUN
ajlm-2375	126	8	)	)	PUNCT
ajlm-2375	126	9	was	be	AUX
ajlm-2375	126	10	found	find	VERB
ajlm-2375	126	11	to	to	PART
ajlm-2375	126	12	increase	increase	VERB
ajlm-2375	126	13	ace2	ace2	NOUN
ajlm-2375	126	14	gene	gene	NOUN
ajlm-2375	126	15	expression	expression	NOUN
ajlm-2375	126	16	up	up	ADP
ajlm-2375	126	17	to	to	ADP
ajlm-2375	126	18	50%.34	50%.34	NUM
ajlm-2375	126	19	however	however	ADV
ajlm-2375	126	20	,	,	PUNCT
ajlm-2375	126	21	controversies	controversy	NOUN
ajlm-2375	126	22	have	have	AUX
ajlm-2375	126	23	been	be	AUX
ajlm-2375	126	24	observed	observe	VERB
ajlm-2375	126	25	regarding	regard	VERB
ajlm-2375	126	26	the	the	DET
ajlm-2375	126	27	effect	effect	NOUN
ajlm-2375	126	28	of	of	ADP
ajlm-2375	126	29	this	this	DET
ajlm-2375	126	30	point	point	NOUN
ajlm-2375	126	31	mutation	mutation	NOUN
ajlm-2375	126	32	;	;	PUNCT
ajlm-2375	126	33	srivastava	srivastava	PROPN
ajlm-2375	126	34	et	et	PROPN
ajlm-2375	126	35	al	al	PROPN
ajlm-2375	126	36	.	.	PROPN
ajlm-2375	126	37	,	,	PUNCT
ajlm-2375	126	38	in	in	ADP
ajlm-2375	126	39	2020	2020	NUM
ajlm-2375	126	40	in	in	ADP
ajlm-2375	126	41	india,35	india,35	ADJ
ajlm-2375	126	42	demonstrated	demonstrate	VERB
ajlm-2375	126	43	a	a	DET
ajlm-2375	126	44	negative	negative	ADJ
ajlm-2375	126	45	correlation	correlation	NOUN
ajlm-2375	126	46	between	between	ADP
ajlm-2375	126	47	the	the	DET
ajlm-2375	126	48	alternate	alternate	ADJ
ajlm-2375	126	49	allele	allele	NOUN
ajlm-2375	126	50	(	(	PUNCT
ajlm-2375	126	51	a	a	NOUN
ajlm-2375	126	52	)	)	PUNCT
ajlm-2375	126	53	and	and	CCONJ
ajlm-2375	126	54	case	case	NOUN
ajlm-2375	126	55	fatality	fatality	NOUN
ajlm-2375	126	56	rate	rate	NOUN
ajlm-2375	126	57	of	of	ADP
ajlm-2375	126	58	sars	sar	NOUN
ajlm-2375	126	59	-	-	PUNCT
ajlm-2375	126	60	cov-2	cov-2	NOUN
ajlm-2375	126	61	infection	infection	NOUN
ajlm-2375	126	62	,	,	PUNCT
ajlm-2375	126	63	and	and	CCONJ
ajlm-2375	126	64	möhlendick	möhlendick	VERB
ajlm-2375	126	65	et	et	PROPN
ajlm-2375	126	66	al	al	PROPN
ajlm-2375	126	67	.	.	PROPN
ajlm-2375	126	68	,	,	PUNCT
ajlm-2375	126	69	in	in	ADP
ajlm-2375	126	70	2021	2021	NUM
ajlm-2375	126	71	in	in	ADP
ajlm-2375	126	72	germany,36	germany,36	PROPN
ajlm-2375	126	73	reported	report	VERB
ajlm-2375	126	74	a	a	DET
ajlm-2375	126	75	threefold	threefold	ADJ
ajlm-2375	126	76	increase	increase	NOUN
ajlm-2375	126	77	in	in	ADP
ajlm-2375	126	78	severity	severity	NOUN
ajlm-2375	126	79	in	in	ADP
ajlm-2375	126	80	cases	case	NOUN
ajlm-2375	126	81	carrying	carry	VERB
ajlm-2375	126	82	the	the	DET
ajlm-2375	126	83	gg	gg	NOUN
ajlm-2375	126	84	genotype	genotype	NOUN
ajlm-2375	126	85	.	.	PUNCT
ajlm-2375	127	1	hence	hence	ADV
ajlm-2375	127	2	,	,	PUNCT
ajlm-2375	127	3	they	they	PRON
ajlm-2375	127	4	suggested	suggest	VERB
ajlm-2375	127	5	that	that	SCONJ
ajlm-2375	127	6	rs2285666	rs2285666	PROPN
ajlm-2375	127	7	harbours	harbour	VERB
ajlm-2375	127	8	a	a	DET
ajlm-2375	127	9	protective	protective	ADJ
ajlm-2375	127	10	role	role	NOUN
ajlm-2375	127	11	against	against	ADP
ajlm-2375	127	12	covid-19	covid-19	PROPN
ajlm-2375	127	13	.	.	PUNCT
ajlm-2375	128	1	a	a	DET
ajlm-2375	128	2	possible	possible	ADJ
ajlm-2375	128	3	explanation	explanation	NOUN
ajlm-2375	128	4	for	for	ADP
ajlm-2375	128	5	this	this	DET
ajlm-2375	128	6	finding	finding	NOUN
ajlm-2375	128	7	is	be	AUX
ajlm-2375	128	8	that	that	SCONJ
ajlm-2375	128	9	the	the	DET
ajlm-2375	128	10	increased	increase	VERB
ajlm-2375	128	11	serum	serum	NOUN
ajlm-2375	128	12	and	and	CCONJ
ajlm-2375	128	13	tissue	tissue	NOUN
ajlm-2375	128	14	-	-	PUNCT
ajlm-2375	128	15	bound	bind	VERB
ajlm-2375	128	16	ace2	ace2	NOUN
ajlm-2375	128	17	protein	protein	NOUN
ajlm-2375	128	18	in	in	ADP
ajlm-2375	128	19	patients	patient	NOUN
ajlm-2375	128	20	carrying	carry	VERB
ajlm-2375	128	21	the	the	DET
ajlm-2375	128	22	aa	aa	PROPN
ajlm-2375	128	23	genotype	genotype	NOUN
ajlm-2375	128	24	counteracts	counteract	VERB
ajlm-2375	128	25	the	the	DET
ajlm-2375	128	26	pro	pro	ADJ
ajlm-2375	128	27	-	-	ADJ
ajlm-2375	128	28	inflammatory	inflammatory	ADJ
ajlm-2375	128	29	and	and	CCONJ
ajlm-2375	128	30	fibrotic	fibrotic	ADJ
ajlm-2375	128	31	effects	effect	NOUN
ajlm-2375	128	32	of	of	ADP
ajlm-2375	128	33	angiotensin	angiotensin	NOUN
ajlm-2375	128	34	ii.37	ii.37	PROPN
ajlm-2375	128	35	however	however	ADV
ajlm-2375	128	36	,	,	PUNCT
ajlm-2375	128	37	martínez	martínez	NOUN
ajlm-2375	128	38	-	-	PUNCT
ajlm-2375	128	39	gómez	gómez	NOUN
ajlm-2375	128	40	et	et	PROPN
ajlm-2375	128	41	al	al	PROPN
ajlm-2375	128	42	.	.	PROPN
ajlm-2375	128	43	,	,	PUNCT
ajlm-2375	128	44	in	in	ADP
ajlm-2375	128	45	2022	2022	NUM
ajlm-2375	128	46	in	in	ADP
ajlm-2375	128	47	mexico,38	mexico,38	NOUN
ajlm-2375	128	48	and	and	CCONJ
ajlm-2375	128	49	sabater	sabater	ADV
ajlm-2375	128	50	et	et	PROPN
ajlm-2375	128	51	al	al	PROPN
ajlm-2375	128	52	.	.	PROPN
ajlm-2375	128	53	,	,	PUNCT
ajlm-2375	128	54	in	in	ADP
ajlm-2375	128	55	2022	2022	NUM
ajlm-2375	128	56	in	in	ADP
ajlm-2375	128	57	spain,39	spain,39	NOUN
ajlm-2375	128	58	found	find	VERB
ajlm-2375	128	59	that	that	SCONJ
ajlm-2375	128	60	the	the	DET
ajlm-2375	128	61	aa	aa	PROPN
ajlm-2375	128	62	genotype	genotype	NOUN
ajlm-2375	128	63	was	be	AUX
ajlm-2375	128	64	associated	associate	VERB
ajlm-2375	128	65	with	with	ADP
ajlm-2375	128	66	critical	critical	ADJ
ajlm-2375	128	67	outcome	outcome	NOUN
ajlm-2375	128	68	.	.	PUNCT
ajlm-2375	129	1	the	the	DET
ajlm-2375	129	2	current	current	ADJ
ajlm-2375	129	3	work	work	NOUN
ajlm-2375	129	4	’s	’s	PART
ajlm-2375	129	5	results	result	NOUN
ajlm-2375	129	6	agree	agree	VERB
ajlm-2375	129	7	with	with	ADP
ajlm-2375	129	8	those	those	PRON
ajlm-2375	129	9	of	of	ADP
ajlm-2375	129	10	alimoradi	alimoradi	NOUN
ajlm-2375	129	11	et	et	PROPN
ajlm-2375	129	12	al	al	PROPN
ajlm-2375	129	13	.	.	PROPN
ajlm-2375	129	14	,	,	PUNCT
ajlm-2375	129	15	in	in	ADP
ajlm-2375	129	16	2022	2022	NUM
ajlm-2375	129	17	in	in	ADP
ajlm-2375	129	18	iran,18	iran,18	NOUN
ajlm-2375	129	19	karakaş	karakaş	PROPN
ajlm-2375	129	20	et	et	PROPN
ajlm-2375	129	21	al	al	PROPN
ajlm-2375	129	22	.	.	PROPN
ajlm-2375	129	23	,	,	PUNCT
ajlm-2375	129	24	in	in	ADP
ajlm-2375	129	25	2021	2021	NUM
ajlm-2375	129	26	in	in	ADP
ajlm-2375	129	27	turkey,40	turkey,40	NOUN
ajlm-2375	129	28	and	and	CCONJ
ajlm-2375	129	29	elnagdy	elnagdy	NOUN
ajlm-2375	129	30	et	et	PROPN
ajlm-2375	129	31	al	al	PROPN
ajlm-2375	129	32	.	.	PROPN
ajlm-2375	129	33	,	,	PUNCT
ajlm-2375	129	34	in	in	ADP
ajlm-2375	129	35	2022	2022	NUM
ajlm-2375	129	36	in	in	ADP
ajlm-2375	129	37	egypt,41	egypt,41	NOUN
ajlm-2375	129	38	that	that	SCONJ
ajlm-2375	129	39	there	there	PRON
ajlm-2375	129	40	is	be	VERB
ajlm-2375	129	41	no	no	DET
ajlm-2375	129	42	significant	significant	ADJ
ajlm-2375	129	43	association	association	NOUN
ajlm-2375	129	44	between	between	ADP
ajlm-2375	129	45	rs2285666	rs2285666	PROPN
ajlm-2375	129	46	and	and	CCONJ
ajlm-2375	129	47	covid-19	covid-19	PROPN
ajlm-2375	129	48	severity	severity	NOUN
ajlm-2375	129	49	and	and	CCONJ
ajlm-2375	129	50	outcome	outcome	NOUN
ajlm-2375	129	51	.	.	PUNCT
ajlm-2375	130	1	variations	variation	NOUN
ajlm-2375	130	2	in	in	ADP
ajlm-2375	130	3	findings	finding	NOUN
ajlm-2375	130	4	between	between	ADP
ajlm-2375	130	5	studies	study	NOUN
ajlm-2375	130	6	can	can	AUX
ajlm-2375	130	7	be	be	AUX
ajlm-2375	130	8	attributed	attribute	VERB
ajlm-2375	130	9	to	to	ADP
ajlm-2375	130	10	factors	factor	NOUN
ajlm-2375	130	11	such	such	ADJ
ajlm-2375	130	12	as	as	ADP
ajlm-2375	130	13	ethnicity	ethnicity	NOUN
ajlm-2375	130	14	variations	variation	NOUN
ajlm-2375	130	15	,	,	PUNCT
ajlm-2375	130	16	sample	sample	NOUN
ajlm-2375	130	17	size	size	NOUN
ajlm-2375	130	18	,	,	PUNCT
ajlm-2375	130	19	patients	patient	NOUN
ajlm-2375	130	20	’	'	PUNCT
ajlm-2375	130	21	habits	habit	NOUN
ajlm-2375	130	22	,	,	PUNCT
ajlm-2375	130	23	and	and	CCONJ
ajlm-2375	130	24	,	,	PUNCT
ajlm-2375	130	25	notably	notably	ADV
ajlm-2375	130	26	,	,	PUNCT
ajlm-2375	130	27	viral	viral	ADJ
ajlm-2375	130	28	load	load	NOUN
ajlm-2375	130	29	.	.	PUNCT
ajlm-2375	131	1	in	in	ADP
ajlm-2375	131	2	addition	addition	NOUN
ajlm-2375	131	3	,	,	PUNCT
ajlm-2375	131	4	along	along	ADP
ajlm-2375	131	5	with	with	ADP
ajlm-2375	131	6	genetic	genetic	ADJ
ajlm-2375	131	7	variations	variation	NOUN
ajlm-2375	131	8	,	,	PUNCT
ajlm-2375	131	9	many	many	ADJ
ajlm-2375	131	10	other	other	ADJ
ajlm-2375	131	11	factors	factor	NOUN
ajlm-2375	131	12	can	can	AUX
ajlm-2375	131	13	influence	influence	VERB
ajlm-2375	131	14	the	the	DET
ajlm-2375	131	15	balance	balance	NOUN
ajlm-2375	131	16	between	between	ADP
ajlm-2375	131	17	the	the	DET
ajlm-2375	131	18	susceptibility	susceptibility	NOUN
ajlm-2375	131	19	and	and	CCONJ
ajlm-2375	131	20	protective	protective	ADJ
ajlm-2375	131	21	roles	role	NOUN
ajlm-2375	131	22	of	of	ADP
ajlm-2375	131	23	ace2	ace2	NOUN
ajlm-2375	131	24	protein	protein	NOUN
ajlm-2375	131	25	,	,	PUNCT
ajlm-2375	131	26	such	such	ADJ
ajlm-2375	131	27	as	as	ADP
ajlm-2375	131	28	smoking	smoking	NOUN
ajlm-2375	131	29	,	,	PUNCT
ajlm-2375	131	30	diet	diet	NOUN
ajlm-2375	131	31	,	,	PUNCT
ajlm-2375	131	32	comorbidities	comorbiditie	NOUN
ajlm-2375	131	33	,	,	PUNCT
ajlm-2375	131	34	age	age	NOUN
ajlm-2375	131	35	,	,	PUNCT
ajlm-2375	131	36	sex	sex	NOUN
ajlm-2375	131	37	,	,	PUNCT
ajlm-2375	131	38	and	and	CCONJ
ajlm-2375	131	39	cleavage	cleavage	NOUN
ajlm-2375	131	40	of	of	ADP
ajlm-2375	131	41	the	the	DET
ajlm-2375	131	42	ace2	ace2	NOUN
ajlm-2375	131	43	protein	protein	NOUN
ajlm-2375	131	44	by	by	ADP
ajlm-2375	131	45	products	product	NOUN
ajlm-2375	131	46	of	of	ADP
ajlm-2375	131	47	the	the	DET
ajlm-2375	131	48	tmprss2	tmprss2	NOUN
ajlm-2375	131	49	and	and	CCONJ
ajlm-2375	131	50	adam17	adam17	VERB
ajlm-2375	131	51	genes.5	genes.5	PROPN
ajlm-2375	131	52	pandey	pandey	PROPN
ajlm-2375	131	53	et	et	PROPN
ajlm-2375	131	54	al	al	PROPN
ajlm-2375	131	55	.	.	PROPN
ajlm-2375	131	56	,	,	PUNCT
ajlm-2375	131	57	in	in	ADP
ajlm-2375	131	58	2022	2022	NUM
ajlm-2375	131	59	in	in	ADP
ajlm-2375	131	60	india,42	india,42	NOUN
ajlm-2375	131	61	and	and	CCONJ
ajlm-2375	131	62	asselta	asselta	PROPN
ajlm-2375	131	63	et	et	PROPN
ajlm-2375	131	64	al	al	PROPN
ajlm-2375	131	65	.	.	PROPN
ajlm-2375	131	66	,	,	PUNCT
ajlm-2375	131	67	in	in	ADP
ajlm-2375	131	68	2020	2020	NUM
ajlm-2375	131	69	in	in	ADP
ajlm-2375	131	70	italy,32	italy,32	NOUN
ajlm-2375	131	71	observed	observe	VERB
ajlm-2375	131	72	that	that	SCONJ
ajlm-2375	131	73	the	the	DET
ajlm-2375	131	74	tmprss2	tmprss2	ADJ
ajlm-2375	131	75	snp	snp	ADJ
ajlm-2375	131	76	rs2070788	rs2070788	NOUN
ajlm-2375	131	77	had	have	VERB
ajlm-2375	131	78	a	a	DET
ajlm-2375	131	79	statistically	statistically	ADV
ajlm-2375	131	80	significant	significant	ADJ
ajlm-2375	131	81	association	association	NOUN
ajlm-2375	131	82	with	with	ADP
ajlm-2375	131	83	disease	disease	NOUN
ajlm-2375	131	84	severity	severity	NOUN
ajlm-2375	131	85	and	and	CCONJ
ajlm-2375	131	86	fatality	fatality	NOUN
ajlm-2375	131	87	rate	rate	NOUN
ajlm-2375	131	88	in	in	ADP
ajlm-2375	131	89	american	american	ADJ
ajlm-2375	131	90	and	and	CCONJ
ajlm-2375	131	91	italian	italian	ADJ
ajlm-2375	131	92	populations	population	NOUN
ajlm-2375	131	93	,	,	PUNCT
ajlm-2375	131	94	respectively	respectively	ADV
ajlm-2375	131	95	.	.	PUNCT
ajlm-2375	132	1	another	another	DET
ajlm-2375	132	2	multicentre	multicentre	NOUN
ajlm-2375	132	3	study	study	NOUN
ajlm-2375	132	4	by	by	ADP
ajlm-2375	132	5	irham	irham	PROPN
ajlm-2375	132	6	et	et	PROPN
ajlm-2375	132	7	al	al	PROPN
ajlm-2375	132	8	.	.	PROPN
ajlm-2375	133	1	in	in	ADP
ajlm-2375	133	2	202011	202011	NUM
ajlm-2375	133	3	showed	show	VERB
ajlm-2375	133	4	that	that	SCONJ
ajlm-2375	133	5	rs2070788	rs2070788	NOUN
ajlm-2375	133	6	and	and	CCONJ
ajlm-2375	133	7	another	another	DET
ajlm-2375	133	8	three	three	NUM
ajlm-2375	133	9	snps	snps	NOUN
ajlm-2375	133	10	,	,	PUNCT
ajlm-2375	133	11	which	which	PRON
ajlm-2375	133	12	affect	affect	VERB
ajlm-2375	133	13	the	the	DET
ajlm-2375	133	14	expression	expression	NOUN
ajlm-2375	133	15	of	of	ADP
ajlm-2375	133	16	the	the	DET
ajlm-2375	133	17	tmprss2	tmprss2	ADJ
ajlm-2375	133	18	gene	gene	NOUN
ajlm-2375	133	19	in	in	ADP
ajlm-2375	133	20	lung	lung	NOUN
ajlm-2375	133	21	tissues	tissue	NOUN
ajlm-2375	133	22	,	,	PUNCT
ajlm-2375	133	23	were	be	AUX
ajlm-2375	133	24	more	more	ADV
ajlm-2375	133	25	prevalent	prevalent	ADJ
ajlm-2375	133	26	in	in	ADP
ajlm-2375	133	27	american	american	ADJ
ajlm-2375	133	28	and	and	CCONJ
ajlm-2375	133	29	european	european	ADJ
ajlm-2375	133	30	populations	population	NOUN
ajlm-2375	133	31	than	than	ADP
ajlm-2375	133	32	in	in	ADP
ajlm-2375	133	33	asian	asian	ADJ
ajlm-2375	133	34	populations	population	NOUN
ajlm-2375	133	35	;	;	PUNCT
ajlm-2375	133	36	this	this	DET
ajlm-2375	133	37	finding	finding	NOUN
ajlm-2375	133	38	can	can	AUX
ajlm-2375	133	39	explain	explain	VERB
ajlm-2375	133	40	the	the	DET
ajlm-2375	133	41	higher	high	ADJ
ajlm-2375	133	42	susceptibility	susceptibility	NOUN
ajlm-2375	133	43	and	and	CCONJ
ajlm-2375	133	44	fatality	fatality	NOUN
ajlm-2375	133	45	rates	rate	NOUN
ajlm-2375	133	46	in	in	ADP
ajlm-2375	133	47	american	american	ADJ
ajlm-2375	133	48	and	and	CCONJ
ajlm-2375	133	49	european	european	ADJ
ajlm-2375	133	50	populations	population	NOUN
ajlm-2375	133	51	.	.	PUNCT
ajlm-2375	134	1	schönfelder	schönfelder	NOUN
ajlm-2375	134	2	et	et	PROPN
ajlm-2375	134	3	al	al	PROPN
ajlm-2375	134	4	.	.	PROPN
ajlm-2375	134	5	,	,	PUNCT
ajlm-2375	134	6	in	in	ADP
ajlm-2375	134	7	2021	2021	NUM
ajlm-2375	134	8	in	in	ADP
ajlm-2375	134	9	germany,43	germany,43	NOUN
ajlm-2375	134	10	observed	observe	VERB
ajlm-2375	134	11	no	no	DET
ajlm-2375	134	12	significant	significant	ADJ
ajlm-2375	134	13	association	association	NOUN
ajlm-2375	134	14	between	between	ADP
ajlm-2375	134	15	rs2070788	rs2070788	NOUN
ajlm-2375	134	16	and	and	CCONJ
ajlm-2375	134	17	covid-19	covid-19	PROPN
ajlm-2375	134	18	severity	severity	NOUN
ajlm-2375	134	19	.	.	PUNCT
ajlm-2375	135	1	in	in	ADP
ajlm-2375	135	2	addition	addition	NOUN
ajlm-2375	135	3	,	,	PUNCT
ajlm-2375	135	4	they	they	PRON
ajlm-2375	135	5	attributed	attribute	VERB
ajlm-2375	135	6	differences	difference	NOUN
ajlm-2375	135	7	among	among	ADP
ajlm-2375	135	8	several	several	ADJ
ajlm-2375	135	9	studies	study	NOUN
ajlm-2375	135	10	to	to	ADP
ajlm-2375	135	11	variations	variation	NOUN
ajlm-2375	135	12	in	in	ADP
ajlm-2375	135	13	sample	sample	NOUN
ajlm-2375	135	14	size	size	NOUN
ajlm-2375	135	15	,	,	PUNCT
ajlm-2375	135	16	ethnicity	ethnicity	NOUN
ajlm-2375	135	17	,	,	PUNCT
ajlm-2375	135	18	and	and	CCONJ
ajlm-2375	135	19	the	the	DET
ajlm-2375	135	20	possibility	possibility	NOUN
ajlm-2375	135	21	of	of	ADP
ajlm-2375	135	22	the	the	DET
ajlm-2375	135	23	presence	presence	NOUN
ajlm-2375	135	24	of	of	ADP
ajlm-2375	135	25	linkage	linkage	NOUN
ajlm-2375	135	26	disequilibrium	disequilibrium	NOUN
ajlm-2375	135	27	with	with	ADP
ajlm-2375	135	28	rs383510	rs383510	PROPN
ajlm-2375	135	29	.	.	PUNCT
ajlm-2375	135	30	limitations	limitation	NOUN
ajlm-2375	135	31	this	this	DET
ajlm-2375	135	32	study	study	NOUN
ajlm-2375	135	33	has	have	VERB
ajlm-2375	135	34	some	some	DET
ajlm-2375	135	35	limitations	limitation	NOUN
ajlm-2375	135	36	that	that	PRON
ajlm-2375	135	37	should	should	AUX
ajlm-2375	135	38	be	be	AUX
ajlm-2375	135	39	considered	consider	VERB
ajlm-2375	135	40	when	when	SCONJ
ajlm-2375	135	41	interpreting	interpret	VERB
ajlm-2375	135	42	the	the	DET
ajlm-2375	135	43	findings	finding	NOUN
ajlm-2375	135	44	.	.	PUNCT
ajlm-2375	136	1	firstly	firstly	ADV
ajlm-2375	136	2	,	,	PUNCT
ajlm-2375	136	3	this	this	PRON
ajlm-2375	136	4	was	be	AUX
ajlm-2375	136	5	a	a	DET
ajlm-2375	136	6	single	single	ADJ
ajlm-2375	136	7	-	-	PUNCT
ajlm-2375	136	8	centre	centre	NOUN
ajlm-2375	136	9	study	study	NOUN
ajlm-2375	136	10	with	with	ADP
ajlm-2375	136	11	a	a	DET
ajlm-2375	136	12	relatively	relatively	ADV
ajlm-2375	136	13	low	low	ADJ
ajlm-2375	136	14	sample	sample	NOUN
ajlm-2375	136	15	size	size	NOUN
ajlm-2375	136	16	.	.	PUNCT
ajlm-2375	137	1	thus	thus	ADV
ajlm-2375	137	2	,	,	PUNCT
ajlm-2375	137	3	the	the	DET
ajlm-2375	137	4	results	result	NOUN
ajlm-2375	137	5	may	may	AUX
ajlm-2375	137	6	be	be	AUX
ajlm-2375	137	7	insufficiently	insufficiently	ADV
ajlm-2375	137	8	powered	power	VERB
ajlm-2375	137	9	and	and	CCONJ
ajlm-2375	137	10	require	require	VERB
ajlm-2375	137	11	further	further	ADJ
ajlm-2375	137	12	confirmation	confirmation	NOUN
ajlm-2375	137	13	by	by	ADP
ajlm-2375	137	14	future	future	ADJ
ajlm-2375	137	15	multicentre	multicentre	NOUN
ajlm-2375	137	16	studies	study	NOUN
ajlm-2375	137	17	with	with	ADP
ajlm-2375	137	18	larger	large	ADJ
ajlm-2375	137	19	cohorts	cohort	NOUN
ajlm-2375	137	20	.	.	PUNCT
ajlm-2375	138	1	secondly	secondly	ADV
ajlm-2375	138	2	,	,	PUNCT
ajlm-2375	138	3	host	host	NOUN
ajlm-2375	138	4	genetics	genetic	NOUN
ajlm-2375	138	5	is	be	AUX
ajlm-2375	138	6	not	not	PART
ajlm-2375	138	7	the	the	DET
ajlm-2375	138	8	only	only	ADJ
ajlm-2375	138	9	factor	factor	NOUN
ajlm-2375	138	10	that	that	PRON
ajlm-2375	138	11	can	can	AUX
ajlm-2375	138	12	influence	influence	VERB
ajlm-2375	138	13	covid-19	covid-19	PROPN
ajlm-2375	138	14	disease	disease	NOUN
ajlm-2375	138	15	:	:	PUNCT
ajlm-2375	138	16	the	the	DET
ajlm-2375	138	17	host	host	NOUN
ajlm-2375	138	18	immunological	immunological	ADJ
ajlm-2375	138	19	status	status	NOUN
ajlm-2375	138	20	as	as	ADV
ajlm-2375	138	21	well	well	ADV
ajlm-2375	138	22	as	as	ADP
ajlm-2375	138	23	sars	sar	NOUN
ajlm-2375	138	24	-	-	PUNCT
ajlm-2375	138	25	cov-2	cov-2	PART
ajlm-2375	138	26	strain	strain	NOUN
ajlm-2375	138	27	variations	variation	NOUN
ajlm-2375	138	28	have	have	VERB
ajlm-2375	138	29	impacts	impact	NOUN
ajlm-2375	138	30	on	on	ADP
ajlm-2375	138	31	disease	disease	NOUN
ajlm-2375	138	32	severity	severity	NOUN
ajlm-2375	138	33	and	and	CCONJ
ajlm-2375	138	34	outcome	outcome	NOUN
ajlm-2375	138	35	.	.	PUNCT
ajlm-2375	139	1	in	in	ADP
ajlm-2375	139	2	addition	addition	NOUN
ajlm-2375	139	3	,	,	PUNCT
ajlm-2375	139	4	an	an	DET
ajlm-2375	139	5	interplay	interplay	NOUN
ajlm-2375	139	6	between	between	ADP
ajlm-2375	139	7	all	all	PRON
ajlm-2375	139	8	of	of	ADP
ajlm-2375	139	9	these	these	DET
ajlm-2375	139	10	factors	factor	NOUN
ajlm-2375	139	11	exists	exist	VERB
ajlm-2375	139	12	;	;	PUNCT
ajlm-2375	139	13	no	no	DET
ajlm-2375	139	14	data	datum	NOUN
ajlm-2375	139	15	were	be	AUX
ajlm-2375	139	16	available	available	ADJ
ajlm-2375	139	17	about	about	ADP
ajlm-2375	139	18	patients	patient	NOUN
ajlm-2375	139	19	’	'	PUNCT
ajlm-2375	139	20	antibody	antibody	NOUN
ajlm-2375	139	21	response	response	NOUN
ajlm-2375	139	22	or	or	CCONJ
ajlm-2375	139	23	viral	viral	ADJ
ajlm-2375	139	24	genotypes	genotype	NOUN
ajlm-2375	139	25	so	so	SCONJ
ajlm-2375	139	26	these	these	DET
ajlm-2375	139	27	factors	factor	NOUN
ajlm-2375	139	28	could	could	AUX
ajlm-2375	139	29	not	not	PART
ajlm-2375	139	30	be	be	AUX
ajlm-2375	139	31	included	include	VERB
ajlm-2375	139	32	in	in	ADP
ajlm-2375	139	33	the	the	DET
ajlm-2375	139	34	analyses	analysis	NOUN
ajlm-2375	139	35	.	.	PUNCT
ajlm-2375	140	1	this	this	PRON
ajlm-2375	140	2	may	may	AUX
ajlm-2375	140	3	have	have	AUX
ajlm-2375	140	4	resulted	result	VERB
ajlm-2375	140	5	in	in	ADP
ajlm-2375	140	6	insufficient	insufficient	ADJ
ajlm-2375	140	7	data	datum	NOUN
ajlm-2375	140	8	about	about	ADP
ajlm-2375	140	9	the	the	DET
ajlm-2375	140	10	impact	impact	NOUN
ajlm-2375	140	11	of	of	ADP
ajlm-2375	140	12	these	these	DET
ajlm-2375	140	13	factors	factor	NOUN
ajlm-2375	140	14	on	on	ADP
ajlm-2375	140	15	disease	disease	NOUN
ajlm-2375	140	16	behaviour	behaviour	NOUN
ajlm-2375	140	17	.	.	PUNCT
ajlm-2375	141	1	conclusion	conclusion	VERB
ajlm-2375	141	2	the	the	DET
ajlm-2375	141	3	genotypes	genotype	NOUN
ajlm-2375	141	4	and	and	CCONJ
ajlm-2375	141	5	allele	allele	NOUN
ajlm-2375	141	6	frequencies	frequency	NOUN
ajlm-2375	141	7	of	of	ADP
ajlm-2375	141	8	the	the	DET
ajlm-2375	141	9	ace2	ace2	PROPN
ajlm-2375	141	10	gene	gene	NOUN
ajlm-2375	141	11	snp	snp	NOUN
ajlm-2375	141	12	rs2285666	rs2285666	PROPN
ajlm-2375	141	13	and	and	CCONJ
ajlm-2375	141	14	the	the	DET
ajlm-2375	141	15	tmprss2	tmprss2	ADJ
ajlm-2375	141	16	gene	gene	NOUN
ajlm-2375	141	17	snp	snp	ADJ
ajlm-2375	141	18	rs2070788	rs2070788	NOUN
ajlm-2375	141	19	showed	show	VERB
ajlm-2375	141	20	no	no	DET
ajlm-2375	141	21	significant	significant	ADJ
ajlm-2375	141	22	associations	association	NOUN
ajlm-2375	141	23	with	with	ADP
ajlm-2375	141	24	the	the	DET
ajlm-2375	141	25	severity	severity	NOUN
ajlm-2375	141	26	and	and	CCONJ
ajlm-2375	141	27	outcome	outcome	NOUN
ajlm-2375	141	28	of	of	ADP
ajlm-2375	141	29	patients	patient	NOUN
ajlm-2375	141	30	.	.	PUNCT
ajlm-2375	142	1	further	further	ADJ
ajlm-2375	142	2	investigation	investigation	NOUN
ajlm-2375	142	3	into	into	ADP
ajlm-2375	142	4	additional	additional	ADJ
ajlm-2375	142	5	genetic	genetic	ADJ
ajlm-2375	142	6	correlations	correlation	NOUN
ajlm-2375	142	7	with	with	ADP
ajlm-2375	142	8	covid-19	covid-19	PROPN
ajlm-2375	142	9	infection	infection	NOUN
ajlm-2375	142	10	is	be	AUX
ajlm-2375	142	11	still	still	ADV
ajlm-2375	142	12	necessary	necessary	ADJ
ajlm-2375	142	13	.	.	PUNCT
ajlm-2375	143	1	acknowledgements	acknowledgement	NOUN
ajlm-2375	143	2	the	the	DET
ajlm-2375	143	3	authors	author	NOUN
ajlm-2375	143	4	would	would	AUX
ajlm-2375	143	5	like	like	VERB
ajlm-2375	143	6	to	to	PART
ajlm-2375	143	7	thank	thank	VERB
ajlm-2375	143	8	the	the	DET
ajlm-2375	143	9	staff	staff	NOUN
ajlm-2375	143	10	members	member	NOUN
ajlm-2375	143	11	of	of	ADP
ajlm-2375	143	12	the	the	DET
ajlm-2375	143	13	zagazig	zagazig	PROPN
ajlm-2375	143	14	scientific	scientific	ADJ
ajlm-2375	143	15	and	and	CCONJ
ajlm-2375	143	16	medical	medical	ADJ
ajlm-2375	143	17	research	research	NOUN
ajlm-2375	143	18	center	center	NOUN
ajlm-2375	143	19	,	,	PUNCT
ajlm-2375	143	20	dr	dr	PROPN
ajlm-2375	143	21	manal	manal	PROPN
ajlm-2375	143	22	abd	abd	PROPN
ajlm-2375	143	23	alhafeez	alhafeez	PROPN
ajlm-2375	143	24	,	,	PUNCT
ajlm-2375	143	25	dr	dr	PROPN
ajlm-2375	143	26	mariem	mariem	PROPN
ajlm-2375	143	27	a.	a.	PROPN
ajlm-2375	143	28	soliman	soliman	PROPN
ajlm-2375	143	29	,	,	PUNCT
ajlm-2375	143	30	mrs	mrs	PROPN
ajlm-2375	143	31	samah	samah	PROPN
ajlm-2375	143	32	alsaeed	alsaeed	PROPN
ajlm-2375	143	33	and	and	CCONJ
ajlm-2375	143	34	mr	mr	PROPN
ajlm-2375	143	35	peter	peter	PROPN
ajlm-2375	143	36	maher	maher	PROPN
ajlm-2375	143	37	,	,	PUNCT
ajlm-2375	143	38	for	for	ADP
ajlm-2375	143	39	their	their	PRON
ajlm-2375	143	40	assistance	assistance	NOUN
ajlm-2375	143	41	during	during	ADP
ajlm-2375	143	42	the	the	DET
ajlm-2375	143	43	laboratory	laboratory	NOUN
ajlm-2375	143	44	work	work	NOUN
ajlm-2375	143	45	.	.	PUNCT
ajlm-2375	144	1	competing	compete	VERB
ajlm-2375	144	2	interests	interest	NOUN
ajlm-2375	144	3	the	the	DET
ajlm-2375	144	4	authors	author	NOUN
ajlm-2375	144	5	declare	declare	VERB
ajlm-2375	144	6	that	that	SCONJ
ajlm-2375	144	7	they	they	PRON
ajlm-2375	144	8	have	have	VERB
ajlm-2375	144	9	no	no	DET
ajlm-2375	144	10	financial	financial	ADJ
ajlm-2375	144	11	or	or	CCONJ
ajlm-2375	144	12	personal	personal	ADJ
ajlm-2375	144	13	relationships	relationship	NOUN
ajlm-2375	144	14	that	that	PRON
ajlm-2375	144	15	may	may	AUX
ajlm-2375	144	16	have	have	AUX
ajlm-2375	144	17	inappropriately	inappropriately	ADV
ajlm-2375	144	18	influenced	influence	VERB
ajlm-2375	144	19	them	they	PRON
ajlm-2375	144	20	in	in	ADP
ajlm-2375	144	21	writing	write	VERB
ajlm-2375	144	22	this	this	DET
ajlm-2375	144	23	article	article	NOUN
ajlm-2375	144	24	.	.	PUNCT
ajlm-2375	145	1	authors	author	NOUN
ajlm-2375	145	2	’	'	PUNCT
ajlm-2375	145	3	contributions	contribution	NOUN
ajlm-2375	145	4	n.a.e.-d	n.a.e.-d	PROPN
ajlm-2375	145	5	.	.	PROPN
ajlm-2375	145	6	,	,	PUNCT
ajlm-2375	145	7	a.a	a.a	PROPN
ajlm-2375	145	8	.	.	PROPN
ajlm-2375	145	9	abdelmoati	abdelmoati	PROPN
ajlm-2375	145	10	,	,	PUNCT
ajlm-2375	145	11	a.l.s	a.l.s	PROPN
ajlm-2375	145	12	.	.	PROPN
ajlm-2375	145	13	,	,	PUNCT
ajlm-2375	145	14	w.s	w.s	AUX
ajlm-2375	145	15	.	.	PROPN
ajlm-2375	145	16	,	,	PUNCT
ajlm-2375	145	17	a.m.e.-g	a.m.e.-g	PROPN
ajlm-2375	145	18	.	.	PROPN
ajlm-2375	145	19	,	,	PUNCT
ajlm-2375	145	20	o.a.g	o.a.g	PROPN
ajlm-2375	145	21	.	.	PROPN
ajlm-2375	145	22	,	,	PUNCT
ajlm-2375	145	23	r.m	r.m	PROPN
ajlm-2375	145	24	.	.	PROPN
ajlm-2375	145	25	,	,	PUNCT
ajlm-2375	145	26	a.f	a.f	PROPN
ajlm-2375	145	27	.	.	PROPN
ajlm-2375	145	28	,	,	PUNCT
ajlm-2375	145	29	r.m.a	r.m.a	NOUN
ajlm-2375	145	30	.	.	PROPN
ajlm-2375	145	31	,	,	PUNCT
ajlm-2375	145	32	m.e.a	m.e.a	PROPN
ajlm-2375	145	33	.	.	PROPN
ajlm-2375	145	34	and	and	CCONJ
ajlm-2375	145	35	a.a	a.a	PROPN
ajlm-2375	145	36	.	.	PROPN
ajlm-2375	145	37	ahmed	ahmed	PROPN
ajlm-2375	145	38	contributed	contribute	VERB
ajlm-2375	145	39	to	to	ADP
ajlm-2375	145	40	the	the	DET
ajlm-2375	145	41	study	study	NOUN
ajlm-2375	145	42	’s	’s	PART
ajlm-2375	145	43	conceptualisation	conceptualisation	NOUN
ajlm-2375	145	44	and	and	CCONJ
ajlm-2375	145	45	design	design	NOUN
ajlm-2375	145	46	.	.	PUNCT
ajlm-2375	146	1	n.a.e.-d	n.a.e.-d	PROPN
ajlm-2375	146	2	.	.	PROPN
ajlm-2375	146	3	,	,	PUNCT
ajlm-2375	146	4	a.a	a.a	PROPN
ajlm-2375	146	5	.	.	PROPN
ajlm-2375	146	6	abdelmoati	abdelmoati	PROPN
ajlm-2375	146	7	,	,	PUNCT
ajlm-2375	146	8	a.l.s	a.l.s	PROPN
ajlm-2375	146	9	.	.	PROPN
ajlm-2375	146	10	,	,	PUNCT
ajlm-2375	146	11	w.s	w.s	PROPN
ajlm-2375	146	12	.	.	PROPN
ajlm-2375	146	13	,	,	PUNCT
ajlm-2375	146	14	and	and	CCONJ
ajlm-2375	146	15	a.m.e.-g	a.m.e.-g	PROPN
ajlm-2375	146	16	.	.	PROPN
ajlm-2375	146	17	contributed	contribute	VERB
ajlm-2375	146	18	to	to	ADP
ajlm-2375	146	19	patient	patient	ADJ
ajlm-2375	146	20	selection	selection	NOUN
ajlm-2375	146	21	and	and	CCONJ
ajlm-2375	146	22	data	datum	NOUN
ajlm-2375	146	23	collection	collection	NOUN
ajlm-2375	146	24	.	.	PUNCT
ajlm-2375	147	1	w.s	w.s	PROPN
ajlm-2375	147	2	.	.	PROPN
ajlm-2375	147	3	,	,	PUNCT
ajlm-2375	147	4	o.a.g	o.a.g	PROPN
ajlm-2375	147	5	.	.	PROPN
ajlm-2375	147	6	,	,	PUNCT
ajlm-2375	147	7	r.m	r.m	PROPN
ajlm-2375	147	8	.	.	PROPN
ajlm-2375	147	9	and	and	CCONJ
ajlm-2375	147	10	a.f	a.f	PROPN
ajlm-2375	147	11	.	.	PROPN
ajlm-2375	147	12	contributed	contribute	VERB
ajlm-2375	147	13	to	to	PART
ajlm-2375	147	14	sample	sample	VERB
ajlm-2375	147	15	collection	collection	NOUN
ajlm-2375	147	16	and	and	CCONJ
ajlm-2375	147	17	processing	processing	NOUN
ajlm-2375	147	18	and	and	CCONJ
ajlm-2375	147	19	manuscript	manuscript	NOUN
ajlm-2375	147	20	revision	revision	NOUN
ajlm-2375	147	21	.	.	PUNCT
ajlm-2375	148	1	r.m.a	r.m.a	NOUN
ajlm-2375	148	2	.	.	PROPN
ajlm-2375	148	3	,	,	PUNCT
ajlm-2375	148	4	a.f	a.f	PROPN
ajlm-2375	148	5	.	.	PROPN
ajlm-2375	148	6	and	and	CCONJ
ajlm-2375	148	7	m.e.a	m.e.a	PROPN
ajlm-2375	148	8	.	.	PROPN
ajlm-2375	148	9	contributed	contribute	VERB
ajlm-2375	148	10	to	to	ADP
ajlm-2375	148	11	data	data	NOUN
ajlm-2375	148	12	collection	collection	NOUN
ajlm-2375	148	13	and	and	CCONJ
ajlm-2375	148	14	analysis	analysis	NOUN
ajlm-2375	148	15	,	,	PUNCT
ajlm-2375	148	16	and	and	CCONJ
ajlm-2375	148	17	manuscript	manuscript	NOUN
ajlm-2375	148	18	revision	revision	NOUN
ajlm-2375	148	19	.	.	PUNCT
ajlm-2375	149	1	a.a	a.a	PROPN
ajlm-2375	149	2	.	.	PROPN
ajlm-2375	149	3	ahmed	ahmed	PROPN
ajlm-2375	149	4	contributed	contribute	VERB
ajlm-2375	149	5	to	to	ADP
ajlm-2375	149	6	data	datum	NOUN
ajlm-2375	149	7	analysis	analysis	NOUN
ajlm-2375	149	8	and	and	CCONJ
ajlm-2375	149	9	manuscript	manuscript	NOUN
ajlm-2375	149	10	writing	writing	NOUN
ajlm-2375	149	11	.	.	PUNCT
ajlm-2375	150	1	finally	finally	ADV
ajlm-2375	150	2	,	,	PUNCT
ajlm-2375	150	3	the	the	DET
ajlm-2375	150	4	manuscript	manuscript	NOUN
ajlm-2375	150	5	has	have	AUX
ajlm-2375	150	6	been	be	AUX
ajlm-2375	150	7	read	read	VERB
ajlm-2375	150	8	and	and	CCONJ
ajlm-2375	150	9	approved	approve	VERB
ajlm-2375	150	10	by	by	ADP
ajlm-2375	150	11	all	all	DET
ajlm-2375	150	12	the	the	DET
ajlm-2375	150	13	authors	author	NOUN
ajlm-2375	150	14	.	.	PUNCT
ajlm-2375	151	1	all	all	DET
ajlm-2375	151	2	authors	author	NOUN
ajlm-2375	151	3	are	be	AUX
ajlm-2375	151	4	responsible	responsible	ADJ
ajlm-2375	151	5	for	for	ADP
ajlm-2375	151	6	the	the	DET
ajlm-2375	151	7	reported	report	VERB
ajlm-2375	151	8	research	research	NOUN
ajlm-2375	151	9	.	.	PUNCT
ajlm-2375	152	1	sources	source	NOUN
ajlm-2375	152	2	of	of	ADP
ajlm-2375	152	3	support	support	NOUN
ajlm-2375	152	4	this	this	DET
ajlm-2375	152	5	research	research	NOUN
ajlm-2375	152	6	received	receive	VERB
ajlm-2375	152	7	no	no	DET
ajlm-2375	152	8	specific	specific	ADJ
ajlm-2375	152	9	grant	grant	NOUN
ajlm-2375	152	10	from	from	ADP
ajlm-2375	152	11	any	any	DET
ajlm-2375	152	12	funding	funding	NOUN
ajlm-2375	152	13	agency	agency	NOUN
ajlm-2375	152	14	in	in	ADP
ajlm-2375	152	15	the	the	DET
ajlm-2375	152	16	public	public	ADJ
ajlm-2375	152	17	,	,	PUNCT
ajlm-2375	152	18	commercial	commercial	ADJ
ajlm-2375	152	19	,	,	PUNCT
ajlm-2375	152	20	or	or	CCONJ
ajlm-2375	152	21	not	not	PART
ajlm-2375	152	22	-	-	PUNCT
ajlm-2375	152	23	for	for	ADP
ajlm-2375	152	24	-	-	PUNCT
ajlm-2375	152	25	profit	profit	NOUN
ajlm-2375	152	26	sectors	sector	NOUN
ajlm-2375	152	27	.	.	PUNCT
ajlm-2375	153	1	data	datum	NOUN
ajlm-2375	153	2	availability	availability	NOUN
ajlm-2375	153	3	the	the	DET
ajlm-2375	153	4	data	datum	NOUN
ajlm-2375	153	5	that	that	PRON
ajlm-2375	153	6	support	support	VERB
ajlm-2375	153	7	the	the	DET
ajlm-2375	153	8	findings	finding	NOUN
ajlm-2375	153	9	of	of	ADP
ajlm-2375	153	10	this	this	DET
ajlm-2375	153	11	study	study	NOUN
ajlm-2375	153	12	are	be	AUX
ajlm-2375	153	13	available	available	ADJ
ajlm-2375	153	14	on	on	ADP
ajlm-2375	153	15	request	request	NOUN
ajlm-2375	153	16	from	from	ADP
ajlm-2375	153	17	the	the	DET
ajlm-2375	153	18	corresponding	corresponding	ADJ
ajlm-2375	153	19	author	author	NOUN
ajlm-2375	153	20	,	,	PUNCT
ajlm-2375	153	21	a.a	a.a	PROPN
ajlm-2375	153	22	.	.	PROPN
ajlm-2375	153	23	ahmed	ahmed	PROPN
ajlm-2375	153	24	.	.	PUNCT
ajlm-2375	154	1	disclaimer	disclaimer	VERB
ajlm-2375	154	2	the	the	DET
ajlm-2375	154	3	views	view	NOUN
ajlm-2375	154	4	and	and	CCONJ
ajlm-2375	154	5	opinions	opinion	NOUN
ajlm-2375	154	6	expressed	express	VERB
ajlm-2375	154	7	in	in	ADP
ajlm-2375	154	8	this	this	DET
ajlm-2375	154	9	article	article	NOUN
ajlm-2375	154	10	are	be	AUX
ajlm-2375	154	11	those	those	PRON
ajlm-2375	154	12	of	of	ADP
ajlm-2375	154	13	the	the	DET
ajlm-2375	154	14	authors	author	NOUN
ajlm-2375	154	15	and	and	CCONJ
ajlm-2375	154	16	are	be	AUX
ajlm-2375	154	17	the	the	DET
ajlm-2375	154	18	product	product	NOUN
ajlm-2375	154	19	of	of	ADP
ajlm-2375	154	20	professional	professional	ADJ
ajlm-2375	154	21	research	research	NOUN
ajlm-2375	154	22	.	.	PUNCT
ajlm-2375	155	1	it	it	PRON
ajlm-2375	155	2	does	do	AUX
ajlm-2375	155	3	not	not	PART
ajlm-2375	155	4	necessarily	necessarily	ADV
ajlm-2375	155	5	reflect	reflect	VERB
ajlm-2375	155	6	the	the	DET
ajlm-2375	155	7	official	official	ADJ
ajlm-2375	155	8	policy	policy	NOUN
ajlm-2375	155	9	or	or	CCONJ
ajlm-2375	155	10	position	position	NOUN
ajlm-2375	155	11	of	of	ADP
ajlm-2375	155	12	any	any	DET
ajlm-2375	155	13	affiliated	affiliated	ADJ
ajlm-2375	155	14	institution	institution	NOUN
ajlm-2375	155	15	,	,	PUNCT
ajlm-2375	155	16	funder	funder	NOUN
ajlm-2375	155	17	,	,	PUNCT
ajlm-2375	155	18	agency	agency	NOUN
ajlm-2375	155	19	,	,	PUNCT
ajlm-2375	155	20	or	or	CCONJ
ajlm-2375	155	21	that	that	PRON
ajlm-2375	155	22	of	of	ADP
ajlm-2375	155	23	the	the	DET
ajlm-2375	155	24	publisher	publisher	NOUN
ajlm-2375	155	25	.	.	PUNCT
ajlm-2375	156	1	the	the	DET
ajlm-2375	156	2	authors	author	NOUN
ajlm-2375	156	3	are	be	AUX
ajlm-2375	156	4	responsible	responsible	ADJ
ajlm-2375	156	5	for	for	ADP
ajlm-2375	156	6	this	this	DET
ajlm-2375	156	7	article	article	NOUN
ajlm-2375	156	8	’s	’s	PART
ajlm-2375	156	9	results	result	NOUN
ajlm-2375	156	10	,	,	PUNCT
ajlm-2375	156	11	findings	finding	NOUN
ajlm-2375	156	12	,	,	PUNCT
ajlm-2375	156	13	and	and	CCONJ
ajlm-2375	156	14	content	content	NOUN
ajlm-2375	156	15	.	.	PUNCT
ajlm-2375	157	1	references	reference	NOUN
ajlm-2375	157	2	world	world	PROPN
ajlm-2375	157	3	health	health	PROPN
ajlm-2375	157	4	organization	organization	NOUN
ajlm-2375	157	5	–	–	PUNCT
ajlm-2375	157	6	live	live	VERB
ajlm-2375	157	7	updates	update	VERB
ajlm-2375	157	8	covid-19	covid-19	PROPN
ajlm-2375	157	9	–	–	PUNCT
ajlm-2375	157	10	who.int	who.int	VERB
ajlm-2375	157	11	2022	2022	NUM
ajlm-2375	157	12	[	[	X
ajlm-2375	157	13	homepage	homepage	NOUN
ajlm-2375	157	14	on	on	ADP
ajlm-2375	157	15	the	the	DET
ajlm-2375	157	16	internet	internet	NOUN
ajlm-2375	157	17	]	]	PUNCT
ajlm-2375	157	18	.	.	PUNCT
ajlm-2375	158	1	[	[	X
ajlm-2375	158	2	cited	cite	VERB
ajlm-2375	158	3	2022	2022	NUM
ajlm-2375	158	4	sep	sep	PROPN
ajlm-2375	158	5	10	10	NUM
ajlm-2375	158	6	]	]	PUNCT
ajlm-2375	158	7	.	.	PUNCT
ajlm-2375	159	1	available	available	ADJ
ajlm-2375	159	2	from	from	ADP
ajlm-2375	159	3	:	:	PUNCT
ajlm-2375	159	4	https://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey={adgroupsurvey}&gclid=cj0kcqjw6_cybhdjarisabnuszo_3rxo8jg92w-nqsf6yzsrlsslq9noayjdg87plgdblhxig6rzovwaauyqealw_wcb	https://www.who.int/emergencies/diseases/novel-coronavirus-2019?adgroupsurvey={adgroupsurvey}&gclid=cj0kcqjw6_cybhdjarisabnuszo_3rxo8jg92w-nqsf6yzsrlsslq9noayjdg87plgdblhxig6rzovwaauyqealw_wcb	PROPN
ajlm-2375	159	5	.	.	PUNCT
ajlm-2375	160	1	van	van	PROPN
ajlm-2375	160	2	der	der	NOUN
ajlm-2375	160	3	made	make	VERB
ajlm-2375	160	4	ci	ci	NOUN
ajlm-2375	160	5	,	,	PUNCT
ajlm-2375	160	6	netea	netea	NOUN
ajlm-2375	160	7	mg	mg	PROPN
ajlm-2375	160	8	,	,	PUNCT
ajlm-2375	160	9	van	van	PROPN
ajlm-2375	160	10	der	der	PROPN
ajlm-2375	160	11	veerdonk	veerdonk	PROPN
ajlm-2375	160	12	fl	fl	PROPN
ajlm-2375	160	13	,	,	PUNCT
ajlm-2375	160	14	hoischen	hoischen	ADV
ajlm-2375	160	15	a.	a.	NOUN
ajlm-2375	160	16	clinical	clinical	ADJ
ajlm-2375	160	17	implications	implication	NOUN
ajlm-2375	160	18	of	of	ADP
ajlm-2375	160	19	host	host	NOUN
ajlm-2375	160	20	genetic	genetic	ADJ
ajlm-2375	160	21	variation	variation	NOUN
ajlm-2375	160	22	and	and	CCONJ
ajlm-2375	160	23	susceptibility	susceptibility	NOUN
ajlm-2375	160	24	to	to	ADP
ajlm-2375	160	25	severe	severe	ADJ
ajlm-2375	160	26	or	or	CCONJ
ajlm-2375	160	27	critical	critical	ADJ
ajlm-2375	160	28	covid-19	covid-19	PROPN
ajlm-2375	160	29	.	.	PUNCT
ajlm-2375	160	30	genome	genome	NOUN
ajlm-2375	160	31	med	me	VERB
ajlm-2375	160	32	.	.	PUNCT
ajlm-2375	161	1	2022;14(1):96	2022;14(1):96	NUM
ajlm-2375	161	2	.	.	PUNCT
ajlm-2375	162	1	https://doi.org/10.1186/s13073-022-01100-3	https://doi.org/10.1186/s13073-022-01100-3	PROPN
ajlm-2375	162	2	statement	statement	NOUN
ajlm-2375	162	3	on	on	ADP
ajlm-2375	162	4	the	the	DET
ajlm-2375	162	5	update	update	NOUN
ajlm-2375	162	6	of	of	ADP
ajlm-2375	162	7	who	who	PRON
ajlm-2375	162	8	’s	’	VERB
ajlm-2375	162	9	working	work	VERB
ajlm-2375	162	10	definitions	definition	NOUN
ajlm-2375	162	11	and	and	CCONJ
ajlm-2375	162	12	tracking	tracking	NOUN
ajlm-2375	162	13	system	system	NOUN
ajlm-2375	162	14	for	for	ADP
ajlm-2375	162	15	sars	sar	NOUN
ajlm-2375	162	16	-	-	PUNCT
ajlm-2375	162	17	cov-2	cov-2	NOUN
ajlm-2375	162	18	variants	variant	NOUN
ajlm-2375	162	19	of	of	ADP
ajlm-2375	162	20	concern	concern	NOUN
ajlm-2375	162	21	and	and	CCONJ
ajlm-2375	162	22	variants	variant	NOUN
ajlm-2375	162	23	of	of	ADP
ajlm-2375	162	24	interest	interest	NOUN
ajlm-2375	163	1	[	[	X
ajlm-2375	163	2	homepage	homepage	NOUN
ajlm-2375	163	3	on	on	ADP
ajlm-2375	163	4	the	the	DET
ajlm-2375	163	5	internet	internet	NOUN
ajlm-2375	163	6	]	]	PUNCT
ajlm-2375	163	7	.	.	PUNCT
ajlm-2375	164	1	2023	2023	NUM
ajlm-2375	165	1	[	[	X
ajlm-2375	165	2	cited	cite	VERB
ajlm-2375	165	3	2023	2023	NUM
ajlm-2375	165	4	mar	mar	PROPN
ajlm-2375	165	5	30	30	NUM
ajlm-2375	165	6	]	]	PUNCT
ajlm-2375	165	7	.	.	PUNCT
ajlm-2375	166	1	available	available	ADJ
ajlm-2375	166	2	from	from	ADP
ajlm-2375	166	3	:	:	PUNCT
ajlm-2375	166	4	https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest	https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest	PROPN
ajlm-2375	166	5	.	.	PUNCT
ajlm-2375	166	6	santos	santos	PROPN
ajlm-2375	166	7	ras	ras	PROPN
ajlm-2375	166	8	,	,	PUNCT
ajlm-2375	166	9	sampaio	sampaio	PROPN
ajlm-2375	166	10	wo	will	AUX
ajlm-2375	166	11	,	,	PUNCT
ajlm-2375	166	12	alzamora	alzamora	PROPN
ajlm-2375	166	13	ac	ac	PROPN
ajlm-2375	166	14	,	,	PUNCT
ajlm-2375	166	15	et	et	PROPN
ajlm-2375	166	16	al	al	PROPN
ajlm-2375	166	17	.	.	PUNCT
ajlm-2375	167	1	the	the	DET
ajlm-2375	167	2	ace2	ace2	PROPN
ajlm-2375	167	3	/	/	SYM
ajlm-2375	167	4	angiotensin-(1	angiotensin-(1	NOUN
ajlm-2375	167	5	-	-	PUNCT
ajlm-2375	167	6	7)/mas	7)/mas	PROPN
ajlm-2375	167	7	axis	axis	NOUN
ajlm-2375	167	8	of	of	ADP
ajlm-2375	167	9	the	the	DET
ajlm-2375	167	10	renin	renin	ADJ
ajlm-2375	167	11	-	-	PUNCT
ajlm-2375	167	12	angiotensin	angiotensin	NOUN
ajlm-2375	167	13	system	system	NOUN
ajlm-2375	167	14	:	:	PUNCT
ajlm-2375	167	15	focus	focus	VERB
ajlm-2375	167	16	on	on	ADP
ajlm-2375	167	17	angiotensin-(1	angiotensin-(1	PROPN
ajlm-2375	167	18	-	-	PUNCT
ajlm-2375	167	19	7	7	NUM
ajlm-2375	167	20	)	)	PUNCT
ajlm-2375	167	21	.	.	PUNCT
ajlm-2375	168	1	physiol	physiol	PROPN
ajlm-2375	168	2	rev	rev	VERB
ajlm-2375	168	3	.	.	PUNCT
ajlm-2375	169	1	2018;98(1):505–553	2018;98(1):505–553	X
ajlm-2375	169	2	.	.	PUNCT
ajlm-2375	170	1	https://doi.org/10.1152/physrev.00023.2016	https://doi.org/10.1152/physrev.00023.2016	PROPN
ajlm-2375	170	2	gheblawi	gheblawi	VERB
ajlm-2375	170	3	m	m	PROPN
ajlm-2375	170	4	,	,	PUNCT
ajlm-2375	170	5	wang	wang	PROPN
ajlm-2375	170	6	k	k	PROPN
ajlm-2375	170	7	,	,	PUNCT
ajlm-2375	170	8	viveiros	viveiro	NOUN
ajlm-2375	170	9	a	a	PRON
ajlm-2375	170	10	,	,	PUNCT
ajlm-2375	170	11	et	et	PROPN
ajlm-2375	170	12	al	al	PROPN
ajlm-2375	170	13	.	.	PUNCT
ajlm-2375	170	14	angiotensin	angiotensin	NOUN
ajlm-2375	170	15	-	-	PUNCT
ajlm-2375	170	16	converting	convert	VERB
ajlm-2375	170	17	enzyme	enzyme	NOUN
ajlm-2375	170	18	2	2	NUM
ajlm-2375	170	19	:	:	PUNCT
ajlm-2375	170	20	sars	sar	NOUN
ajlm-2375	170	21	-	-	PUNCT
ajlm-2375	170	22	cov-2	cov-2	NOUN
ajlm-2375	170	23	receptor	receptor	NOUN
ajlm-2375	170	24	and	and	CCONJ
ajlm-2375	170	25	regulator	regulator	NOUN
ajlm-2375	170	26	of	of	ADP
ajlm-2375	170	27	the	the	DET
ajlm-2375	170	28	renin	renin	ADJ
ajlm-2375	170	29	-	-	PUNCT
ajlm-2375	170	30	angiotensin	angiotensin	NOUN
ajlm-2375	170	31	system	system	NOUN
ajlm-2375	170	32	:	:	PUNCT
ajlm-2375	170	33	celebrating	celebrate	VERB
ajlm-2375	170	34	the	the	DET
ajlm-2375	170	35	20th	20th	ADJ
ajlm-2375	170	36	anniversary	anniversary	NOUN
ajlm-2375	170	37	of	of	ADP
ajlm-2375	170	38	the	the	DET
ajlm-2375	170	39	discovery	discovery	NOUN
ajlm-2375	170	40	of	of	ADP
ajlm-2375	170	41	ace2	ace2	PROPN
ajlm-2375	170	42	.	.	PUNCT
ajlm-2375	171	1	circ	circ	PROPN
ajlm-2375	171	2	res	re	NOUN
ajlm-2375	171	3	.	.	PUNCT
ajlm-2375	172	1	2020;126(10):1456–1474	2020;126(10):1456–1474	NUM
ajlm-2375	172	2	.	.	PUNCT
ajlm-2375	173	1	https://doi.org/10.1161/circresaha.120.317015	https://doi.org/10.1161/circresaha.120.317015	PROPN
ajlm-2375	173	2	chatterjee	chatterjee	PROPN
ajlm-2375	173	3	b	b	PROPN
ajlm-2375	173	4	,	,	PUNCT
ajlm-2375	173	5	thakur	thakur	PROPN
ajlm-2375	173	6	ss	ss	PROPN
ajlm-2375	173	7	.	.	PROPN
ajlm-2375	173	8	ace2	ace2	PROPN
ajlm-2375	173	9	as	as	ADP
ajlm-2375	173	10	a	a	DET
ajlm-2375	173	11	potential	potential	ADJ
ajlm-2375	173	12	therapeutic	therapeutic	ADJ
ajlm-2375	173	13	target	target	NOUN
ajlm-2375	173	14	for	for	ADP
ajlm-2375	173	15	pandemic	pandemic	ADJ
ajlm-2375	173	16	covid-19	covid-19	PROPN
ajlm-2375	173	17	.	.	PUNCT
ajlm-2375	174	1	rsc	rsc	PROPN
ajlm-2375	174	2	adv	adv	PROPN
ajlm-2375	174	3	.	.	PUNCT
ajlm-2375	175	1	2020;10(65):39808–39813	2020;10(65):39808–39813	NUM
ajlm-2375	175	2	.	.	PUNCT
ajlm-2375	176	1	https://doi.org/10.1039/d0ra08228	https://doi.org/10.1039/d0ra08228	PROPN
ajlm-2375	176	2	g	g	PROPN
ajlm-2375	176	3	patel	patel	PROPN
ajlm-2375	176	4	sk	sk	PROPN
ajlm-2375	176	5	,	,	PUNCT
ajlm-2375	176	6	velkoska	velkoska	NOUN
ajlm-2375	176	7	e	e	PROPN
ajlm-2375	176	8	,	,	PUNCT
ajlm-2375	176	9	freeman	freeman	PROPN
ajlm-2375	176	10	m	m	PROPN
ajlm-2375	176	11	,	,	PUNCT
ajlm-2375	176	12	wai	wai	PROPN
ajlm-2375	176	13	b	b	PROPN
ajlm-2375	176	14	,	,	PUNCT
ajlm-2375	176	15	lancefield	lancefield	PROPN
ajlm-2375	176	16	tf	tf	PROPN
ajlm-2375	176	17	,	,	PUNCT
ajlm-2375	176	18	burrell	burrell	PROPN
ajlm-2375	176	19	lm	lm	PROPN
ajlm-2375	176	20	.	.	PROPN
ajlm-2375	177	1	from	from	ADP
ajlm-2375	177	2	gene	gene	NOUN
ajlm-2375	177	3	to	to	ADP
ajlm-2375	177	4	protein	protein	NOUN
ajlm-2375	177	5	–	–	PUNCT
ajlm-2375	177	6	experimental	experimental	ADJ
ajlm-2375	177	7	and	and	CCONJ
ajlm-2375	177	8	clinical	clinical	ADJ
ajlm-2375	177	9	studies	study	NOUN
ajlm-2375	177	10	of	of	ADP
ajlm-2375	177	11	ace2	ace2	NOUN
ajlm-2375	177	12	in	in	ADP
ajlm-2375	177	13	blood	blood	NOUN
ajlm-2375	177	14	pressure	pressure	NOUN
ajlm-2375	177	15	control	control	NOUN
ajlm-2375	177	16	and	and	CCONJ
ajlm-2375	177	17	arterial	arterial	ADJ
ajlm-2375	177	18	hypertension	hypertension	NOUN
ajlm-2375	177	19	.	.	PUNCT
ajlm-2375	178	1	front	front	ADJ
ajlm-2375	178	2	physiol	physiol	PROPN
ajlm-2375	178	3	.	.	PUNCT
ajlm-2375	179	1	2014;5:227	2014;5:227	X
ajlm-2375	179	2	.	.	PUNCT
ajlm-2375	180	1	https://doi.org/10.3389/fphys.2014.00227	https://doi.org/10.3389/fphys.2014.00227	PROPN
ajlm-2375	180	2	pouladi	pouladi	NOUN
ajlm-2375	180	3	n	n	CCONJ
ajlm-2375	180	4	,	,	PUNCT
ajlm-2375	180	5	abdolahi	abdolahi	PROPN
ajlm-2375	180	6	s.	s.	PROPN
ajlm-2375	180	7	investigating	investigate	VERB
ajlm-2375	180	8	the	the	DET
ajlm-2375	180	9	ace2	ace2	NOUN
ajlm-2375	180	10	polymorphisms	polymorphism	NOUN
ajlm-2375	180	11	in	in	ADP
ajlm-2375	180	12	covid-19	covid-19	PROPN
ajlm-2375	180	13	susceptibility	susceptibility	NOUN
ajlm-2375	180	14	:	:	PUNCT
ajlm-2375	180	15	an	an	PRON
ajlm-2375	180	16	in	in	ADP
ajlm-2375	180	17	silico	silico	NOUN
ajlm-2375	180	18	analysis	analysis	NOUN
ajlm-2375	180	19	.	.	PUNCT
ajlm-2375	181	1	mol	mol	ADP
ajlm-2375	181	2	genet	genet	PROPN
ajlm-2375	181	3	genomic	genomic	NOUN
ajlm-2375	181	4	med	me	VERB
ajlm-2375	181	5	.	.	PUNCT
ajlm-2375	182	1	2021;9(6):e1672	2021;9(6):e1672	NUM
ajlm-2375	182	2	.	.	PUNCT
ajlm-2375	182	3	https://doi.org/10.1002/mgg3.1672	https://doi.org/10.1002/mgg3.1672	NOUN
ajlm-2375	182	4	hoffmann	hoffmann	PROPN
ajlm-2375	182	5	m	m	PROPN
ajlm-2375	182	6	,	,	PUNCT
ajlm-2375	182	7	kleine	kleine	PROPN
ajlm-2375	182	8	-	-	PUNCT
ajlm-2375	182	9	weber	weber	PROPN
ajlm-2375	182	10	h	h	PROPN
ajlm-2375	182	11	,	,	PUNCT
ajlm-2375	182	12	schroeder	schroeder	PROPN
ajlm-2375	182	13	s	s	PROPN
ajlm-2375	182	14	,	,	PUNCT
ajlm-2375	182	15	et	et	PROPN
ajlm-2375	182	16	al	al	PROPN
ajlm-2375	182	17	.	.	PUNCT
ajlm-2375	183	1	sars	sars	PROPN
ajlm-2375	183	2	-	-	PUNCT
ajlm-2375	183	3	cov-2	cov-2	PART
ajlm-2375	183	4	cell	cell	NOUN
ajlm-2375	183	5	entry	entry	NOUN
ajlm-2375	183	6	depends	depend	VERB
ajlm-2375	183	7	on	on	ADP
ajlm-2375	183	8	ace2	ace2	NOUN
ajlm-2375	183	9	and	and	CCONJ
ajlm-2375	183	10	tmprss2	tmprss2	ADV
ajlm-2375	183	11	and	and	CCONJ
ajlm-2375	183	12	is	be	AUX
ajlm-2375	183	13	blocked	block	VERB
ajlm-2375	183	14	by	by	ADP
ajlm-2375	183	15	a	a	DET
ajlm-2375	183	16	clinically	clinically	ADV
ajlm-2375	183	17	proven	prove	VERB
ajlm-2375	183	18	protease	protease	NOUN
ajlm-2375	183	19	inhibitor	inhibitor	NOUN
ajlm-2375	183	20	.	.	PUNCT
ajlm-2375	184	1	cell	cell	NOUN
ajlm-2375	184	2	.	.	PUNCT
ajlm-2375	185	1	2020;181(2):271.e8–280.e8	2020;181(2):271.e8–280.e8	NUM
ajlm-2375	185	2	.	.	PUNCT
ajlm-2375	186	1	https://doi.org/10.1016/j.cell.2020.02.052	https://doi.org/10.1016/j.cell.2020.02.052	PROPN
ajlm-2375	186	2	chen	chen	PROPN
ajlm-2375	186	3	y	y	PROPN
ajlm-2375	186	4	,	,	PUNCT
ajlm-2375	186	5	guo	guo	PROPN
ajlm-2375	186	6	y	y	PROPN
ajlm-2375	186	7	,	,	PUNCT
ajlm-2375	186	8	pan	pan	VERB
ajlm-2375	186	9	y	y	PROPN
ajlm-2375	186	10	,	,	PUNCT
ajlm-2375	186	11	zhao	zhao	PROPN
ajlm-2375	186	12	zj	zj	PROPN
ajlm-2375	186	13	.	.	PROPN
ajlm-2375	186	14	structure	structure	NOUN
ajlm-2375	186	15	analysis	analysis	NOUN
ajlm-2375	186	16	of	of	ADP
ajlm-2375	186	17	the	the	DET
ajlm-2375	186	18	receptor	receptor	NOUN
ajlm-2375	186	19	binding	bind	VERB
ajlm-2375	186	20	of	of	ADP
ajlm-2375	186	21	2019	2019	NUM
ajlm-2375	186	22	-	-	PUNCT
ajlm-2375	186	23	ncov	ncov	NOUN
ajlm-2375	186	24	.	.	PUNCT
ajlm-2375	187	1	biochem	biochem	PROPN
ajlm-2375	187	2	biophys	biophys	PROPN
ajlm-2375	187	3	res	re	NOUN
ajlm-2375	187	4	commun	commun	PROPN
ajlm-2375	187	5	.	.	PUNCT
ajlm-2375	188	1	2020;525(1):135–140	2020;525(1):135–140	NUM
ajlm-2375	188	2	.	.	PUNCT
ajlm-2375	189	1	https://doi.org/10.1016/j.bbrc.2020.02.071	https://doi.org/10.1016/j.bbrc.2020.02.071	PROPN
ajlm-2375	189	2	irham	irham	PROPN
ajlm-2375	189	3	lm	lm	PROPN
ajlm-2375	189	4	,	,	PUNCT
ajlm-2375	189	5	chou	chou	PROPN
ajlm-2375	189	6	wh	wh	PROPN
ajlm-2375	189	7	,	,	PUNCT
ajlm-2375	189	8	calkins	calkins	PROPN
ajlm-2375	189	9	mj	mj	PROPN
ajlm-2375	189	10	,	,	PUNCT
ajlm-2375	189	11	adikusuma	adikusuma	PROPN
ajlm-2375	189	12	w	w	NOUN
ajlm-2375	189	13	,	,	PUNCT
ajlm-2375	189	14	hsieh	hsieh	PROPN
ajlm-2375	189	15	sl	sl	PROPN
ajlm-2375	189	16	,	,	PUNCT
ajlm-2375	189	17	chang	chang	PROPN
ajlm-2375	189	18	wc	wc	PROPN
ajlm-2375	189	19	.	.	PROPN
ajlm-2375	190	1	genetic	genetic	ADJ
ajlm-2375	190	2	variants	variant	NOUN
ajlm-2375	190	3	that	that	PRON
ajlm-2375	190	4	influence	influence	VERB
ajlm-2375	190	5	sars	sar	NOUN
ajlm-2375	190	6	-	-	PUNCT
ajlm-2375	190	7	cov-2	cov-2	NOUN
ajlm-2375	190	8	receptor	receptor	NOUN
ajlm-2375	190	9	tmprss2	tmprss2	VERB
ajlm-2375	190	10	expression	expression	NOUN
ajlm-2375	190	11	among	among	ADP
ajlm-2375	190	12	population	population	NOUN
ajlm-2375	190	13	cohorts	cohort	NOUN
ajlm-2375	190	14	from	from	ADP
ajlm-2375	190	15	multiple	multiple	ADJ
ajlm-2375	190	16	continents	continent	NOUN
ajlm-2375	190	17	.	.	PUNCT
ajlm-2375	191	1	biochem	biochem	PROPN
ajlm-2375	191	2	biophys	biophys	PROPN
ajlm-2375	191	3	res	re	NOUN
ajlm-2375	191	4	commun	commun	PROPN
ajlm-2375	191	5	.	.	PUNCT
ajlm-2375	192	1	2020;529(2):263–269	2020;529(2):263–269	X
ajlm-2375	192	2	.	.	PUNCT
ajlm-2375	192	3	https://doi.org/10.1016/j.bbrc.2020.05.179	https://doi.org/10.1016/j.bbrc.2020.05.179	PROPN
ajlm-2375	192	4	hong	hong	PROPN
ajlm-2375	192	5	kh	kh	PROPN
ajlm-2375	192	6	,	,	PUNCT
ajlm-2375	192	7	lee	lee	PROPN
ajlm-2375	192	8	sw	sw	PROPN
ajlm-2375	192	9	,	,	PUNCT
ajlm-2375	192	10	kim	kim	PROPN
ajlm-2375	192	11	ts	ts	PROPN
ajlm-2375	192	12	,	,	PUNCT
ajlm-2375	192	13	et	et	PROPN
ajlm-2375	192	14	al	al	PROPN
ajlm-2375	192	15	.	.	PUNCT
ajlm-2375	193	1	guidelines	guideline	NOUN
ajlm-2375	193	2	for	for	ADP
ajlm-2375	193	3	laboratory	laboratory	NOUN
ajlm-2375	193	4	diagnosis	diagnosis	NOUN
ajlm-2375	193	5	of	of	ADP
ajlm-2375	193	6	coronavirus	coronavirus	NOUN
ajlm-2375	193	7	disease	disease	NOUN
ajlm-2375	193	8	2019	2019	NUM
ajlm-2375	193	9	(	(	PUNCT
ajlm-2375	193	10	covid-19	covid-19	PROPN
ajlm-2375	193	11	)	)	PUNCT
ajlm-2375	193	12	in	in	ADP
ajlm-2375	193	13	korea	korea	PROPN
ajlm-2375	193	14	.	.	PUNCT
ajlm-2375	194	1	ann	ann	PROPN
ajlm-2375	194	2	lab	lab	PROPN
ajlm-2375	194	3	med	me	VERB
ajlm-2375	194	4	.	.	PUNCT
ajlm-2375	195	1	2020;40(5):351–360	2020;40(5):351–360	X
ajlm-2375	195	2	.	.	PROPN
ajlm-2375	195	3	amer	amer	PROPN
ajlm-2375	195	4	rm	rm	PROPN
ajlm-2375	195	5	,	,	PUNCT
ajlm-2375	195	6	samir	samir	PROPN
ajlm-2375	195	7	m	m	PROPN
ajlm-2375	195	8	,	,	PUNCT
ajlm-2375	195	9	gaber	gaber	PROPN
ajlm-2375	195	10	oa	oa	PROPN
ajlm-2375	195	11	,	,	PUNCT
ajlm-2375	195	12	et	et	PROPN
ajlm-2375	195	13	al	al	PROPN
ajlm-2375	195	14	.	.	PUNCT
ajlm-2375	196	1	diagnostic	diagnostic	ADJ
ajlm-2375	196	2	performance	performance	NOUN
ajlm-2375	196	3	of	of	ADP
ajlm-2375	196	4	rapid	rapid	ADJ
ajlm-2375	196	5	antigen	antigen	ADJ
ajlm-2375	196	6	test	test	NOUN
ajlm-2375	196	7	for	for	ADP
ajlm-2375	196	8	covid-19	covid-19	PROPN
ajlm-2375	196	9	and	and	CCONJ
ajlm-2375	196	10	the	the	DET
ajlm-2375	196	11	effect	effect	NOUN
ajlm-2375	196	12	of	of	ADP
ajlm-2375	196	13	viral	viral	ADJ
ajlm-2375	196	14	load	load	NOUN
ajlm-2375	196	15	,	,	PUNCT
ajlm-2375	196	16	sampling	sample	VERB
ajlm-2375	196	17	time	time	NOUN
ajlm-2375	196	18	,	,	PUNCT
ajlm-2375	196	19	subject‘s	subject‘s	NOUN
ajlm-2375	196	20	clinical	clinical	ADJ
ajlm-2375	196	21	and	and	CCONJ
ajlm-2375	196	22	laboratory	laboratory	NOUN
ajlm-2375	196	23	parameters	parameter	NOUN
ajlm-2375	196	24	on	on	ADP
ajlm-2375	196	25	test	test	NOUN
ajlm-2375	196	26	accuracy	accuracy	NOUN
ajlm-2375	196	27	.	.	PUNCT
ajlm-2375	197	1	j	j	PROPN
ajlm-2375	197	2	infect	infect	VERB
ajlm-2375	197	3	public	public	ADJ
ajlm-2375	197	4	health	health	NOUN
ajlm-2375	197	5	.	.	PUNCT
ajlm-2375	198	1	2021;14(10):1446–1453	2021;14(10):1446–1453	NUM
ajlm-2375	198	2	.	.	PUNCT
ajlm-2375	199	1	https://doi.org/10.1016/j.jiph.2021.06.002	https://doi.org/10.1016/j.jiph.2021.06.002	PROPN
ajlm-2375	199	2	masoud	masoud	PROPN
ajlm-2375	199	3	h	h	PROPN
ajlm-2375	199	4	,	,	PUNCT
ajlm-2375	199	5	elassal	elassal	PROPN
ajlm-2375	199	6	g	g	PROPN
ajlm-2375	199	7	,	,	PUNCT
ajlm-2375	199	8	hassany	hassany	PROPN
ajlm-2375	199	9	m	m	PROPN
ajlm-2375	199	10	,	,	PUNCT
ajlm-2375	199	11	et	et	PROPN
ajlm-2375	199	12	al	al	PROPN
ajlm-2375	199	13	.	.	PUNCT
ajlm-2375	199	14	management	management	NOUN
ajlm-2375	199	15	protocol	protocol	NOUN
ajlm-2375	199	16	for	for	ADP
ajlm-2375	199	17	covid-19	covid-19	PROPN
ajlm-2375	199	18	patients	patient	NOUN
ajlm-2375	199	19	mohp	mohp	ADJ
ajlm-2375	199	20	protocol	protocol	NOUN
ajlm-2375	199	21	for	for	ADP
ajlm-2375	199	22	covid19	covid19	NOUN
ajlm-2375	199	23	,	,	PUNCT
ajlm-2375	199	24	version	version	NOUN
ajlm-2375	199	25	1.3	1.3	NUM
ajlm-2375	199	26	.	.	PUNCT
ajlm-2375	200	1	ministry	ministry	PROPN
ajlm-2375	200	2	of	of	ADP
ajlm-2375	200	3	health	health	PROPN
ajlm-2375	200	4	and	and	CCONJ
ajlm-2375	200	5	population	population	NOUN
ajlm-2375	200	6	,	,	PUNCT
ajlm-2375	200	7	cairo	cairo	PROPN
ajlm-2375	200	8	.	.	PUNCT
ajlm-2375	201	1	2020	2020	NUM
ajlm-2375	201	2	.	.	PUNCT
ajlm-2375	202	1	al	al	PROPN
ajlm-2375	202	2	bayat	bayat	PROPN
ajlm-2375	202	3	s	s	PROPN
ajlm-2375	202	4	,	,	PUNCT
ajlm-2375	202	5	mundodan	mundodan	PROPN
ajlm-2375	202	6	j	j	PROPN
ajlm-2375	202	7	,	,	PUNCT
ajlm-2375	202	8	hasnain	hasnain	VERB
ajlm-2375	202	9	s	s	PROPN
ajlm-2375	202	10	,	,	PUNCT
ajlm-2375	202	11	et	et	PROPN
ajlm-2375	202	12	al	al	PROPN
ajlm-2375	202	13	.	.	PUNCT
ajlm-2375	203	1	can	can	AUX
ajlm-2375	203	2	the	the	DET
ajlm-2375	203	3	cycle	cycle	NOUN
ajlm-2375	203	4	threshold	threshold	NOUN
ajlm-2375	203	5	(	(	PUNCT
ajlm-2375	203	6	ct	ct	NOUN
ajlm-2375	203	7	)	)	PUNCT
ajlm-2375	203	8	value	value	NOUN
ajlm-2375	203	9	of	of	ADP
ajlm-2375	203	10	rt	rt	ADJ
ajlm-2375	203	11	-	-	PUNCT
ajlm-2375	203	12	pcr	pcr	ADJ
ajlm-2375	203	13	test	test	NOUN
ajlm-2375	203	14	for	for	ADP
ajlm-2375	203	15	sars	sars	PROPN
ajlm-2375	203	16	cov2	cov2	PROPN
ajlm-2375	203	17	predict	predict	VERB
ajlm-2375	203	18	infectivity	infectivity	NOUN
ajlm-2375	203	19	among	among	ADP
ajlm-2375	203	20	close	close	ADJ
ajlm-2375	203	21	contacts	contact	NOUN
ajlm-2375	203	22	?	?	PUNCT
ajlm-2375	204	1	j	j	PROPN
ajlm-2375	204	2	infect	infect	VERB
ajlm-2375	204	3	public	public	ADJ
ajlm-2375	204	4	health	health	NOUN
ajlm-2375	204	5	.	.	PUNCT
ajlm-2375	205	1	2021;14(9):1201–1205	2021;14(9):1201–1205	NUM
ajlm-2375	205	2	.	.	PUNCT
ajlm-2375	206	1	https://doi.org/10.1016/j.jiph.2021.08.013	https://doi.org/10.1016/j.jiph.2021.08.013	PROPN
ajlm-2375	206	2	stals	stal	NOUN
ajlm-2375	206	3	m	m	PROPN
ajlm-2375	206	4	,	,	PUNCT
ajlm-2375	206	5	kaptein	kaptein	PROPN
ajlm-2375	206	6	f	f	X
ajlm-2375	206	7	,	,	PUNCT
ajlm-2375	206	8	kroft	kroft	PROPN
ajlm-2375	206	9	l	l	PROPN
ajlm-2375	206	10	,	,	PUNCT
ajlm-2375	206	11	klok	klok	PROPN
ajlm-2375	206	12	fa	fa	PROPN
ajlm-2375	206	13	,	,	PUNCT
ajlm-2375	206	14	huisman	huisman	PROPN
ajlm-2375	206	15	mv	mv	PROPN
ajlm-2375	206	16	.	.	PROPN
ajlm-2375	206	17	challenges	challenge	NOUN
ajlm-2375	206	18	in	in	ADP
ajlm-2375	206	19	the	the	DET
ajlm-2375	206	20	diagnostic	diagnostic	ADJ
ajlm-2375	206	21	approach	approach	NOUN
ajlm-2375	206	22	of	of	ADP
ajlm-2375	206	23	suspected	suspect	VERB
ajlm-2375	206	24	pulmonary	pulmonary	ADJ
ajlm-2375	206	25	embolism	embolism	NOUN
ajlm-2375	206	26	in	in	ADP
ajlm-2375	206	27	covid-19	covid-19	PROPN
ajlm-2375	206	28	patients	patient	NOUN
ajlm-2375	206	29	.	.	PUNCT
ajlm-2375	207	1	postgrad	postgrad	PROPN
ajlm-2375	207	2	med	med	PROPN
ajlm-2375	207	3	.	.	PUNCT
ajlm-2375	208	1	2021;133(sup1):36–41	2021;133(sup1):36–41	NUM
ajlm-2375	208	2	.	.	PUNCT
ajlm-2375	208	3	https://doi.org/10.1080/00325481.2021.1920723	https://doi.org/10.1080/00325481.2021.1920723	PROPN
ajlm-2375	208	4	benjafield	benjafield	NOUN
ajlm-2375	208	5	av	av	PROPN
ajlm-2375	208	6	,	,	PUNCT
ajlm-2375	208	7	wang	wang	PROPN
ajlm-2375	208	8	wy	wy	PROPN
ajlm-2375	208	9	,	,	PUNCT
ajlm-2375	208	10	morris	morris	PROPN
ajlm-2375	208	11	bj	bj	NOUN
ajlm-2375	208	12	.	.	PUNCT
ajlm-2375	209	1	no	no	DET
ajlm-2375	209	2	association	association	NOUN
ajlm-2375	209	3	of	of	ADP
ajlm-2375	209	4	angiotensin	angiotensin	NOUN
ajlm-2375	209	5	-	-	PUNCT
ajlm-2375	209	6	converting	convert	VERB
ajlm-2375	209	7	enzyme	enzyme	NOUN
ajlm-2375	209	8	2	2	NUM
ajlm-2375	209	9	gene	gene	NOUN
ajlm-2375	209	10	(	(	PUNCT
ajlm-2375	209	11	ace2	ace2	NOUN
ajlm-2375	209	12	)	)	PUNCT
ajlm-2375	209	13	polymorphisms	polymorphism	NOUN
ajlm-2375	209	14	with	with	ADP
ajlm-2375	209	15	essential	essential	ADJ
ajlm-2375	209	16	hypertension	hypertension	NOUN
ajlm-2375	209	17	.	.	PUNCT
ajlm-2375	210	1	am	be	AUX
ajlm-2375	210	2	j	j	PROPN
ajlm-2375	210	3	hypertens	hyperten	NOUN
ajlm-2375	210	4	.	.	PUNCT
ajlm-2375	211	1	2004;17(7):624–628	2004;17(7):624–628	NUM
ajlm-2375	211	2	.	.	PUNCT
ajlm-2375	212	1	https://doi.org/10.1016/j.amjhyper.2004.02.022	https://doi.org/10.1016/j.amjhyper.2004.02.022	PROPN
ajlm-2375	212	2	alimoradi	alimoradi	PROPN
ajlm-2375	212	3	n	n	CCONJ
ajlm-2375	212	4	,	,	PUNCT
ajlm-2375	212	5	sharqi	sharqi	PROPN
ajlm-2375	212	6	m	m	PROPN
ajlm-2375	212	7	,	,	PUNCT
ajlm-2375	212	8	firouzabadi	firouzabadi	NOUN
ajlm-2375	212	9	d	d	PROPN
ajlm-2375	212	10	,	,	PUNCT
ajlm-2375	212	11	sadeghi	sadeghi	PROPN
ajlm-2375	212	12	mm	mm	PROPN
ajlm-2375	212	13	,	,	PUNCT
ajlm-2375	212	14	moezzi	moezzi	PROPN
ajlm-2375	212	15	mi	mi	PROPN
ajlm-2375	212	16	,	,	PUNCT
ajlm-2375	212	17	firouzabadi	firouzabadi	PROPN
ajlm-2375	212	18	n.	n.	PROPN
ajlm-2375	212	19	snps	snps	PROPN
ajlm-2375	212	20	of	of	ADP
ajlm-2375	212	21	ace1	ace1	PROPN
ajlm-2375	212	22	(	(	PUNCT
ajlm-2375	212	23	rs4343	rs4343	PROPN
ajlm-2375	212	24	)	)	PUNCT
ajlm-2375	212	25	and	and	CCONJ
ajlm-2375	212	26	ace2	ace2	PROPN
ajlm-2375	212	27	(	(	PUNCT
ajlm-2375	212	28	rs2285666	rs2285666	NOUN
ajlm-2375	212	29	)	)	PUNCT
ajlm-2375	212	30	genes	gene	NOUN
ajlm-2375	212	31	are	be	AUX
ajlm-2375	212	32	linked	link	VERB
ajlm-2375	212	33	to	to	ADP
ajlm-2375	212	34	sars	sar	NOUN
ajlm-2375	212	35	-	-	PUNCT
ajlm-2375	212	36	cov-2	cov-2	PART
ajlm-2375	212	37	infection	infection	NOUN
ajlm-2375	212	38	but	but	CCONJ
ajlm-2375	212	39	not	not	PART
ajlm-2375	212	40	with	with	ADP
ajlm-2375	212	41	the	the	DET
ajlm-2375	212	42	severity	severity	NOUN
ajlm-2375	212	43	of	of	ADP
ajlm-2375	212	44	disease	disease	NOUN
ajlm-2375	212	45	.	.	PUNCT
ajlm-2375	213	1	virol	virol	PROPN
ajlm-2375	213	2	j.	j.	PROPN
ajlm-2375	213	3	2022;19(1):48	2022;19(1):48	PROPN
ajlm-2375	213	4	.	.	PROPN
ajlm-2375	214	1	https://doi.org/10.1186/s12985-022-01782-6	https://doi.org/10.1186/s12985-022-01782-6	NUM
ajlm-2375	214	2	fernández	fernández	PROPN
ajlm-2375	214	3	-	-	PUNCT
ajlm-2375	214	4	de	de	PROPN
ajlm-2375	214	5	-	-	ADJ
ajlm-2375	214	6	las	las	NOUN
ajlm-2375	214	7	-	-	PROPN
ajlm-2375	214	8	peñas	peñas	PROPN
ajlm-2375	214	9	c	c	PROPN
ajlm-2375	214	10	,	,	PUNCT
ajlm-2375	214	11	arendt	arendt	PROPN
ajlm-2375	214	12	-	-	PUNCT
ajlm-2375	214	13	nielsen	nielsen	PROPN
ajlm-2375	214	14	l	l	PROPN
ajlm-2375	214	15	,	,	PUNCT
ajlm-2375	214	16	díaz	díaz	NOUN
ajlm-2375	214	17	-	-	PUNCT
ajlm-2375	214	18	gil	gil	NOUN
ajlm-2375	214	19	g	g	NOUN
ajlm-2375	214	20	,	,	PUNCT
ajlm-2375	214	21	et	et	PROPN
ajlm-2375	214	22	al	al	PROPN
ajlm-2375	214	23	.	.	PUNCT
ajlm-2375	214	24	genetic	genetic	PROPN
ajlm-2375	214	25	association	association	NOUN
ajlm-2375	214	26	between	between	ADP
ajlm-2375	214	27	ace2	ace2	PROPN
ajlm-2375	214	28	(	(	PUNCT
ajlm-2375	214	29	rs2285666	rs2285666	NOUN
ajlm-2375	214	30	and	and	CCONJ
ajlm-2375	214	31	rs2074192	rs2074192	ADJ
ajlm-2375	214	32	)	)	PUNCT
ajlm-2375	214	33	and	and	CCONJ
ajlm-2375	214	34	tmprss2	tmprss2	ADP
ajlm-2375	214	35	(	(	PUNCT
ajlm-2375	214	36	rs12329760	rs12329760	NOUN
ajlm-2375	214	37	and	and	CCONJ
ajlm-2375	214	38	rs2070788	rs2070788	ADJ
ajlm-2375	214	39	)	)	PUNCT
ajlm-2375	214	40	polymorphisms	polymorphism	NOUN
ajlm-2375	214	41	with	with	ADP
ajlm-2375	214	42	post	post	ADJ
ajlm-2375	214	43	-	-	ADJ
ajlm-2375	214	44	covid	covid	ADJ
ajlm-2375	214	45	symptoms	symptom	NOUN
ajlm-2375	214	46	in	in	ADP
ajlm-2375	214	47	previously	previously	ADV
ajlm-2375	214	48	hospitalized	hospitalize	VERB
ajlm-2375	214	49	covid-19	covid-19	PROPN
ajlm-2375	214	50	survivors	survivor	NOUN
ajlm-2375	214	51	.	.	PUNCT
ajlm-2375	215	1	genes	gene	NOUN
ajlm-2375	215	2	.	.	PUNCT
ajlm-2375	216	1	2022;13(11):1935	2022;13(11):1935	X
ajlm-2375	216	2	.	.	PUNCT
ajlm-2375	217	1	https://doi.org/10.3390/genes13111935	https://doi.org/10.3390/genes13111935	PROPN
ajlm-2375	217	2	jones	jones	PROPN
ajlm-2375	217	3	tc	tc	PROPN
ajlm-2375	217	4	,	,	PUNCT
ajlm-2375	217	5	biele	biele	PROPN
ajlm-2375	217	6	g	g	PROPN
ajlm-2375	217	7	,	,	PUNCT
ajlm-2375	217	8	mühlemann	mühlemann	PROPN
ajlm-2375	217	9	b	b	PROPN
ajlm-2375	217	10	,	,	PUNCT
ajlm-2375	217	11	et	et	PROPN
ajlm-2375	217	12	al	al	PROPN
ajlm-2375	217	13	.	.	PUNCT
ajlm-2375	217	14	estimating	estimate	VERB
ajlm-2375	217	15	infectiousness	infectiousness	NOUN
ajlm-2375	217	16	throughout	throughout	ADP
ajlm-2375	217	17	sars	sar	NOUN
ajlm-2375	217	18	-	-	PUNCT
ajlm-2375	217	19	cov-2	cov-2	NOUN
ajlm-2375	217	20	infection	infection	NOUN
ajlm-2375	217	21	course	course	NOUN
ajlm-2375	217	22	.	.	PUNCT
ajlm-2375	218	1	science	science	NOUN
ajlm-2375	218	2	(	(	PUNCT
ajlm-2375	218	3	new	new	PROPN
ajlm-2375	218	4	york	york	PROPN
ajlm-2375	218	5	,	,	PUNCT
ajlm-2375	218	6	ny	ny	PROPN
ajlm-2375	218	7	)	)	PUNCT
ajlm-2375	218	8	.	.	PUNCT
ajlm-2375	219	1	2021;373(6551):eabi5273	2021;373(6551):eabi5273	X
ajlm-2375	219	2	.	.	PUNCT
ajlm-2375	220	1	https://doi.org/10.1126/science.abi5273	https://doi.org/10.1126/science.abi5273	VERB
ajlm-2375	220	2	hachim	hachim	PROPN
ajlm-2375	220	3	iy	iy	INTJ
ajlm-2375	220	4	,	,	PUNCT
ajlm-2375	220	5	hachim	hachim	PRON
ajlm-2375	220	6	my	my	PRON
ajlm-2375	220	7	,	,	PUNCT
ajlm-2375	220	8	naeem	naeem	PROPN
ajlm-2375	220	9	kb	kb	PROPN
ajlm-2375	220	10	,	,	PUNCT
ajlm-2375	220	11	et	et	PROPN
ajlm-2375	220	12	al	al	PROPN
ajlm-2375	220	13	.	.	PUNCT
ajlm-2375	221	1	kidney	kidney	PROPN
ajlm-2375	221	2	dysfunction	dysfunction	NOUN
ajlm-2375	221	3	among	among	ADP
ajlm-2375	221	4	covid-19	covid-19	PROPN
ajlm-2375	221	5	patients	patient	NOUN
ajlm-2375	221	6	in	in	ADP
ajlm-2375	221	7	the	the	DET
ajlm-2375	221	8	united	united	PROPN
ajlm-2375	221	9	arab	arab	PROPN
ajlm-2375	221	10	emirates	emirates	PROPN
ajlm-2375	221	11	.	.	PUNCT
ajlm-2375	222	1	oman	oman	PROPN
ajlm-2375	222	2	med	med	PROPN
ajlm-2375	222	3	j.	j.	PROPN
ajlm-2375	222	4	2021;36(1):e221	2021;36(1):e221	PROPN
ajlm-2375	222	5	.	.	PUNCT
ajlm-2375	223	1	https://doi.org/10.5001/omj.2020.92	https://doi.org/10.5001/omj.2020.92	PROPN
ajlm-2375	223	2	gabarre	gabarre	VERB
ajlm-2375	223	3	p	p	X
ajlm-2375	223	4	,	,	PUNCT
ajlm-2375	223	5	dumas	dumas	PROPN
ajlm-2375	223	6	g	g	PROPN
ajlm-2375	223	7	,	,	PUNCT
ajlm-2375	223	8	dupont	dupont	PROPN
ajlm-2375	223	9	t	t	PROPN
ajlm-2375	223	10	,	,	PUNCT
ajlm-2375	223	11	darmon	darmon	VERB
ajlm-2375	223	12	m	m	PRON
ajlm-2375	223	13	,	,	PUNCT
ajlm-2375	223	14	azoulay	azoulay	VERB
ajlm-2375	223	15	e	e	NOUN
ajlm-2375	223	16	,	,	PUNCT
ajlm-2375	223	17	zafrani	zafrani	PROPN
ajlm-2375	223	18	l.	l.	PROPN
ajlm-2375	223	19	acute	acute	PROPN
ajlm-2375	223	20	kidney	kidney	PROPN
ajlm-2375	223	21	injury	injury	NOUN
ajlm-2375	223	22	in	in	ADP
ajlm-2375	223	23	critically	critically	ADV
ajlm-2375	223	24	ill	ill	ADJ
ajlm-2375	223	25	patients	patient	NOUN
ajlm-2375	223	26	with	with	ADP
ajlm-2375	223	27	covid-19	covid-19	PROPN
ajlm-2375	223	28	.	.	PUNCT
ajlm-2375	224	1	intensive	intensive	ADJ
ajlm-2375	224	2	care	care	NOUN
ajlm-2375	224	3	med	me	VERB
ajlm-2375	224	4	.	.	PUNCT
ajlm-2375	225	1	2020;46(7):1339–1348	2020;46(7):1339–1348	NUM
ajlm-2375	225	2	.	.	PUNCT
ajlm-2375	226	1	wang	wang	PROPN
ajlm-2375	226	2	g	g	PROPN
ajlm-2375	226	3	,	,	PUNCT
ajlm-2375	226	4	wu	wu	PROPN
ajlm-2375	226	5	c	c	PROPN
ajlm-2375	226	6	,	,	PUNCT
ajlm-2375	226	7	zhang	zhang	PROPN
ajlm-2375	226	8	q	q	PROPN
ajlm-2375	226	9	,	,	PUNCT
ajlm-2375	226	10	et	et	PROPN
ajlm-2375	226	11	al	al	PROPN
ajlm-2375	226	12	.	.	PROPN
ajlm-2375	226	13	,	,	PUNCT
ajlm-2375	226	14	editors	editor	NOUN
ajlm-2375	226	15	.	.	PUNCT
ajlm-2375	227	1	c	c	X
ajlm-2375	227	2	-	-	PUNCT
ajlm-2375	227	3	reactive	reactive	ADJ
ajlm-2375	227	4	protein	protein	NOUN
ajlm-2375	227	5	level	level	NOUN
ajlm-2375	227	6	may	may	AUX
ajlm-2375	227	7	predict	predict	VERB
ajlm-2375	227	8	the	the	DET
ajlm-2375	227	9	risk	risk	NOUN
ajlm-2375	227	10	of	of	ADP
ajlm-2375	227	11	covid-19	covid-19	PROPN
ajlm-2375	227	12	aggravation	aggravation	NOUN
ajlm-2375	227	13	.	.	PUNCT
ajlm-2375	228	1	open	open	ADJ
ajlm-2375	228	2	forum	forum	PROPN
ajlm-2375	228	3	infect	infect	VERB
ajlm-2375	228	4	dis	dis	PROPN
ajlm-2375	228	5	.	.	PUNCT
ajlm-2375	229	1	2020;29;7(5):ofaa153	2020;29;7(5):ofaa153	NUM
ajlm-2375	229	2	.	.	PUNCT
ajlm-2375	229	3	https://doi.org/10.1093/ofid/ofaa153	https://doi.org/10.1093/ofid/ofaa153	NOUN
ajlm-2375	229	4	potempa	potempa	PROPN
ajlm-2375	229	5	la	la	PROPN
ajlm-2375	229	6	,	,	PUNCT
ajlm-2375	229	7	rajab	rajab	VERB
ajlm-2375	229	8	i	i	PRON
ajlm-2375	229	9	m	m	PROPN
ajlm-2375	229	10	,	,	PUNCT
ajlm-2375	229	11	hart	hart	PROPN
ajlm-2375	229	12	pc	pc	PROPN
ajlm-2375	229	13	,	,	PUNCT
ajlm-2375	229	14	bordon	bordon	PROPN
ajlm-2375	229	15	j	j	PROPN
ajlm-2375	229	16	,	,	PUNCT
ajlm-2375	229	17	fernandez	fernandez	PROPN
ajlm-2375	229	18	-	-	PUNCT
ajlm-2375	229	19	botran	botran	NOUN
ajlm-2375	229	20	r.	r.	NOUN
ajlm-2375	229	21	insights	insight	NOUN
ajlm-2375	229	22	into	into	ADP
ajlm-2375	229	23	the	the	DET
ajlm-2375	229	24	use	use	NOUN
ajlm-2375	229	25	of	of	ADP
ajlm-2375	229	26	c	c	NOUN
ajlm-2375	229	27	-	-	PUNCT
ajlm-2375	229	28	reactive	reactive	ADJ
ajlm-2375	229	29	protein	protein	NOUN
ajlm-2375	229	30	as	as	ADP
ajlm-2375	229	31	a	a	DET
ajlm-2375	229	32	diagnostic	diagnostic	ADJ
ajlm-2375	229	33	index	index	NOUN
ajlm-2375	229	34	of	of	ADP
ajlm-2375	229	35	disease	disease	NOUN
ajlm-2375	229	36	severity	severity	NOUN
ajlm-2375	229	37	in	in	ADP
ajlm-2375	229	38	covid-19	covid-19	PROPN
ajlm-2375	229	39	infections	infection	NOUN
ajlm-2375	229	40	.	.	PUNCT
ajlm-2375	230	1	am	be	AUX
ajlm-2375	230	2	j	j	PROPN
ajlm-2375	230	3	trop	trop	X
ajlm-2375	230	4	med	med	PROPN
ajlm-2375	230	5	hyg	hyg	PROPN
ajlm-2375	230	6	.	.	PUNCT
ajlm-2375	231	1	2020;103(2):561	2020;103(2):561	NOUN
ajlm-2375	231	2	.	.	PUNCT
ajlm-2375	232	1	https://doi.org/10.4269/ajtmh.20-0473	https://doi.org/10.4269/ajtmh.20-0473	PROPN
ajlm-2375	232	2	cho	cho	PROPN
ajlm-2375	232	3	rh	rh	PROPN
ajlm-2375	232	4	,	,	PUNCT
ajlm-2375	232	5	to	to	ADP
ajlm-2375	232	6	zw	zw	PROPN
ajlm-2375	232	7	,	,	PUNCT
ajlm-2375	232	8	yeung	yeung	PROPN
ajlm-2375	232	9	zw	zw	PROPN
ajlm-2375	232	10	,	,	PUNCT
ajlm-2375	232	11	et	et	PROPN
ajlm-2375	232	12	al	al	PROPN
ajlm-2375	232	13	.	.	PUNCT
ajlm-2375	233	1	covid-19	covid-19	PROPN
ajlm-2375	233	2	viral	viral	ADJ
ajlm-2375	233	3	load	load	NOUN
ajlm-2375	233	4	in	in	ADP
ajlm-2375	233	5	the	the	DET
ajlm-2375	233	6	severity	severity	NOUN
ajlm-2375	233	7	of	of	ADP
ajlm-2375	233	8	and	and	CCONJ
ajlm-2375	233	9	recovery	recovery	NOUN
ajlm-2375	233	10	from	from	ADP
ajlm-2375	233	11	olfactory	olfactory	NOUN
ajlm-2375	233	12	and	and	CCONJ
ajlm-2375	233	13	gustatory	gustatory	ADJ
ajlm-2375	233	14	dysfunction	dysfunction	NOUN
ajlm-2375	233	15	.	.	PUNCT
ajlm-2375	234	1	laryngoscope	laryngoscope	NOUN
ajlm-2375	234	2	.	.	PUNCT
ajlm-2375	235	1	2020;130(11):2680–2685	2020;130(11):2680–2685	NUM
ajlm-2375	235	2	.	.	PUNCT
ajlm-2375	235	3	https://doi.org/10.1002/lary.29056	https://doi.org/10.1002/lary.29056	PROPN
ajlm-2375	235	4	abdulrahman	abdulrahman	PROPN
ajlm-2375	235	5	a	a	PROPN
ajlm-2375	235	6	,	,	PUNCT
ajlm-2375	235	7	mallah	mallah	PROPN
ajlm-2375	235	8	si	si	PROPN
ajlm-2375	235	9	,	,	PUNCT
ajlm-2375	235	10	alqahtani	alqahtani	PROPN
ajlm-2375	235	11	m.	m.	NOUN
ajlm-2375	235	12	covid-19	covid-19	PROPN
ajlm-2375	235	13	viral	viral	ADJ
ajlm-2375	235	14	load	load	NOUN
ajlm-2375	235	15	not	not	PART
ajlm-2375	235	16	associated	associate	VERB
ajlm-2375	235	17	with	with	ADP
ajlm-2375	235	18	disease	disease	NOUN
ajlm-2375	235	19	severity	severity	NOUN
ajlm-2375	235	20	:	:	PUNCT
ajlm-2375	235	21	findings	finding	NOUN
ajlm-2375	235	22	from	from	ADP
ajlm-2375	235	23	a	a	DET
ajlm-2375	235	24	retrospective	retrospective	ADJ
ajlm-2375	235	25	cohort	cohort	NOUN
ajlm-2375	235	26	study	study	NOUN
ajlm-2375	235	27	.	.	PUNCT
ajlm-2375	236	1	bmc	bmc	PROPN
ajlm-2375	236	2	infect	infect	PROPN
ajlm-2375	236	3	dis	dis	PROPN
ajlm-2375	236	4	.	.	PUNCT
ajlm-2375	237	1	2021;21(1):688	2021;21(1):688	PROPN
ajlm-2375	237	2	.	.	PUNCT
ajlm-2375	238	1	gaber	gaber	PROPN
ajlm-2375	238	2	sn	sn	PROPN
ajlm-2375	238	3	,	,	PUNCT
ajlm-2375	238	4	elkhateeb	elkhateeb	PROPN
ajlm-2375	238	5	af	af	PROPN
ajlm-2375	238	6	,	,	PUNCT
ajlm-2375	238	7	magdy	magdy	PROPN
ajlm-2375	238	8	am	be	AUX
ajlm-2375	238	9	,	,	PUNCT
ajlm-2375	238	10	botros	botros	PROPN
ajlm-2375	238	11	jm	jm	PROPN
ajlm-2375	238	12	,	,	PUNCT
ajlm-2375	238	13	bassyouni	bassyouni	PROPN
ajlm-2375	238	14	rh	rh	PROPN
ajlm-2375	238	15	.	.	PUNCT
ajlm-2375	239	1	parameters	parameter	NOUN
ajlm-2375	239	2	linked	link	VERB
ajlm-2375	239	3	with	with	ADP
ajlm-2375	239	4	mortality	mortality	NOUN
ajlm-2375	239	5	in	in	ADP
ajlm-2375	239	6	egyptian	egyptian	PROPN
ajlm-2375	239	7	covid-19	covid-19	PROPN
ajlm-2375	239	8	hospitalized	hospitalize	VERB
ajlm-2375	239	9	patients	patient	NOUN
ajlm-2375	239	10	.	.	PUNCT
ajlm-2375	240	1	egypt	egypt	PROPN
ajlm-2375	240	2	j	j	PROPN
ajlm-2375	240	3	med	med	PROPN
ajlm-2375	240	4	microbiol	microbiol	PROPN
ajlm-2375	240	5	.	.	PUNCT
ajlm-2375	241	1	2022;31(1):89–95	2022;31(1):89–95	X
ajlm-2375	241	2	.	.	PUNCT
ajlm-2375	242	1	https://doi.org/10.21608/ejmm.2022.211990	https://doi.org/10.21608/ejmm.2022.211990	PROPN
ajlm-2375	242	2	assal	assal	VERB
ajlm-2375	242	3	hh	hh	PROPN
ajlm-2375	242	4	,	,	PUNCT
ajlm-2375	242	5	abdel	abdel	PROPN
ajlm-2375	242	6	-	-	PUNCT
ajlm-2375	242	7	hamid	hamid	PROPN
ajlm-2375	242	8	hm	hm	PROPN
ajlm-2375	242	9	,	,	PUNCT
ajlm-2375	242	10	magdy	magdy	PROPN
ajlm-2375	242	11	s	s	PROPN
ajlm-2375	242	12	,	,	PUNCT
ajlm-2375	242	13	et	et	PROPN
ajlm-2375	242	14	al	al	PROPN
ajlm-2375	242	15	.	.	PUNCT
ajlm-2375	242	16	predictors	predictor	NOUN
ajlm-2375	242	17	of	of	ADP
ajlm-2375	242	18	severity	severity	NOUN
ajlm-2375	242	19	and	and	CCONJ
ajlm-2375	242	20	mortality	mortality	NOUN
ajlm-2375	242	21	in	in	ADP
ajlm-2375	242	22	covid-19	covid-19	PROPN
ajlm-2375	242	23	patients	patient	NOUN
ajlm-2375	242	24	.	.	PUNCT
ajlm-2375	243	1	egypt	egypt	PROPN
ajlm-2375	243	2	j	j	PROPN
ajlm-2375	243	3	bronchol	bronchol	PROPN
ajlm-2375	243	4	.	.	PUNCT
ajlm-2375	244	1	2022;16(1):18	2022;16(1):18	X
ajlm-2375	244	2	.	.	PUNCT
ajlm-2375	245	1	https://doi.org/10.1186/s43168-022-00122-0	https://doi.org/10.1186/s43168-022-00122-0	PROPN
ajlm-2375	246	1	mahendra	mahendra	PROPN
ajlm-2375	246	2	m	m	PROPN
ajlm-2375	246	3	,	,	PUNCT
ajlm-2375	246	4	nuchin	nuchin	NOUN
ajlm-2375	246	5	a	a	PRON
ajlm-2375	246	6	,	,	PUNCT
ajlm-2375	246	7	kumar	kumar	PROPN
ajlm-2375	246	8	r	r	PROPN
ajlm-2375	246	9	,	,	PUNCT
ajlm-2375	246	10	shreedhar	shreedhar	VERB
ajlm-2375	246	11	s	s	PROPN
ajlm-2375	246	12	,	,	PUNCT
ajlm-2375	246	13	mahesh	mahesh	PROPN
ajlm-2375	246	14	pa	pa	PROPN
ajlm-2375	246	15	.	.	PROPN
ajlm-2375	246	16	predictors	predictor	NOUN
ajlm-2375	246	17	of	of	ADP
ajlm-2375	246	18	mortality	mortality	NOUN
ajlm-2375	246	19	in	in	ADP
ajlm-2375	246	20	patients	patient	NOUN
ajlm-2375	246	21	with	with	ADP
ajlm-2375	246	22	severe	severe	ADJ
ajlm-2375	246	23	covid-19	covid-19	PROPN
ajlm-2375	246	24	pneumonia	pneumonia	NOUN
ajlm-2375	246	25	–	–	PUNCT
ajlm-2375	246	26	a	a	DET
ajlm-2375	246	27	retrospective	retrospective	ADJ
ajlm-2375	246	28	study	study	NOUN
ajlm-2375	246	29	.	.	PUNCT
ajlm-2375	247	1	adv	adv	PROPN
ajlm-2375	247	2	respir	respir	VERB
ajlm-2375	247	3	med	med	ADJ
ajlm-2375	247	4	.	.	PUNCT
ajlm-2375	248	1	2021;89(2):135–144	2021;89(2):135–144	NUM
ajlm-2375	248	2	.	.	PUNCT
ajlm-2375	249	1	https://doi.org/10.5603/arm.a2021.0036	https://doi.org/10.5603/arm.a2021.0036	PROPN
ajlm-2375	249	2	hashemi	hashemi	PROPN
ajlm-2375	249	3	sma	sma	PROPN
ajlm-2375	249	4	,	,	PUNCT
ajlm-2375	249	5	thijssen	thijssen	PROPN
ajlm-2375	249	6	m	m	PROPN
ajlm-2375	249	7	,	,	PUNCT
ajlm-2375	249	8	hosseini	hosseini	PROPN
ajlm-2375	249	9	sy	sy	PROPN
ajlm-2375	249	10	,	,	PUNCT
ajlm-2375	249	11	tabarraei	tabarraei	NOUN
ajlm-2375	249	12	a	a	PRON
ajlm-2375	249	13	,	,	PUNCT
ajlm-2375	249	14	pourkarim	pourkarim	PROPN
ajlm-2375	249	15	mr	mr	PROPN
ajlm-2375	249	16	,	,	PUNCT
ajlm-2375	249	17	sarvari	sarvari	PROPN
ajlm-2375	249	18	j.	j.	PROPN
ajlm-2375	249	19	human	human	PROPN
ajlm-2375	249	20	gene	gene	NOUN
ajlm-2375	249	21	polymorphisms	polymorphism	NOUN
ajlm-2375	249	22	and	and	CCONJ
ajlm-2375	249	23	their	their	PRON
ajlm-2375	249	24	possible	possible	ADJ
ajlm-2375	249	25	impact	impact	NOUN
ajlm-2375	249	26	on	on	ADP
ajlm-2375	249	27	the	the	DET
ajlm-2375	249	28	clinical	clinical	ADJ
ajlm-2375	249	29	outcome	outcome	NOUN
ajlm-2375	249	30	of	of	ADP
ajlm-2375	249	31	sars	sar	NOUN
ajlm-2375	249	32	-	-	PUNCT
ajlm-2375	249	33	cov-2	cov-2	NOUN
ajlm-2375	249	34	infection	infection	NOUN
ajlm-2375	249	35	.	.	PUNCT
ajlm-2375	250	1	archiv	archiv	PROPN
ajlm-2375	250	2	virol	virol	PROPN
ajlm-2375	250	3	.	.	PUNCT
ajlm-2375	251	1	2021;166(8):2089–2108	2021;166(8):2089–2108	NUM
ajlm-2375	251	2	.	.	PUNCT
ajlm-2375	252	1	https://doi.org/10.1007/s00705-021-05070-6	https://doi.org/10.1007/s00705-021-05070-6	PROPN
ajlm-2375	252	2	wang	wang	PROPN
ajlm-2375	252	3	j	j	PROPN
ajlm-2375	252	4	,	,	PUNCT
ajlm-2375	252	5	xu	xu	PROPN
ajlm-2375	253	1	x	x	PROPN
ajlm-2375	253	2	,	,	PUNCT
ajlm-2375	253	3	zhou	zhou	PROPN
ajlm-2375	253	4	x	x	PROPN
ajlm-2375	253	5	,	,	PUNCT
ajlm-2375	253	6	et	et	PROPN
ajlm-2375	253	7	al	al	PROPN
ajlm-2375	253	8	.	.	PROPN
ajlm-2375	254	1	molecular	molecular	ADJ
ajlm-2375	254	2	simulation	simulation	NOUN
ajlm-2375	254	3	of	of	ADP
ajlm-2375	254	4	sars	sars	PROPN
ajlm-2375	254	5	-	-	PUNCT
ajlm-2375	254	6	cov-2	cov-2	NOUN
ajlm-2375	254	7	spike	spike	ADJ
ajlm-2375	254	8	protein	protein	NOUN
ajlm-2375	254	9	binding	bind	VERB
ajlm-2375	254	10	to	to	ADP
ajlm-2375	254	11	pangolin	pangolin	PROPN
ajlm-2375	254	12	ace2	ace2	PROPN
ajlm-2375	254	13	or	or	CCONJ
ajlm-2375	254	14	human	human	ADJ
ajlm-2375	254	15	ace2	ace2	PROPN
ajlm-2375	254	16	natural	natural	ADJ
ajlm-2375	254	17	variants	variant	NOUN
ajlm-2375	254	18	reveals	reveal	NOUN
ajlm-2375	254	19	altered	alter	VERB
ajlm-2375	254	20	susceptibility	susceptibility	NOUN
ajlm-2375	254	21	to	to	ADP
ajlm-2375	254	22	infection	infection	NOUN
ajlm-2375	254	23	.	.	PUNCT
ajlm-2375	255	1	j	j	PROPN
ajlm-2375	255	2	gen	gen	PROPN
ajlm-2375	255	3	virol	virol	NOUN
ajlm-2375	255	4	.	.	PUNCT
ajlm-2375	256	1	2020;101(9):921	2020;101(9):921	X
ajlm-2375	256	2	.	.	PUNCT
ajlm-2375	256	3	asselta	asselta	PROPN
ajlm-2375	256	4	r	r	PROPN
ajlm-2375	256	5	,	,	PUNCT
ajlm-2375	256	6	paraboschi	paraboschi	NOUN
ajlm-2375	256	7	em	em	PRON
ajlm-2375	256	8	,	,	PUNCT
ajlm-2375	256	9	mantovani	mantovani	PROPN
ajlm-2375	256	10	a	a	PROPN
ajlm-2375	256	11	,	,	PUNCT
ajlm-2375	256	12	duga	duga	PROPN
ajlm-2375	256	13	s.	s.	PROPN
ajlm-2375	256	14	ace2	ace2	PROPN
ajlm-2375	256	15	and	and	CCONJ
ajlm-2375	256	16	tmprss2	tmprss2	ADP
ajlm-2375	256	17	variants	variant	NOUN
ajlm-2375	256	18	and	and	CCONJ
ajlm-2375	256	19	expression	expression	NOUN
ajlm-2375	256	20	as	as	ADP
ajlm-2375	256	21	candidates	candidate	NOUN
ajlm-2375	256	22	to	to	ADP
ajlm-2375	256	23	sex	sex	NOUN
ajlm-2375	256	24	and	and	CCONJ
ajlm-2375	256	25	country	country	NOUN
ajlm-2375	256	26	differences	difference	NOUN
ajlm-2375	256	27	in	in	ADP
ajlm-2375	256	28	covid-19	covid-19	PROPN
ajlm-2375	256	29	severity	severity	NOUN
ajlm-2375	256	30	in	in	ADP
ajlm-2375	256	31	italy	italy	PROPN
ajlm-2375	256	32	.	.	PUNCT
ajlm-2375	257	1	aging	age	VERB
ajlm-2375	257	2	.	.	PUNCT
ajlm-2375	258	1	2020;12(11):10087–10098	2020;12(11):10087–10098	X
ajlm-2375	258	2	.	.	PUNCT
ajlm-2375	259	1	https://doi.org/10.18632/aging.103415	https://doi.org/10.18632/aging.103415	PRON
ajlm-2375	259	2	torre	torre	PROPN
ajlm-2375	259	3	-	-	PUNCT
ajlm-2375	259	4	fuentes	fuentes	PROPN
ajlm-2375	259	5	l	l	NOUN
ajlm-2375	259	6	,	,	PUNCT
ajlm-2375	259	7	matías	matías	NOUN
ajlm-2375	259	8	-	-	PUNCT
ajlm-2375	259	9	guiu	guiu	NOUN
ajlm-2375	259	10	j	j	PROPN
ajlm-2375	259	11	,	,	PUNCT
ajlm-2375	259	12	hernández	hernández	PROPN
ajlm-2375	259	13	-	-	PUNCT
ajlm-2375	259	14	lorenzo	lorenzo	PROPN
ajlm-2375	259	15	l	l	PROPN
ajlm-2375	259	16	,	,	PUNCT
ajlm-2375	259	17	et	et	PROPN
ajlm-2375	259	18	al	al	PROPN
ajlm-2375	259	19	.	.	PROPN
ajlm-2375	259	20	ace2	ace2	PROPN
ajlm-2375	259	21	,	,	PUNCT
ajlm-2375	259	22	tmprss2	tmprss2	ADV
ajlm-2375	259	23	,	,	PUNCT
ajlm-2375	259	24	and	and	CCONJ
ajlm-2375	259	25	furin	furin	NOUN
ajlm-2375	259	26	variants	variant	NOUN
ajlm-2375	259	27	and	and	CCONJ
ajlm-2375	259	28	sars	sar	NOUN
ajlm-2375	259	29	-	-	PUNCT
ajlm-2375	259	30	cov-2	cov-2	NOUN
ajlm-2375	259	31	infection	infection	NOUN
ajlm-2375	259	32	in	in	ADP
ajlm-2375	259	33	madrid	madrid	PROPN
ajlm-2375	259	34	,	,	PUNCT
ajlm-2375	259	35	spain	spain	PROPN
ajlm-2375	259	36	.	.	PUNCT
ajlm-2375	260	1	j	j	PROPN
ajlm-2375	260	2	med	med	PROPN
ajlm-2375	260	3	virol	virol	NOUN
ajlm-2375	260	4	.	.	PUNCT
ajlm-2375	261	1	2021;93(2):863–869	2021;93(2):863–869	X
ajlm-2375	261	2	.	.	PUNCT
ajlm-2375	261	3	wu	wu	PROPN
ajlm-2375	261	4	yh	yh	PROPN
ajlm-2375	261	5	,	,	PUNCT
ajlm-2375	261	6	li	li	PROPN
ajlm-2375	261	7	jy	jy	PROPN
ajlm-2375	261	8	,	,	PUNCT
ajlm-2375	261	9	wang	wang	PROPN
ajlm-2375	261	10	c	c	PROPN
ajlm-2375	261	11	,	,	PUNCT
ajlm-2375	261	12	zhang	zhang	PROPN
ajlm-2375	261	13	lm	lm	PROPN
ajlm-2375	261	14	,	,	PUNCT
ajlm-2375	261	15	qiao	qiao	PROPN
ajlm-2375	261	16	h.	h.	PROPN
ajlm-2375	261	17	the	the	DET
ajlm-2375	261	18	ace	ace	PROPN
ajlm-2375	261	19	2	2	NUM
ajlm-2375	261	20	g8790a	g8790a	PROPN
ajlm-2375	261	21	polymorphism	polymorphism	NOUN
ajlm-2375	261	22	:	:	PUNCT
ajlm-2375	261	23	involvement	involvement	NOUN
ajlm-2375	261	24	in	in	ADP
ajlm-2375	261	25	type	type	NOUN
ajlm-2375	261	26	2	2	NUM
ajlm-2375	261	27	diabetes	diabetes	NOUN
ajlm-2375	261	28	mellitus	mellitus	NOUN
ajlm-2375	261	29	combined	combine	VERB
ajlm-2375	261	30	with	with	ADP
ajlm-2375	261	31	cerebral	cerebral	ADJ
ajlm-2375	261	32	stroke	stroke	NOUN
ajlm-2375	261	33	.	.	PUNCT
ajlm-2375	262	1	j	j	PROPN
ajlm-2375	262	2	clin	clin	PROPN
ajlm-2375	262	3	lab	lab	PROPN
ajlm-2375	262	4	anal	anal	PROPN
ajlm-2375	262	5	.	.	PUNCT
ajlm-2375	263	1	2017;31(2):e22033	2017;31(2):e22033	NUM
ajlm-2375	263	2	.	.	NUM
ajlm-2375	263	3	https://doi.org/10.1002/jcla.22033	https://doi.org/10.1002/jcla.22033	PROPN
ajlm-2375	263	4	srivastava	srivastava	PROPN
ajlm-2375	263	5	a	a	PROPN
ajlm-2375	263	6	,	,	PUNCT
ajlm-2375	263	7	bandopadhyay	bandopadhyay	PROPN
ajlm-2375	263	8	a	a	PROPN
ajlm-2375	263	9	,	,	PUNCT
ajlm-2375	263	10	das	das	PROPN
ajlm-2375	263	11	d	d	PROPN
ajlm-2375	263	12	,	,	PUNCT
ajlm-2375	263	13	et	et	PROPN
ajlm-2375	263	14	al	al	PROPN
ajlm-2375	263	15	.	.	PUNCT
ajlm-2375	264	1	genetic	genetic	PROPN
ajlm-2375	264	2	association	association	PROPN
ajlm-2375	264	3	of	of	ADP
ajlm-2375	264	4	ace2	ace2	PROPN
ajlm-2375	264	5	rs2285666	rs2285666	VERB
ajlm-2375	264	6	polymorphism	polymorphism	NOUN
ajlm-2375	264	7	with	with	ADP
ajlm-2375	264	8	covid-19	covid-19	PROPN
ajlm-2375	264	9	spatial	spatial	ADJ
ajlm-2375	264	10	distribution	distribution	NOUN
ajlm-2375	264	11	in	in	ADP
ajlm-2375	264	12	india	india	PROPN
ajlm-2375	264	13	.	.	PUNCT
ajlm-2375	265	1	front	front	ADJ
ajlm-2375	265	2	genet	genet	NOUN
ajlm-2375	265	3	.	.	PUNCT
ajlm-2375	266	1	2020;11:564741	2020;11:564741	X
ajlm-2375	266	2	.	.	PUNCT
ajlm-2375	267	1	möhlendick	möhlendick	PROPN
ajlm-2375	267	2	b	b	PROPN
ajlm-2375	267	3	,	,	PUNCT
ajlm-2375	267	4	schönfelder	schönfelder	X
ajlm-2375	267	5	k	k	PROPN
ajlm-2375	267	6	,	,	PUNCT
ajlm-2375	267	7	breuckmann	breuckmann	PROPN
ajlm-2375	267	8	k	k	PROPN
ajlm-2375	267	9	,	,	PUNCT
ajlm-2375	267	10	et	et	PROPN
ajlm-2375	267	11	al	al	PROPN
ajlm-2375	267	12	.	.	PROPN
ajlm-2375	267	13	ace2	ace2	PROPN
ajlm-2375	267	14	polymorphism	polymorphism	NOUN
ajlm-2375	267	15	and	and	CCONJ
ajlm-2375	267	16	susceptibility	susceptibility	NOUN
ajlm-2375	267	17	for	for	ADP
ajlm-2375	267	18	sars	sar	NOUN
ajlm-2375	267	19	-	-	PUNCT
ajlm-2375	267	20	cov-2	cov-2	NOUN
ajlm-2375	267	21	infection	infection	NOUN
ajlm-2375	267	22	and	and	CCONJ
ajlm-2375	267	23	severity	severity	NOUN
ajlm-2375	267	24	of	of	ADP
ajlm-2375	267	25	covid-19	covid-19	PROPN
ajlm-2375	267	26	.	.	PUNCT
ajlm-2375	267	27	pharmacogenet	pharmacogenet	PROPN
ajlm-2375	267	28	genom	genom	NOUN
ajlm-2375	267	29	.	.	PUNCT
ajlm-2375	268	1	2021;31(8):165–171	2021;31(8):165–171	X
ajlm-2375	268	2	.	.	PUNCT
ajlm-2375	269	1	https://doi.org/10.1097/fpc.0000000000000436	https://doi.org/10.1097/fpc.0000000000000436	NOUN
ajlm-2375	269	2	lumbers	lumber	NOUN
ajlm-2375	269	3	er	er	INTJ
ajlm-2375	269	4	,	,	PUNCT
ajlm-2375	269	5	delforce	delforce	NOUN
ajlm-2375	269	6	sj	sj	PROPN
ajlm-2375	269	7	,	,	PUNCT
ajlm-2375	269	8	pringle	pringle	PROPN
ajlm-2375	269	9	kg	kg	PROPN
ajlm-2375	269	10	,	,	PUNCT
ajlm-2375	269	11	smith	smith	PROPN
ajlm-2375	269	12	gr	gr	PROPN
ajlm-2375	269	13	.	.	PUNCT
ajlm-2375	270	1	the	the	DET
ajlm-2375	270	2	lung	lung	NOUN
ajlm-2375	270	3	,	,	PUNCT
ajlm-2375	270	4	the	the	DET
ajlm-2375	270	5	heart	heart	NOUN
ajlm-2375	270	6	,	,	PUNCT
ajlm-2375	270	7	the	the	DET
ajlm-2375	270	8	novel	novel	ADJ
ajlm-2375	270	9	coronavirus	coronavirus	NOUN
ajlm-2375	270	10	,	,	PUNCT
ajlm-2375	270	11	and	and	CCONJ
ajlm-2375	270	12	the	the	DET
ajlm-2375	270	13	renin	renin	ADJ
ajlm-2375	270	14	-	-	PUNCT
ajlm-2375	270	15	angiotensin	angiotensin	NOUN
ajlm-2375	270	16	system	system	NOUN
ajlm-2375	270	17	;	;	PUNCT
ajlm-2375	270	18	the	the	DET
ajlm-2375	270	19	need	need	NOUN
ajlm-2375	270	20	for	for	ADP
ajlm-2375	270	21	clinical	clinical	ADJ
ajlm-2375	270	22	trials	trial	NOUN
ajlm-2375	270	23	.	.	PUNCT
ajlm-2375	271	1	front	front	PROPN
ajlm-2375	271	2	med	med	PROPN
ajlm-2375	271	3	.	.	PUNCT
ajlm-2375	272	1	2020;7:248	2020;7:248	ADV
ajlm-2375	272	2	.	.	PUNCT
ajlm-2375	273	1	https://doi.org/10.3389/fmed.2020.00248	https://doi.org/10.3389/fmed.2020.00248	PROPN
ajlm-2375	273	2	martínez	martínez	NOUN
ajlm-2375	273	3	-	-	PUNCT
ajlm-2375	273	4	gómez	gómez	NOUN
ajlm-2375	273	5	le	le	X
ajlm-2375	273	6	,	,	PUNCT
ajlm-2375	273	7	herrera	herrera	NOUN
ajlm-2375	273	8	-	-	PUNCT
ajlm-2375	273	9	lópez	lópez	NOUN
ajlm-2375	273	10	b	b	PROPN
ajlm-2375	273	11	,	,	PUNCT
ajlm-2375	273	12	martinez	martinez	PROPN
ajlm-2375	273	13	-	-	PUNCT
ajlm-2375	273	14	armenta	armenta	PROPN
ajlm-2375	273	15	c	c	PROPN
ajlm-2375	273	16	,	,	PUNCT
ajlm-2375	273	17	et	et	PROPN
ajlm-2375	273	18	al	al	PROPN
ajlm-2375	273	19	.	.	PROPN
ajlm-2375	273	20	ace	ace	PROPN
ajlm-2375	273	21	and	and	CCONJ
ajlm-2375	273	22	ace2	ace2	PROPN
ajlm-2375	273	23	gene	gene	NOUN
ajlm-2375	273	24	variants	variant	NOUN
ajlm-2375	273	25	are	be	AUX
ajlm-2375	273	26	associated	associate	VERB
ajlm-2375	273	27	with	with	ADP
ajlm-2375	273	28	severe	severe	ADJ
ajlm-2375	273	29	outcomes	outcome	NOUN
ajlm-2375	273	30	of	of	ADP
ajlm-2375	273	31	covid-19	covid-19	PROPN
ajlm-2375	273	32	in	in	ADP
ajlm-2375	273	33	men	man	NOUN
ajlm-2375	273	34	.	.	PUNCT
ajlm-2375	274	1	front	front	ADJ
ajlm-2375	274	2	immunol	immunol	NOUN
ajlm-2375	274	3	.	.	PUNCT
ajlm-2375	275	1	2022;13:812940	2022;13:812940	X
ajlm-2375	275	2	.	.	NOUN
ajlm-2375	275	3	sabater	sabater	PROPN
ajlm-2375	275	4	molina	molina	PROPN
ajlm-2375	275	5	m	m	PROPN
ajlm-2375	275	6	,	,	PUNCT
ajlm-2375	275	7	nicolás	nicolás	X
ajlm-2375	275	8	rocamora	rocamora	PROPN
ajlm-2375	275	9	e	e	PROPN
ajlm-2375	275	10	,	,	PUNCT
ajlm-2375	275	11	bendicho	bendicho	PROPN
ajlm-2375	275	12	ai	ai	PROPN
ajlm-2375	275	13	,	,	PUNCT
ajlm-2375	275	14	et	et	PROPN
ajlm-2375	275	15	al	al	PROPN
ajlm-2375	275	16	.	.	PROPN
ajlm-2375	275	17	polymorphisms	polymorphism	NOUN
ajlm-2375	275	18	in	in	ADP
ajlm-2375	275	19	ace	ace	NOUN
ajlm-2375	275	20	,	,	PUNCT
ajlm-2375	275	21	ace2	ace2	PROPN
ajlm-2375	275	22	,	,	PUNCT
ajlm-2375	275	23	agtr1	agtr1	NOUN
ajlm-2375	275	24	genes	gene	NOUN
ajlm-2375	275	25	and	and	CCONJ
ajlm-2375	275	26	severity	severity	NOUN
ajlm-2375	275	27	of	of	ADP
ajlm-2375	275	28	covid-19	covid-19	PROPN
ajlm-2375	275	29	disease	disease	NOUN
ajlm-2375	275	30	.	.	PUNCT
ajlm-2375	276	1	plos	plos	PROPN
ajlm-2375	276	2	one	one	NUM
ajlm-2375	276	3	.	.	PUNCT
ajlm-2375	277	1	2022;17(2):e0263140	2022;17(2):e0263140	X
ajlm-2375	277	2	.	.	PUNCT
ajlm-2375	278	1	https://doi.org/10.1371/journal.pone.0263140	https://doi.org/10.1371/journal.pone.0263140	PROPN
ajlm-2375	278	2	karakaş	karakaş	PROPN
ajlm-2375	278	3	çelik	çelik	PROPN
ajlm-2375	278	4	s	s	PART
ajlm-2375	278	5	,	,	PUNCT
ajlm-2375	278	6	çakmak	çakmak	PROPN
ajlm-2375	278	7	genç	genç	VERB
ajlm-2375	278	8	g	g	PROPN
ajlm-2375	278	9	,	,	PUNCT
ajlm-2375	278	10	pişkin	pişkin	PROPN
ajlm-2375	278	11	n	n	CCONJ
ajlm-2375	278	12	,	,	PUNCT
ajlm-2375	278	13	et	et	PROPN
ajlm-2375	278	14	al	al	PROPN
ajlm-2375	278	15	.	.	PUNCT
ajlm-2375	278	16	polymorphisms	polymorphism	NOUN
ajlm-2375	278	17	of	of	ADP
ajlm-2375	278	18	ace	ace	NOUN
ajlm-2375	278	19	(	(	PUNCT
ajlm-2375	278	20	i	i	NOUN
ajlm-2375	278	21	/	/	SYM
ajlm-2375	278	22	d	d	NOUN
ajlm-2375	278	23	)	)	PUNCT
ajlm-2375	278	24	and	and	CCONJ
ajlm-2375	278	25	ace2	ace2	NOUN
ajlm-2375	278	26	receptor	receptor	NOUN
ajlm-2375	278	27	gene	gene	NOUN
ajlm-2375	278	28	(	(	PUNCT
ajlm-2375	278	29	rs2106809	rs2106809	NOUN
ajlm-2375	278	30	,	,	PUNCT
ajlm-2375	278	31	rs2285666	rs2285666	PROPN
ajlm-2375	278	32	)	)	PUNCT
ajlm-2375	278	33	are	be	AUX
ajlm-2375	278	34	not	not	PART
ajlm-2375	278	35	related	relate	VERB
ajlm-2375	278	36	to	to	ADP
ajlm-2375	278	37	the	the	DET
ajlm-2375	278	38	clinical	clinical	ADJ
ajlm-2375	278	39	course	course	NOUN
ajlm-2375	278	40	of	of	ADP
ajlm-2375	278	41	covid-19	covid-19	PROPN
ajlm-2375	278	42	:	:	PUNCT
ajlm-2375	278	43	a	a	DET
ajlm-2375	278	44	case	case	NOUN
ajlm-2375	278	45	study	study	NOUN
ajlm-2375	278	46	.	.	PUNCT
ajlm-2375	279	1	j	j	PROPN
ajlm-2375	279	2	med	med	PROPN
ajlm-2375	279	3	virol	virol	NOUN
ajlm-2375	279	4	.	.	PUNCT
ajlm-2375	280	1	2021;93(10):5947–5952	2021;93(10):5947–5952	X
ajlm-2375	280	2	.	.	PUNCT
ajlm-2375	281	1	https://doi.org/10.1002/jmv.27160	https://doi.org/10.1002/jmv.27160	PROPN
ajlm-2375	281	2	elnagdy	elnagdy	PROPN
ajlm-2375	281	3	mh	mh	PROPN
ajlm-2375	281	4	,	,	PUNCT
ajlm-2375	281	5	magdy	magdy	PROPN
ajlm-2375	281	6	a	a	PRON
ajlm-2375	281	7	,	,	PUNCT
ajlm-2375	281	8	eldars	eldar	NOUN
ajlm-2375	281	9	w	w	PROPN
ajlm-2375	281	10	,	,	PUNCT
ajlm-2375	281	11	et	et	PROPN
ajlm-2375	281	12	al	al	PROPN
ajlm-2375	281	13	.	.	PUNCT
ajlm-2375	282	1	genetic	genetic	PROPN
ajlm-2375	282	2	association	association	NOUN
ajlm-2375	282	3	of	of	ADP
ajlm-2375	282	4	ace2	ace2	PROPN
ajlm-2375	282	5	and	and	CCONJ
ajlm-2375	282	6	tmprss2	tmprss2	ADP
ajlm-2375	282	7	polymorphisms	polymorphism	NOUN
ajlm-2375	282	8	with	with	ADP
ajlm-2375	282	9	covid-19	covid-19	PROPN
ajlm-2375	282	10	severity	severity	NOUN
ajlm-2375	282	11	;	;	PUNCT
ajlm-2375	282	12	a	a	DET
ajlm-2375	282	13	single	single	ADJ
ajlm-2375	282	14	centre	centre	NOUN
ajlm-2375	282	15	study	study	NOUN
ajlm-2375	282	16	from	from	ADP
ajlm-2375	282	17	egypt	egypt	PROPN
ajlm-2375	282	18	.	.	PUNCT
ajlm-2375	283	1	virol	virol	PROPN
ajlm-2375	283	2	j.	j.	PROPN
ajlm-2375	283	3	2024;21(1):27	2024;21(1):27	PROPN
ajlm-2375	283	4	.	.	PUNCT
ajlm-2375	284	1	https://doi.org/10.1186/s12985-024-02298-x	https://doi.org/10.1186/s12985-024-02298-x	PROPN
ajlm-2375	284	2	pandey	pandey	PROPN
ajlm-2375	284	3	rk	rk	PROPN
ajlm-2375	284	4	,	,	PUNCT
ajlm-2375	284	5	srivastava	srivastava	PROPN
ajlm-2375	284	6	a	a	PROPN
ajlm-2375	284	7	,	,	PUNCT
ajlm-2375	284	8	singh	singh	PROPN
ajlm-2375	284	9	pp	pp	PROPN
ajlm-2375	284	10	,	,	PUNCT
ajlm-2375	284	11	chaubey	chaubey	PROPN
ajlm-2375	284	12	g.	g.	PROPN
ajlm-2375	284	13	genetic	genetic	PROPN
ajlm-2375	284	14	association	association	PROPN
ajlm-2375	284	15	of	of	ADP
ajlm-2375	284	16	tmprss2	tmprss2	DET
ajlm-2375	284	17	rs2070788	rs2070788	ADJ
ajlm-2375	284	18	polymorphism	polymorphism	NOUN
ajlm-2375	284	19	with	with	ADP
ajlm-2375	284	20	covid-19	covid-19	PROPN
ajlm-2375	284	21	case	case	NOUN
ajlm-2375	284	22	fatality	fatality	NOUN
ajlm-2375	284	23	rate	rate	NOUN
ajlm-2375	284	24	among	among	ADP
ajlm-2375	284	25	indian	indian	ADJ
ajlm-2375	284	26	populations	population	NOUN
ajlm-2375	284	27	.	.	PUNCT
ajlm-2375	285	1	infect	infect	VERB
ajlm-2375	285	2	genet	genet	NOUN
ajlm-2375	285	3	evol	evol	NOUN
ajlm-2375	285	4	.	.	PUNCT
ajlm-2375	286	1	2022;98:105206	2022;98:105206	NUM
ajlm-2375	286	2	.	.	PUNCT
ajlm-2375	287	1	https://doi.org/10.1016/j.meegid.2022.105206	https://doi.org/10.1016/j.meegid.2022.105206	PROPN
ajlm-2375	287	2	schönfelder	schönfelder	NOUN
ajlm-2375	288	1	k	k	PROPN
ajlm-2375	288	2	,	,	PUNCT
ajlm-2375	288	3	breuckmann	breuckmann	PROPN
ajlm-2375	288	4	k	k	PROPN
ajlm-2375	288	5	,	,	PUNCT
ajlm-2375	288	6	elsner	elsner	NOUN
ajlm-2375	288	7	c	c	NOUN
ajlm-2375	288	8	,	,	PUNCT
ajlm-2375	288	9	et	et	PROPN
ajlm-2375	288	10	al	al	PROPN
ajlm-2375	288	11	.	.	PROPN
ajlm-2375	288	12	transmembrane	transmembrane	ADJ
ajlm-2375	288	13	serine	serine	NOUN
ajlm-2375	288	14	protease	protease	NOUN
ajlm-2375	288	15	2	2	NUM
ajlm-2375	288	16	polymorphisms	polymorphism	NOUN
ajlm-2375	288	17	and	and	CCONJ
ajlm-2375	288	18	susceptibility	susceptibility	NOUN
ajlm-2375	288	19	to	to	ADP
ajlm-2375	288	20	severe	severe	ADJ
ajlm-2375	288	21	acute	acute	ADJ
ajlm-2375	288	22	respiratory	respiratory	ADJ
ajlm-2375	288	23	syndrome	syndrome	NOUN
ajlm-2375	288	24	coronavirus	coronavirus	NOUN
ajlm-2375	288	25	type	type	NOUN
ajlm-2375	288	26	2	2	NUM
ajlm-2375	288	27	infection	infection	NOUN
ajlm-2375	288	28	:	:	PUNCT
ajlm-2375	288	29	a	a	DET
ajlm-2375	288	30	german	german	ADJ
ajlm-2375	288	31	case	case	NOUN
ajlm-2375	288	32	-	-	PUNCT
ajlm-2375	288	33	control	control	NOUN
ajlm-2375	288	34	study	study	NOUN
ajlm-2375	288	35	.	.	PUNCT
ajlm-2375	289	1	front	front	ADJ
ajlm-2375	289	2	genet	genet	NOUN
ajlm-2375	289	3	.	.	PUNCT
ajlm-2375	290	1	2021;12:667231	2021;12:667231	NUM
ajlm-2375	290	2	.	.	PUNCT
ajlm-2375	291	1	https://doi.org/10.3389/fgene.2021.667231	https://doi.org/10.3389/fgene.2021.667231	NOUN